
<html lang="en"     class="pb-page"  data-request-id="b5ed490a-7af0-4332-9fb3-74ba8b88100f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.5b01029"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma" /></meta><meta name="dc.Creator" content="Stuart T.  Onions" /></meta><meta name="dc.Creator" content="Kazuhiro  Ito" /></meta><meta name="dc.Creator" content="Catherine E.  Charron" /></meta><meta name="dc.Creator" content="Richard J.  Brown" /></meta><meta name="dc.Creator" content="Marie  Colucci" /></meta><meta name="dc.Creator" content="Fritz  Frickel" /></meta><meta name="dc.Creator" content="George  Hardy" /></meta><meta name="dc.Creator" content="Kevin  Joly" /></meta><meta name="dc.Creator" content="John  King-Underwood" /></meta><meta name="dc.Creator" content="Yasuo  Kizawa" /></meta><meta name="dc.Creator" content="Ian  Knowles" /></meta><meta name="dc.Creator" content="P. John  Murray" /></meta><meta name="dc.Creator" content="Andrew  Novak" /></meta><meta name="dc.Creator" content="Anjna  Rani" /></meta><meta name="dc.Creator" content="Garth  Rapeport" /></meta><meta name="dc.Creator" content="Alun  Smith" /></meta><meta name="dc.Creator" content="Peter  Strong" /></meta><meta name="dc.Creator" content="David M.  Taddei" /></meta><meta name="dc.Creator" content="Jonathan G.  Williams" /></meta><meta name="dc.Description" content="The discovery of a novel series of therapeutic agents that has been designed and optimized for treating chronic obstructive pulmonary disease is reported. The pharmacological strategy was based on ..." /></meta><meta name="Description" content="The discovery of a novel series of therapeutic agents that has been designed and optimized for treating chronic obstructive pulmonary disease is reported. The pharmacological strategy was based on ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 4, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01029" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01029" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01029" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01029" /></link>
        
    
    

<title>Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01029" /></meta><meta property="og:title" content="Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0010.jpeg" /></meta><meta property="og:description" content="The discovery of a novel series of therapeutic agents that has been designed and optimized for treating chronic obstructive pulmonary disease is reported. The pharmacological strategy was based on the identification of compounds that inhibit a defined subset of kinase enzymes modulating inflammatory processes that would be effective against steroid refractory disease and exhibit a sustained duration of action after inhaled delivery." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01029"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01029">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01029&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01029&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01029&amp;href=/doi/10.1021/acs.jmedchem.5b01029" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1727-1746</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01647" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01203" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stuart+T.++Onions">Stuart T. Onions</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kazuhiro++Ito">Kazuhiro Ito</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Catherine+E.++Charron">Catherine E. Charron</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+J.++Brown">Richard J. Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marie++Colucci">Marie Colucci</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fritz++Frickel">Fritz Frickel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George++Hardy">George Hardy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Joly">Kevin Joly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++King-Underwood">John King-Underwood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yasuo++Kizawa">Yasuo Kizawa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ian++Knowles">Ian Knowles</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=P.+John++Murray">P. John Murray</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Novak">Andrew Novak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anjna++Rani">Anjna Rani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Garth++Rapeport">Garth Rapeport</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alun++Smith">Alun Smith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Strong">Peter Strong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+M.++Taddei">David M. Taddei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+G.++Williams">Jonathan G. Williams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff2"><span class="aff-symbol">†</span> <span class="aff-text">Sygnature Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div><div class="aff-info" id="aff1"><span class="aff-symbol">‡</span> <span class="aff-text">RespiVert Limited, 2 Royal College Street, The London Bioscience Innovation Centre, London NW1 0NH, United Kingdom</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">CompChem Resource, Old Cottage Hospital, Homend, Ledbury, Herefordshire HR8 1ED, United Kingdom</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Physiology and Anatomy, Nihon University School of Pharmacy, 7-7-1, Narashinodai, Funabashi, Chiba 274-8555, Japan</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Pneumolabs UK Limited, Harrow, Middlesex HA1 3UJ, United Kingdom</span></div><div class="corresp-info"><strong>*</strong>(S.T.O.) E-mail: <a href="/cdn-cgi/l/email-protection#83f0adecedeaecedf0c3f0fae4ede2f7f6f1e6e7eaf0e0ecf5e6f1faade0ecee"><span class="__cf_email__" data-cfemail="57247938393e38392417242e30393623222532333e2434382132252e7934383a">[email protected]</span></a>. Phone: +44 (0)1159 415401.</div><div class="corresp-info"><strong>*</strong>(C.E.C.) E-mail: <a href="/cdn-cgi/l/email-protection#731012071b16011a1d1633011600031a051601075d101c1e"><span class="__cf_email__" data-cfemail="81e2e0f5e9e4f3e8efe4c1f3e4f2f1e8f7e4f3f5afe2eeec">[email protected]</span></a>. Phone: +44 20 7388 9903.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01029&amp;href=/doi/10.1021%2Facs.jmedchem.5b01029" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1727–1746</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 22, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 July 2015</li><li><span class="item_label"><b>Published</b> online</span>4 February 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 March 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01029" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01029</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1727%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DStuart%2BT.%2BOnions%252C%2BKazuhiro%2BIto%252C%2BCatherine%2BE.%2BCharron%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D5%26contentID%3Dacs.jmedchem.5b01029%26title%3DDiscovery%2Bof%2BNarrow%2BSpectrum%2BKinase%2BInhibitors%253A%2BNew%2BTherapeutic%2BAgents%2Bfor%2Bthe%2BTreatment%2Bof%2BCOPD%2Band%2BSteroid-Resistant%2BAsthma%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1746%26publicationDate%3DMarch%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01029"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2394</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01029" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stuart&quot;,&quot;last_name&quot;:&quot;T. Onions&quot;},{&quot;first_name&quot;:&quot;Kazuhiro&quot;,&quot;last_name&quot;:&quot;Ito&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;E. Charron&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;J. Brown&quot;},{&quot;first_name&quot;:&quot;Marie&quot;,&quot;last_name&quot;:&quot;Colucci&quot;},{&quot;first_name&quot;:&quot;Fritz&quot;,&quot;last_name&quot;:&quot;Frickel&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Hardy&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Joly&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;King-Underwood&quot;},{&quot;first_name&quot;:&quot;Yasuo&quot;,&quot;last_name&quot;:&quot;Kizawa&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;Knowles&quot;},{&quot;first_name&quot;:&quot;P.&quot;,&quot;last_name&quot;:&quot;John Murray&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Novak&quot;},{&quot;first_name&quot;:&quot;Anjna&quot;,&quot;last_name&quot;:&quot;Rani&quot;},{&quot;first_name&quot;:&quot;Garth&quot;,&quot;last_name&quot;:&quot;Rapeport&quot;},{&quot;first_name&quot;:&quot;Alun&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Strong&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;M. Taddei&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;G. Williams&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;1727-1746&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01029&quot;},&quot;abstract&quot;:&quot;The discovery of a novel series of therapeutic agents that has been designed and optimized for treating chronic obstructive pulmonary disease is reported. The pharmacological strategy was based on the identification of compounds that inhibit a defined subset of kinase enzymes modulating inflammatory processes that would be effective against steroid refractory disease and exhibit a sustained duration of action after inhaled delivery.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01029&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01029" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01029&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01029" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01029&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01029" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01029&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01029&amp;href=/doi/10.1021/acs.jmedchem.5b01029" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01029" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01029" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01029%26sid%3Dliteratum%253Aachs%26pmid%3D26800309%26genre%3Darticle%26aulast%3DOnions%26date%3D2016%26atitle%3DDiscovery%2Bof%2BNarrow%2BSpectrum%2BKinase%2BInhibitors%253A%2BNew%2BTherapeutic%2BAgents%2Bfor%2Bthe%2BTreatment%2Bof%2BCOPD%2Band%2BSteroid-Resistant%2BAsthma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D5%26spage%3D1727%26epage%3D1746%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=290723" title="Solutions">Solutions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292593" title="Liquid chromatography-mass spectrometry">Liquid chromatography-mass spectrometry</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/jmcmar.2016.59.issue-5/20160310-01/jmcmar.2016.59.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery of a novel series of therapeutic agents that has been designed and optimized for treating chronic obstructive pulmonary disease is reported. The pharmacological strategy was based on the identification of compounds that inhibit a defined subset of kinase enzymes modulating inflammatory processes that would be effective against steroid refractory disease and exhibit a sustained duration of action after inhaled delivery.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Corticosteroids are widely used in the clinic for the treatment of pulmonary inflammatory disorders, including asthma and chronic obstructive pulmonary disease (COPD). However, their therapeutic benefit is frequently limited by a steroid-refractory phenotype.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> This resistance to treatment can be an inherent feature of the condition or may be induced by external factors that provoke disease exacerbation, such as a viral infection,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> or by long-term inhalation of noxious gases and particles, such as cigarette smoke or kitchen smoke.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Marked steroid resistance impedes the effective management of these maladies, and increasing the drug load in order to compensate for reduced efficacy is often associated with potentially severe side-effects, especially on chronic treatment.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> The objective of the present study was to identify effective agents for the treatment of corticosteroid-resistant symptoms of COPD and asthma that would be suitable for chronic use.</div><div class="NLM_p">COPD is a major and increasing global health problem with an enormous expenditure of indirect/direct health care costs.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> COPD now affects over 10% of the world population over the age of 40,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and the burden of the disease is particularly high in developing countries. COPD is a complex disease combining inflammatory processes and structural changes to the affected tissues,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and long-acting bronchodilators (LAMA and LABA), not anti-inflammatory drugs, are currently the mainstay of COPD pharmacological treatment.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> While the underlying inflammatory mechanisms are complex, alveolar macrophages are known to play a critical role in the pathophysiology of the disease by secreting proinflammatory proteins, including certain cytokines, chemokines, reactive oxygen species, and electrolytic enzymes.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Macrophages are markedly elevated in number in the lung and alveolar spaces of patients with COPD and are localized to sites of alveolar destruction.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The higher number of macrophages observed may result from increased recruitment of blood monocytes as well as prolonged survival in the lung.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> To a lesser extent, the rise in macrophage levels may derive from increased proliferation in response to oxidative stress, such as exposure to tobacco smoke.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> It is relevant to the disease symptomology that alveolar macrophages obtained from COPD patients are resistant to the anti-inflammatory effects of corticosteroids.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> These differentiated cells recruit neutrophils from the bloodstream to the site of inflammation by the production of cytokines such as CXCL8 and TNFα.</div><div class="NLM_p">Oral therapies targeting the p38 mitogen activated protein kinases (MAPK) have been proposed as an alternative treatment to corticosteroids owing to their ability to inhibit the production of proinflammatory cytokines.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The p38 MAP kinase family comprises four distinct protein isoforms, α, β, γ, and δ, each of which displays different patterns of tissue expression.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The p38 MAPK α and β isoforms are distributed widely in the body, being present in many cell types. While the α isoform is well-characterized as a mediator of inflammation, p38 MAPK δ and γ are less well studied. There is evidence to suggest that inhibition of p38 MAPK γ is the mechanism by which the β2-agonist formoterol reverses steroid resistance in asthma.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In addition, p38 MAPK γ expression is reported to be upregulated in peripheral blood mononuclear cells obtained from severe asthmatics.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> This body of evidence has impelled numerous efforts to discover small molecule inhibitors of the p38 MAPK family, in particular the α isoform.</div><div class="NLM_p">A recent example of a p38 MAPK α inhibitor entering the clinic is <b>1</b> (Pamapimod, RO4402257; <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). It was previously reported to be efficacious in several in vivo models of inflammatory arthritis.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> However, in a 12 week clinical study in patients with rheumatoid arthritis, the compound did not demonstrate significant efficacy either as a monotherapy or in combination with methotrexate.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Moreover, typical side effects associated with orally delivered p38 MAPK inhibitors were observed, including skin rash and elevated activity levels of liver enzymes.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Dose-limiting toxicology is the norm for p38 MAPK inhibitors, and it has been suggested that first-generation compounds, such as <b>1</b>, are much less selective agents than was first considered.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The latest generation of inhibitors, typified by <b>2</b> (PH-797804), is reported to be more selective and demonstrate little off-target kinase activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In a 6 week trial involving 230 patients with COPD, the oral administration of <b>2</b> was well-tolerated and demonstrated a statistical improvement in FEV1, while the usual skin rash was observed in only 7% of patients.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Another oral p38 MAPK inhibitor, <b>3</b> (Losmapimod, GW856553), was tested in a 12 week trial involving 302 patients with COPD. This compound was also well-tolerated and demonstrated a statistical reduction of plasma fibrinogen, although there was no significant improvement on lung function or sputum neutrophils.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> However, the effect was not sustained in a 6 month study.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Selective p38 MAPK α inhibitors may not provide an effective therapeutic intervention in a chronic setting.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. p38 MAPK inhibitors profiled in the clinic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In contrast to <b>1</b>–<b>3</b>, urea <b>4</b> (Doramapimod, BIRB-796) from Boehringer Ingelheim is a pan active inhibitor of the four p38 MAPK isoforms as well as other non-MAP kinases.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> This compound has undergone clinical assessment in healthy patients injected with LPS and was found to reduce the levels of induced TNFα and IL-1β release, along with other cytokines.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> However, in patients with Crohn’s disease, little efficacy was demonstrated and only a transient reduction in the inflammation marker, C-reactive protein (CRP), was observed.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> These transient effects and disease resistance have been observed with other p38 MAP kinase inhibitors, such as VX702<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and <b>1</b> Pamapimod,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> in rheumatoid arthritis and could be explained by activation of both redundant and/or alternative kinase signaling pathways.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">For lung diseases, topical administration of p38 MAPK inhibitors is expected to significantly reduce their resulting systemic exposure, especially to the liver, and thereby minimize the likelihood of side effects.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This method of delivery is ideally suited to treating conditions like COPD in which the principal drug targets are epithelial cells and/or resident inflammatory cells such as macrophages. It remains a concern that for selective p38 MAPK agents redundancy in cell signaling cascades will result in disease resistance.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In addition, Smith and colleagues reported while p38 MAPK α inhibitors proved to be effective on LPS-stimulated IL-6 and GM-CSF release in monocytes they displayed limited maximal inhibition in macrophages and also no beneficial effects on LPS-stimulated CXCL8 release in macrophages.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">In addition to the p38 MAPK family, tyrosine kinases have been implicated in inflammatory disease. Of particular interest is hematopoietic kinase (HCK), which has been shown to modulate adhesion, granulocytosis, and cytokine production in neutrophils.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> HCK is also reported to possess a preeminent role in LPS/toll like-receptor-4-induced TNF and IL-6 production in human primary macrophages and is upregulated in PBMCs from COPD patients.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> This kinase belongs to the Src family, and its expression is limited to the hematopoietic cells, predominantly in neutrophils.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> It was postulated that additional inhibition of relevant kinases, such as HCK, could enhance the efficacy of p38 inhibitors. This approach of inhibiting a subset of kinases is increasingly used in the oncology field and has provided compounds showing greater efficacy when compared to those that act on a single kinase target.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a></div><div class="NLM_p">The two main objectives for the project were to design molecules that, first, had p38α/γ activity and, second, had a longer duration of action than BIRB-796 when delivered topically to the lung. To the first end, we were assisted by the availability of crystallography data for our target enzymes with an array of ligands in the Protein Data Bank (PDB).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The design paradigm was to identify commonalities between the p38 isoforms that would also promote the DFG-out protein conformation observed for BIRB-796 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1kv2">1kv2</a>.pdb). A second design parameter was to focus on lower solubility derivatives that were anticipated to promote slow dissolution in the airways, leading to persistent target occupancy that is not dependent on systemic PK.</div><div class="NLM_p last">This article describes the discovery of novel, small molecule agents that inhibit a selected set of therapeutically relevant kinases for the treatment of steroid-refractory pulmonary disorders such as COPD. In addition, the compounds possess pharmacokinetic properties that enable sustained activity in vivo.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The compound examples described herein were prepared by one of three alternative processes as the final or penultimate step. Formation of the unsymmetrical central urea (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, Route 1) was performed via activation of aminopyrazole <b>34</b><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> by its transformation into the corresponding isocyanate or equivalent, followed by addition of the desired naphthylamine <b>35</b>. However, many analogues differed only in the nature of the substituent appended to the pyridine nucleus. In some instances, this structural divergence was readily incorporated by a displacement reaction on chloroacetamide intermediate <b>36</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, Route 2) with an appropriate nucleophile. In most cases, the compounds were obtained from common pyridine amines <b>9</b>, <b>10</b>, <b>37</b>, <b>40</b>, and <b>41</b> or carboxylic acid building blocks <b>38</b> and <b>39</b> by acylation or an amide coupling reaction, respectively (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, Route 3).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Strategy</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Intermediates containing an ethylene linker (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, L, −CH<sub>2</sub>CH<sub>2</sub>−) were obtained from the corresponding ethyl alcohol precursors (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, <b>42</b>, <b>44</b>, and <b>45</b>). Boc-protected 2-aminopyridine <b>42</b> was derived from ethyl 2-(2-chloropyridin-4-yl)acetate by a Buchwald coupling<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> with <i>tert</i>-butylcarbamate followed by reduction of the ester to the alcohol, under standard conditions. The corresponding methyl ester <b>44</b> was accessed via hydrolysis of a protected picolinonitrile,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><b>43</b>, which, in turn, was obtained from commercial 2-(pyridin-4-yl)ethanol by silyl ether protection, followed by N-oxide formation and cyanide insertion. Treatment of 4-methyl-3-nitropyridine with base and <i>para</i>-formaldehyde provided aminopyridine ethanol <b>45</b> after nitro reduction.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Ether intermediates <b>46a</b>–<b>c</b> were generated either by an S<sub>N</sub>Ar displacement on 1-fluoro-4-nitronaphthalene or by a Mitsonobu coupling reaction on 4-nitronaphthalen-1-ol. Subsequent reduction of the nitro groups, with iron in acetic acid or by catalytic hydrogenation, gave the desired naphthylamines <b>47a</b>–<b>c</b>. The unsymmetrical ureas <b>9/10</b> and <b>38</b> were produced by prior activation of aminopyrazole <b>34</b> with either CDI or a phosgene equivalent followed by treatment with the requisite naphthylamine <b>47a</b>–<b>c</b> and, where necessary, deprotection of the product. In the case of 2-aminopyridine <b>9</b>, the Boc group was removed from intermediate <b>48</b> by exposure to TFA, whereas for pyridine carboxylic acid <b>38</b>, the acid was revealed by saponification of ester <b>49</b>. These advanced intermediates were transformed into final test substances by an N-acylation reaction with an acid chloride or isocyanate or amidation under standard peptide bond forming conditions.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route To Access the Ethylene Linker Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <i>t</i>-BuOCONH<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Xantphos, THF, 65 °C; (b) DIBAL, −78 °C, THF; (c) TBDMSCl, imidazole, DCM, rt; (d) H<sub>2</sub>O<sub>2</sub>, MeReO<sub>3</sub>, DCM, rt; (e) TMS-CN, Me<sub>2</sub>NC(O)Cl, DCM, rt; (f) Na, MeOH, then aq. HCl, rt; (g) Triton B, paraformaldehyde, DMSO, rt; (h) H<sub>2</sub>, Pd/C, MeOH; (j) NaH, 1-fluoro-4-nitronaphthalene, THF, 0 °C; (k) 4-nitronaphthalen-1-ol, DIAD, PPh<sub>3</sub>, THF, −78 °C; (m) Fe, AcOH, 50 °C (<b>46a</b>) or H<sub>2</sub>, Pt/C, rt (<b>46b</b> and <b>46c</b>); (n) CDI, DCM (<b>47a</b> and <b>47b</b>) or diphosgene, aq. NaHCO<sub>3</sub> (<b>47c</b>); (p) TFA, DCM; (q) aq. NaOH; (r) RCOCl, base, THF/DMF, rt; (s) RNH<sub>2</sub>, HATU, DMF, rt.</p></p></figure><div class="NLM_p">Imidazolyl analogue <b>17</b> was readily accessible via an amination reaction on the known alkyl iodide <b>50</b><a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> with 2-nitroimidazole under basic conditions (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The resulting nitroarene <b>51</b> was converted into the test compound by reduction of the nitro group followed by acylation with acetyl chloride in the presence of DIPEA.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the Imidazolyl Analogue<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 2-nitro-1<i>H</i>-imidazole, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C; (b) Fe, AcOH, 50 °C; (c) MeCOCl, DIPEA, DCM, rt.</p></p></figure><div class="NLM_p">Most of the lower homologues (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, L, −CH<sub>2</sub>−) were prepared using essentially the same synthetic strategies outlined above, starting from the appropriately substituted pyridinemethyl alcohols <b>52</b> and <b>53</b>, which were available from commercial sources (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The corresponding methoxy linked biaryls <b>54a</b>–<b>b</b> were obtained by a Mitsunobu coupling. N-Methyl methoxyacetamide <b>55b</b> was prepared by alkylation of acylated intermediate <b>55a</b> with methyl iodide in the presence of sodium hydride. The resulting nitronaphthylenes were converted into naphthylamines <b>35</b> and <b>56a</b>–<b>b</b> either by a dissolving metal reduction or by catalytic hydrogenation, and the products were subsequently exposed to a preactivated solution of 5-aminopyrazole <b>34</b>. In the case of tertiary amide <b>35</b>, this provided N-methylated analogue <b>31</b> directly. The protected intermediate obtained from the urea coupling step, ester <b>57,</b> was transformed into carboxylic acid <b>39</b> by basic hydrolysis. Final drug substances were generated from amine precursors <b>37</b> by acylation and sulfonylation and from acid <b>39</b> by amide couplings.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route To Access the Methylene Linker Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 4-nitronaphthalen-1-ol, DIAD, PPh<sub>3</sub>, −78 °C, THF; (b) MeOCH<sub>2</sub>COCl, DIPEA, THF, rt; (c) Fe, AcOH, 50 °C or H<sub>2</sub>, Pt/C, rt; (d) NaH, MeI, THF, 0 °C; (e) CDI, <b>34</b>, DCM; or diphosgene, NaHCO<sub>3</sub>, DCM, 0 °C; (f) LiOH, THF/H<sub>2</sub>O, rt; (g) RCOCl, DIPEA, THF/DMF, rt; or ROCOCl, DIPEA, THF/DMF, rt; or RSO<sub>2</sub>Cl, DIPEA, THF/DMF, rt; or RNCO, DCM/DMF, rt; (h) HATU, RNH<sub>2</sub>, DMF, rt.</p></p></figure><div class="NLM_p">Additional 2-aminopyridine N-acetyl analogues were prepared by a process that is highly convergent and expedient for preparing this compound class (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Reaction of the parent amine <b>37</b> with chloroacetyl chloride provided chloroacetamide intermediate <b>36</b>. This reactive alkylating agent was isolated and then subjected to displacement reactions with nucleophiles to provide, inter alia, aminoacetamide derivatives <b>26</b> and <b>27</b> and thioether <b>28</b>.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of N-Acetyl Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) ClCH<sub>2</sub>COCl, DCM, DIPEA, rt; (b) RYH, DIPEA, DCM/DMF, 40 °C (Y = N, S).</p></p></figure><div class="NLM_p">Analogues <b>32</b> and <b>33</b> were accessed with similar chemistry as that for compounds <b>18</b>–<b>25</b>; however, the side chain substitution (R<sup>2</sup> = H, Me) was introduced early in the synthesis. Treatment of commercial methyl 2-aminoisonicotinate with methyl lithium furnished both ketone <b>58</b> and tertiary alcohol <b>59a</b>. Standard reduction of <b>58</b> with NaBH<sub>4</sub> gave secondary alcohol <b>59b</b>. Elaboration of <b>59a</b>–<b>b</b> under standard chemistry gave <b>32</b> and <b>33</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route To Access the Side-Chain-Substituted Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) MeLi, THF, −78 °C; (b) NaBH<sub>4</sub>, MeOH, 0 °C; (c) NaH, 1-fluoro-4-nitronaphthalene, DMF, 0 °C; (d) H<sub>2</sub>, Pt/C, rt; (e) diphosgene, aq. NaHCO<sub>3</sub>, 0 °C to rt; (f) MeOCH<sub>2</sub>COCl, DIPEA, THF/DCM, 0 °C.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23828" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23828" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Highly potent drugs are usually required for inhaled administration owing to the small doses that can be delivered conveniently, typically no more than a few hundred micrograms as a single dose. A long duration of action is also highly desirable to maintain therapeutic benefit, for example, during the night and to allow once daily dosing. In addition to these characteristics, low oral bioavailability (<5%) is an important advantageous property to minimize systemic availability and side effects. Slow dissolution and absorption through the lungs have also been implicated as desirable properties, and these attributes have recently been referred to as forming part of an “inhalation by design” strategy.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In view of the modest metabolizing potential of lung epithelium and the route administration, functional groups and molecular properties that might be considered detrimental for the development of an oral medicine were not necessarily excluded from consideration.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> Indeed, increasing the molecular complexity by the introduction of additional polar groups and hydrogen-bond donors was anticipated to modulate both solubility and permeability positively for our inhaled program.</div><div class="NLM_p">For this purpose, U937 cells were treated with phorbol myristate acetate (PMA) to evoke their differentiation into macrophages-like cells. Stimulation of the resulting cells (d-U937 cells) with lipopolysaccharide (LPS) induces the production of proinflammatory cytokines including TNFα and CXCL8. The potency of test compounds in this system was evaluated by the determination of both IC<sub>50</sub> values as well as their maximum inhibitory effect (<i>E</i><sub>max</sub>). This latter property was considered to be an important criterion that resulted from the inhibition of multiple targets and was therefore used to select compounds that displayed the kinase profile described above.</div><div class="NLM_p">Upon evaluation of potential alternative hinge binders in the pyrazole urea series in comparison to BIRB-796 (<b>4</b>), <b>5</b>–<b>8</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> demonstrated that p38 inhibition could be maintained. 4-Pyridyl analogue <b>8</b> was superior to its regioisomeric analogues <b>6</b> and <b>7</b> and to imidazole <b>5</b>, as the former maintained significant potency toward the γ isozyme and introduced reasonable potency against HCK. Additionally, compound <b>8</b> demonstrated moderate activity in d-U937 cells.</div><div class="NLM_table-wrap" id="tbl1">Table 1<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0005.gif" alt="" id="fx1" /></img><div></div></div><div class="NLM_p">We next focused on further modification of compound <b>8</b>; with the aim of promoting interactions with the peptide backbone of the kinase hinge, a number of heteroaryl amine, amide, and urea analogues were prepared (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_p">From public X-ray structures of BIRB-796 with p38 α (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a>.pdb) and atrial natriuretic peptide (ANP) with p38 γ (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1CM8">1CM8</a>.pdb), we identified a difference in the presentation of hydrogen-bonding residues to the ligand from the hinge region of the protein: BIRB-796 being monodentate in p38 α and ANP being bidentate in p38 γ. Inspection of other p38 α structures (e.g., <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FLN">3FLN</a>.pdb) showed that, when it is presented with a ligand with bidentate hydrogen-bonding capacity, p38 α is able to undergo a rotation of the hinge region to accommodate the extra hydrogen bond. This suggested that a bidentate hinge binder would be tolerated by p38 α and would yield stronger binding to p38 γ. It was also postulated that the firmer anchor of the bidentate hinge binding in p38 γ may help to promote the trapping of a DFG-out protein conformation, which was suspected to be required for a longer duration of action. An unintended consequence of this change to a bidentate ligand was to promote the inhibition of other kinases such as HCK, which was found to be beneficial to the overall cellular profile of the compounds (greater <i>E</i><sub>max</sub> for the inhibition of TNFα in U937 cells).</div><div class="NLM_p">Simple amines <b>9</b> and <b>10</b> maintained moderate activity toward the kinases of interest and displayed a promising increase in cellular potency. In addition, it was encouraging to see that the pyridine nucleus could be functionalized with such a synthetically useful and adaptable amino group. The corresponding acetamide derivatives <b>11</b> and <b>12</b> demonstrated similar p38 MAPK profiles as those of the amine precursors as well as a modest increase in activity at HCK. Of particular interest at this stage was the ability of ortho-substituted analogue <b>11</b> to inhibit the stimulated release of TNFα from d-U937 cells with an IC<sub>50</sub> value of <20 nM and with a high maximal activity.</div><div class="NLM_p">A consistent SAR trend in favor of the ortho-isomer was evident for the two methoxyacetamido-substituted pyridines, <b>13</b> and <b>14</b>. Although activity against the γ isoform of p38 MAPK remained weak, ortho-analogue <b>14</b> displayed an impressive cellular profile, especially against TNFα release, for which the IC<sub>50</sub> value was single-digit nanomolar. This compound was also the first from this chemotype to potently inhibit the release of CXCL8 from the differentiated, macrophage-like U937 cells.</div><div class="NLM_table-wrap" id="tbl2">Table 2<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0006.gif" alt="" id="fx3" /></img><div></div></div><div class="NLM_p">In contrast, “reverse” amides <b>15</b> and <b>16</b> retained activity against p38 MAPK α, failing to demonstrate any activity at the γ isoform or at HCK together with little activity at the cellular level. This data suggested that the disposition of the amidic carbonyl is of critical importance in determining the pharmacology of this compound series. Imidazole analogue <b>17</b> was also largely selective for the α isoform of p38 MAPK. Its cellular profile was comparable with that of 2-aminopyridine <b>9</b>, and consequently this chemotype was discounted from further study.</div><div class="NLM_p">The in vitro biology of the compounds, summarized in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, together with that of additional analogues (data not shown) revealed that 2-acylaminopyridine was a favored fragment that promoted inhibitory activity against the triad of isolated enzymes as well as potency in cellular systems. The data also indicated that p38 MAPK inhibitors with additional HCK kinase activity demonstrate an anti-inflammatory biological phenotype in a disease-relevant cell line.</div><div class="NLM_p">To assess the degree of CYP inhibition inherent in this series, 4-pyridyl derivative <b>8</b> was compared, against a standard isoform panel, with the corresponding 2- and 3-N-acylamino derivatives, <b>11</b> and <b>13</b>, respectively (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The former compound exhibited significant inhibitory activity, particularly against the enzyme CYP 3A4. This is most likely to arise from a direct interaction with the pyridyl nitrogen as a similar profile is evident for meta-substituted analogue <b>13</b>. In contrast, 2-acetamido derivative <b>11</b> displayed hardly any activity at either the CYP 2D6 or 3A4 isoform. The superior profile shown by <b>11</b> likely derives from the presence of the ortho substituent in the pyridine nucleus, which presumably disrupts the undesired interaction with the basic nitrogen.</div><div class="NLM_table-wrap" id="tbl3">Table 3<div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">Inhibition (%) of CYP 450 enzyme isoforms at 30 μM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">2C19</th><th class="colsep0 rowsep0" align="center">2D6</th><th class="colsep0 rowsep0" align="center">3A4</th><th class="colsep0 rowsep0" align="center">2C9</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BIRB-796</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">–23</td><td class="colsep0 rowsep0" align="left">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">37</td></tr></tbody></table></div></div><div class="NLM_p">Despite the encouraging efficacy results for acylaminopyridine <b>11</b>, a significant increase in potency in d-U937 cells was deemed to be necessary for such compounds to meet their intended product profile as inhaled medicines. We next studied shortening of the three-atom spacer between the naphthyl and pyridine groups (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Consistent with the early findings for these chemotypes, pyridine carboxamides <b>18</b> and <b>19</b> remained selective potent inhibitors of the p38 MAPK α isozyme while being, at best, weak inhibitors of p38 MAPK γ and HCK, and they did not reach maximum efficacy in cells. In contrast, the profiles of a series of functionalized 2-aminopyridines was markedly enhanced by the reduction in the chain length to a two-atom linker. For example, carbamate derivative <b>20</b> is a potent, dual p38 MAPK α/HCK inhibitor, and this is reflected by its superior potency in cells. Sulfonamide <b>21</b> has more modest but comparable activity at the γ isoform and HCK. Notable is the direct comparison of the in vitro profile of acetamide <b>22</b> and its higher homologue, compound <b>11</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). This reveals that the methoxy-linked compounds can possess good to excellent activity against the triad of isolated enzymes examined in this study and potently inhibit the inflammatory mediators TNFα and CXCL8 in differentiated macrophage-type cells. Equally gratifying was the observation that the maximal inhibitory values reached in these latter assay systems were ≥90%, which is a highly desirable property, postulated to be the result of simultaneous inhibition of the α and γ protein isoforms of p38 MAPK.</div><div class="NLM_table-wrap" id="tbl4">Table 4<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0007.gif" alt="" id="fx5" /></img><div></div></div><div class="NLM_p">The markedly superior pharmacological profile of N-sulfonyl and N-acyl 2-aminopyridines <b>21</b>–<b>23</b> provided the incentive to explore this particular compound class in more detail (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Results obtained for benzamide <b>24</b> and phenylacetamide <b>25</b> were both surprising and disappointing. Both compounds displayed in vitro profiles comparable to those of earlier structures, namely, inhibitory activity strongly in favor of the p38 MAPK α enzyme. While high potencies are preserved in the cellular system, the corresponding <i>E</i><sub>max</sub> values are less than or equal to 80% for these two compounds.</div><div class="NLM_p">Additional compound analogues revealed that a diversity of functional modification was well-tolerated and could be exploited to refine the biological phenotype. Tertiary amines <b>26</b> and <b>27</b> exhibited characteristics similar to those of earlier, favored analogues (<b>21</b>–<b>23</b>, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) and offer the opportunity to modulate global physicochemical parameters, including the possibility of salt formation and selection. Incorporation of a thioether, <b>28</b>, or a sulfone, <b>29</b>, was also tolerated as both exhibited the desired narrow spectrum kinase inhibitor (NSKI) activity and showed excellent potencies and efficacies in cells. These findings confirm that a broad range of functionality can be introduced at the β carbon of the acetamido group while maintaining the desired biological profile. Methoxyacetamide analogue <b>30</b> was found to be a highly active NSKI and to potently inhibit the release of inflammatory mediators in d-U937 cells. The poor activity of N-methylated analogue <b>31</b> supports the hypothesis that the N-acyl 2-aminopyridine pharmacophore operates in a donor/acceptor binding mode. Perturbation of this critical interaction has a negative impact on p38 MAPK γ and HCK kinase inhibition. This disruption often leads to a loss of the NSKI phenotypic profile and reduction in cellular efficacy.</div><div class="NLM_table-wrap" id="tbl5">Table 5<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0008.gif" alt="" id="fx7" /></img><div></div></div><div class="NLM_p">As reducing the linker length had such a profound enhancing effect on the pharmacological profile of N-acyl 2-aminopyridine series, additional modifications were investigated that would either perturb its conformation or shorten it further. Increasing steric constraints from monomethyl <b>32</b> (as a racemate) to gem-dimethyl analogue <b>33</b> gave a general decrease in isolated enzyme and cellular profile (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Further reduction to an ether or methane linker lead to a significant change in pharmacological profile, which is beyond the scope of this article.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_table-wrap" id="tbl6">Table 6<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0009.gif" alt="" id="fx9" /></img><div></div></div><div class="NLM_p">In view of its promising in vitro biology, methoxyacetamide <b>30</b> was selected for further profiling in an in vivo time course experiment to assess the compound’s duration of action against BIRB-796 (<a class="ref internalNav" href="#fig4" aria-label="Figure 2">Figure 2</a>). The test compound was dosed (at 0.2 mg mL<sup>–1</sup>) by intratracheal (it) administration to mice (<i>N</i> = 8). Following this event and after increasing intervals of time (the preincubation time) starting with a delay of 2 h, which was incrementally increased up to 18 hours, animals were challenged with an endotoxin (LPS) to evoke an inflammatory response in the lungs. An additional 8 h after the insult, each animal was sacrificed and bronchoalveolar lavage fluid (BALF) was collected. The number of neutrophils per milliliter of fluid was counted to determine the effectiveness of the potential drug.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Comparison of the effects of treatment with BIRB-796 or compound <b>30</b> on LPS-induced airway neutrophilia in mice. it = intratracheal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The decrease in the number of neutrophils at <i>t</i> = 2 h is an indication of an agent’s anti-inflammatory activity. The persistence of the observed effect as the delay (preincubation time) before administration of the challenge is increased indicates the compound’s duration of action. BIRB-796 and compound <b>30</b> initially show comparable anti-inflammatory effects in murine lung, but the therapeutic effect of BIRB-796 rapidly diminishes and has all but disappeared at 8 h post dose. By contrast, compound <b>30</b> retained a significant proportion of its initial activity out to the 12 hour time point, indicating a <i>t</i><sub>1/2</sub> in the region of 14 h and its likely suitability for once daily dosing in the clinic.</div><div class="NLM_p">It is interesting to compare the physiochemical properties of BIRB-796 and compound <b>30</b>. While they have similar lipophilicity (cLog P 6.87 vs 6.66), BIRB-796 has a more strongly basic center, which would be anticipated to lead to better solubility. Lung permeability may also be reduced by the additional H-bond present in compound <b>30</b> and its higher polar surface area (tPSA 78.43 vs 116.6).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> We postulate that these properties contribute to the excellent in vivo duration of action of compound <b>30</b>.</div><div class="NLM_p">Since the above pharmacodynamic screening method is sensitive to corticosteroid, compound <b>30</b> was next evaluated in an animal model of steroid-refractory inflammation.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Mice exposed repeatedly, over 11 days, to cigarette smoke (CS) develop pulmonary inflammation that is inert to treatment with fluticasone propionate (FP) (<a class="ref internalNav" href="#fig5" aria-label="Figure 3">Figure 3</a>). The two test substances were administered to mice intranasally at 40 μg mL<sup>–1</sup> (35 μL per mouse, <i>N</i> = 6) twice daily for 3 days following their exposure to cigarette smoke. The ineffectiveness of FP, when given at 50 μg mL<sup>–1</sup>, to reduce neutrophil influx into the lungs of the animals attests to the steroid insensitivity of the stimulated inflammatory response. It is particularly relevant that BIRB-796 demonstrated little or no effect on neutrophil accumulation when dosed intranasally at 40 μg mL<sup>–1</sup>. This result confirms that the compound is ineffective at controlling inflammatory processes that are untreatable with corticosteroids. However, when administered at the same dose, <b>30</b> brought about a dramatic reduction in the number of neutrophils recruited into mouse lung. These results support the hypothesis that a NSKI such as <b>30</b> is able to inhibit corticosteroid-refractory inflammation by exerting inhibitory activity on a predefined panel of therapeutically relevant kinases.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of treatment with either FP (A), BIRB-796 (A), or <b>30</b> (B) on tobacco smoke-induced airway neutrophilia in mice. in = intranasal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additional attributes of the drug substance <b>30</b> enhance its suitability as a prospective inhaled medicine. Separate studies (data not shown) reveal that the compound has an oral bioavailability of less than 5% and displays high plasma protein binding of >99%. When used at therapeutically relevant doses, these properties should ensure that systemic exposure will be very low, reducing the risk of side effects. Relevant physical properties of the compound were also investigated and are suitable for dry powder inhaled formulation, the intended method of use in the clinic. Compound <b>30</b> is currently undergoing clinical trials.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A series of functionalized 2-aminopyridines has been derived that potently inhibit both p38 and SRC family kinases. It has been demonstrated that these kinase inhibitors, such as acetamide <b>22</b>, urea <b>23</b>, thioether <b>28</b>, and sulfonyl derivative <b>29</b>, potently reduce the stimulated release of proinflammatory mediators from disease-relevant cells, with high maximal efficacy. As an example of this chemotype, methoxy acetamide <b>30</b> has been identified to demonstrate a long and advantageous duration of action in an in vivo pharmacodynamic model. The same compound is also highly effective at reversing cigarette smoke-induced inflammation in mice, showing that it is effective against a model of the disease state that is normally resistant to treatment with corticosteroids. It has been established that a diverse range of substituents, appended to a common pharmacophore, is compatible with the desired pharmacological profile. This permits the selection of compounds having physicochemical properties that are suitable for various pharmaceutical formulations including those used for dry powder inhalation.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Enzyme Inhibition Assays</h3><div class="NLM_p">The enzyme inhibitory activities of compounds disclosed herein were determined by FRET using synthetic peptides labeled with both donor and acceptor fluorophores (Z-LYTE, Invitrogen Ltd., Paisley, UK). Inhibitory activities against the p38 MAPK α isoform (MAPK14: Invitrogen) were evaluated indirectly by determining the level of activation/phosphorylation of the downstream molecule, MAPKAP-K2. The p38 MAPK α protein (80 ng mL<sup>–1</sup>, 2.5 μL in 2× kinase buffer provided in the kit) was mixed with the test compound (2.5 μL of either 4.000, 0.400, 0.040, or 0.004 μg mL<sup>–1</sup> in 4% DMSO in H<sub>2</sub>O) for 2 h at rt. The mix solution in 1× kinase buffer (2.5 μL) of the p38 α inactive target MAPKAP-K2 (Invitrogen, 600 ng mL<sup>–1</sup>) and FRET peptide (8.0 μM; a phosphorylation target for MAPKAP-K2) was then added, and the kinase reaction was initiated by adding ATP (40 μM, 2.5 μL in 1× kinase buffer). The mixture was incubated for 1 h at rt. Development reagent (protease diluted 1:100 in development buffer, 5.0 μL) was added 1 h prior to detection in a fluorescence microplate reader (Varioskan Flash, ThermoFisher Scientific).</div><div class="NLM_p">The inhibitory activities against p38 MAPK γ (MAPK12: Invitrogen) and HCK were evaluated in a similar fashion to that described above. The enzyme (800 ng mL<sup>–1</sup>, 2.5 μL in 2× kinase buffer) was incubated with the test compound (2.5 μL at either 4.000, 0.400, 0.040, or 0.004 μg mL<sup>–1</sup> in 4% DMSO in H<sub>2</sub>O) for 2 h at rt. The FRET peptides (8.0 μM, 2.5 μL in 1× kinase buffer) and the appropriate ATP solution (2.5 μL, 400 μM for p38 MAPK γ or 2.5 μL, 60 μM for HCK in 1× kinase buffer) were then added to the enzyme/compound mixtures and incubated for 1 h.</div><div class="NLM_p last">In all cases, the site-specific protease cleaves nonphosphorylated peptide only and eliminates the FRET signal. Phosphorylation levels of each reaction were calculated using the ratio of coumarin emission (donor) over fluorescein emission (acceptor), for which high ratios indicate low levels of phosphorylation and low ratios indicate high levels of phosphorylation. The percentage inhibition of each reaction was calculated relative to noninhibited control, compounds were tested in quadruplicate at each concentration, and the 50% inhibitory concentration (IC<sub>50</sub> value) was then calculated from the concentration–response curve.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> LPS-Induced TNFα/CXCL8 Release in d-U937 Cells</h3><div class="NLM_p last">U937 cells, a human monocytic cell line, suspended in 50 mL of 10% FBS RPMI-1640 media were incubated with 5.0 μL of PMA stock solution (1.0 mg mL<sup>–1</sup> in neat DMSO), resulting in a final PMA concentration of 100 ng mL<sup>–1</sup>, for 48 to 72 h and differentiated into macrophage-type cells. The resulting cells were incubated in 5% FBS RPMI-1640 media. The test compounds were prepared as 2.0 mg mL<sup>–1</sup> neat DMSO solution. The stock solutions were serially diluted in DMSO to be 200-fold desirable final concentrations. This allows the final DMSO concentration to be constant across the plate at 0.5%. The cells were then preincubated with the test compound in triplicate prepared above for 2 h and stimulated with 50 μL of LPS (1 mg mL<sup>–1</sup> in PBS) (from <i>E. coli</i>: O111:B4, Sigma) for 4 h. Thus, the final concentration of LPS was 0.1 μg mL<sup>–1</sup>. The supernatant was collected for determination of TNFα and CXCL8 concentrations by sandwich ELISA (DuoSet, R&D systems). The inhibition of TNFα and CXCL8 production was calculated at each concentration of test compound by comparison with vehicle control. The 50% inhibitory concentration (IC<sub>50</sub>) was determined from the resultant concentration–response curve.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> LPS-Induced Neutrophil Accumulation in Mice</h3><div class="NLM_p last">Nonfasted Balb/c mice were dosed by the intratracheal route with either 20 μL of vehicle (10% DMSO in isotonic saline) or the test substance at the indicated times (within the range 2–18 h) before stimulation of the inflammatory response by application of an LPS challenge. At <i>t</i> = 0, mice were placed into an exposure chamber and exposed to LPS (7.0 mL, 0.5 mg mL<sup>–1</sup> solution in PBS for 30 min). After a further 8 h, the animals were anesthetized, their tracheas were cannulated, and bronchoalveolar lavage fluid (BALF) was extracted by infusing and then withdrawing from their lungs 1.0 mL of PBS via the tracheal catheter. Total and differential white cell counts in the BALF samples were measured using a Neubaur hemocytometer. Cytospin smears of the BALF samples were prepared by centrifugation at 200 rpm for 5 min at rt and stained using a DiffQuik stain system (Dade Behring). Cells were counted using oil immersion microscopy. Data for the number of neutrophils in BAL are shown as mean ± SEM (standard error of the mean). The percentage inhibition of neutrophil accumulation was calculated for each treatment relative to vehicle treatment. This study was conducted at Pneumolabs UK Ltd. (London, UK).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Cigarette Smoke-Induced Inflammatory Accumulation in Mice</h3><div class="NLM_p last">A/J mice (males, 5 weeks old) were exposed to cigarette smoke (4% cigarette smoke, diluted with compressed air) for 30 min per day for 11 days using a tobacco smoke inhalation experiment system for small animals (model SIS-CS; Sibata Scientific Technology, Tokyo, Japan). Test substances were given intranasally (35 μL of solution in 50% DMSO in isotonic saline) and therapeutically twice daily for 3 days after the final cigarette smoke exposure. At 96 h after the last tobacco smoke exposure (meaning 12 h after the last dosing), animals were anesthetized, the trachea was cannulated, and BALF was collected as previously reported.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The procedure for this involved infusing at one-third of 20 mL/kg of PBS, leaving it in the airway for 10 s, and withdrawing infused PBS gradually at room temperature. This step was repeated three times in total. The BALF was then centrifuged (1200 rpm for 10 min at 4 °C), the supernatant was drawn off, and the resulting cell pellet was resuspended in 0.2% NaCl to induce hemolysis of erythrocytes. After isotonization with the same volume of 1.6% NaCl, the total BAL cells were counted. The percent population of alveolar macrophages and neutrophils was determined by FACS analysis (EPICS ALTRA II, Beckman Coulter, Inc., Fullerton, CA, USA) using anti-mouse MOMA2 antibody (macrophage) or anti-mouse 7/4 antibody (neutrophil), and the cell number was calculated with % population and total BAL cell number. This study was conducted at the Department of Physiology and Anatomy, Nihon University School of Pharmacy (Chiba, Japan).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p">All starting materials and solvents were obtained either from commercial sources or prepared according to the literature citation. Unless otherwise stated, all reactions were stirred magnetically. Organic solutions were routinely dried over anhydrous magnesium sulfate and filtered. Hydrogenations were performed on a ThalesNano H-cube flow reactor under the conditions stated. In the case of aniline products, these were analyzed by LC-MS and used directly without isolation.</div><div class="NLM_p last">Column chromatography was performed on prepacked silica cartridges (230–400 mesh, 40–63 μm) using the amount indicated. SCX resin was purchased from Supelco and treated with 1 M hydrochloric acid prior to use. Unless stated otherwise, the reaction mixture to be purified was first diluted with MeOH and then made acidic with a few drops of AcOH. The resulting solution was loaded directly onto a column packed with the SCX resin, which was washed with MeOH. The desired material was then eluted with 0.7 M NH<sub>3</sub> in MeOH. All <sup>1</sup>H NMR spectra were acquired on a Bruker Avance III spectrometer at 400 MHz using residual undeuterated solvent as reference and, unless specified otherwise, were run in DMSO-<i>d</i><sub>6</sub>. Test compounds were all >95% pure, as determined by HPLC and <sup>1</sup>H NMR except where indicated otherwise.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Preparative Reverse-Phase High-Performance Liquid Chromatography</h3><div class="NLM_p last">Agilent Scalar column C18, 5 μm (21.2 × 50 mm), flow rate 28 mL/min, eluting with a H<sub>2</sub>O–MeCN gradient containing 0.1% v/v formic acid over 10 min using UV detection at 215 and 254 nm. Gradient information: 0.0–0.5 min, 95% H<sub>2</sub>O–5% MeCN; 0.5–7.0 min, ramped from 95% H<sub>2</sub>O–5% MeCN to 5% H<sub>2</sub>O–95% MeCN; 7.0–7.9 min, held at 5% H<sub>2</sub>O–95% MeCN; 7.9–8.0 min, returned to 95% H<sub>2</sub>O–5% MeCN; 8.0–10.0 min, held at 95% H<sub>2</sub>O–5% MeCN.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Analytical Reverse-Phase High-Performance Liquid Chromatography-Mass Spectrometry</h3><div class="NLM_p last">Agilent Scalar column C18, 5 μm (4.6 × 50 mm), or Waters XBridge C18, 5 μm (4.6 × 50 mm), flow rate 2.5 mL/min, eluting with a H<sub>2</sub>O–MeCN gradient containing 0.1% v/v formic acid over 7 min employing UV detection at 215 and 254 nm. Gradient information: 0.0–0.1 min, 95% H<sub>2</sub>O–5% MeCN; 0.1–5.0 min, ramped from 95% H<sub>2</sub>O–5% MeCN to 5% H<sub>2</sub>O–95% MeCN; 5.0–5.5 min, held at 5% H<sub>2</sub>O–95% MeCN; 5.5–5.6 min, held at 5% H<sub>2</sub>O–95% MeCN, flow rate increased to 3.5 mL/min; 5.6–6.6 min, held at 5% H<sub>2</sub>O–95% MeCN, flow rate 3.5 mL/min; 6.6–6.75 min, returned to 95% H<sub>2</sub>O–5% MeCN, flow rate 3.5 mL/min; 6.75–6.9 min, held at 95% H<sub>2</sub>O–5% MeCN, flow rate 3.5 mL/min; 6.9–7.0 min, held at 95% H<sub>2</sub>O–5% MeCN, flow rate reduced to 2.5 mL/min.</div></div><div id="sec5_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>tert</i>-Butyl 4-(2-Hydroxyethyl)pyridin-2-ylcarbamate (<b>42</b>)</h3><div class="NLM_p last">To a solution of ethyl 2-(2-(<i>tert</i>-butoxycarbonylamino)pyridin-4-yl)acetate<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (10.0 g, 35.7 mmol) under nitrogen in THF (100 mL) at −78 °C was added a solution of DIBAL (1 M in THF, 71 mL, 71 mmol) over 1 h. The reaction mixture was stirred at −78 to −60 °C for 40 min and was then warmed to −15 °C over 1 h. The solution was recooled to −78 °C and was treated with additional DIBAL (1 M in THF, 36 mL, 36 mmol). The mixture was allowed to warm to −40 °C and was stirred for 1 h. Water (10 mL) was added cautiously to quench the reaction followed by MgSO<sub>4</sub> (20 g), and the solids were removed by filtration. The filtrate was concentrated to dryness in vacuo, and the residue was purified by flash column chromatography (SiO<sub>2</sub>, 330 g, EtOAc in isohexanes, 65%, isocratic elution) to give the title compound (<b>42</b>) as a yellow solid (6.00 g, 64%). LC-MS: <i>m</i>/<i>z</i> 239 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.47 (9H, s), 2.70 (2H, t), 3.62 (2H, m), 4.68 (1H, t), 6.88 (1H, dd), 7.67 (1H, m), 8.10 (1H, d), 9.61 (1H, s).</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>tert</i>-Butyl 4-(2-(4-Nitronaphthalen-1-yloxy)ethyl)pyridin-2-ylcarbamate (<b>46a</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(2-hydroxyethyl)pyridin-2-ylcarbamate (<b>42</b>) (6.00 g, 25.2 mmol) in THF (70 mL) was added sodium hydride (2.52 g, 60 wt % dispersion in mineral oil, 63.0 mmol) at 0 °C. The resulting bright yellow suspension was stirred for 20 min at 0 °C, and then 1-fluoro-4-nitronaphthalene (4.81 g, 25.2 mmol) was added in a single portion. The reaction mixture was warmed to rt for 2 h, and then water (100 mL) and EtOAc (100 mL) were added. An insoluble solid formed between the layers and was collected by filtration. The organic phase was separated and washed with saturated aq. NaHCO<sub>3</sub> (100 mL) and brine (100 mL) and then dried and evaporated in vacuo. The residue was combined with the collected solid and triturated with MeOH (50 mL) to afford the title compound (<b>46a</b>) as a yellow solid (11.9 g, 94%). LC-MS: <i>m</i>/<i>z</i> 410 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 3.20 (2H, t), 4.55 (2H, t), 7.08 (1H, d), 7.17 (1H, d), 7.63 (1H, m), 7.82 (1H, m), 7.91 (1H, bs), 8.16 (1H, dd), 8.32 (1H, m), 8.44 (1H, d), 8.58 (1H, dt), 9.68 (1H, bs).</div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>tert</i>-Butyl 4-(2-(4-Aminonaphthalen-1-yloxy)ethyl)pyridin-2-ylcarbamate (<b>47a</b>)</h3><div class="NLM_p last">A suspension of <i>tert</i>-butyl 4-(2-(4-nitronaphthalen-1-yloxy)ethyl)pyridin-2-ylcarbamate (<b>46a</b>) (5.20 g, 12.7 mmol) and iron mesh (4.30 g, 76.0 mmol) in a mixture of AcOH and EtOH (1:2 v/v, 120 mL) was placed in a preheated oil bath at 60 °C and stirred rapidly for 2 h. The mixture was cooled to rt, poured carefully onto saturated aq. NaHCO<sub>3</sub> (1 L), and extracted with EtOAc (2 × 500 mL). The combined organic extracts were washed with saturated aq. NaHCO<sub>3</sub> (1 L), water (1 L), and brine (1 L) and then dried and evaporated in vacuo to furnish the title compound (<b>47a</b>) as a yellow oil (5.00 g, 95%). LC-MS: <i>m</i>/<i>z</i> 380 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.92 (2H, t), 4.05 (2H, t), 4.97 (2H, bs), 6.40 (1H, d), 6.57 (1H, d), 6.86 (1H, dd), 7.18 (2H, overlapping m), 7.69 (1H, bs), 7.81 (2H, overlapping m), 7.96 (1H, d), 9.47 (1H, bs).</div></div><div id="sec5_7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 4-(2-((4-Nitronaphthalen-1-yl)oxy)ethyl)pyridin-3-amine (<b>46c</b>)</h3><div class="NLM_p last">To a solution of 4-nitronaphthol (0.95 g, 5.0 mmol), PPh<sub>3</sub> (1.97 g, 7.50 mmol), and 2-(3-aminopyridin-4-yl)ethanol<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (<b>45</b>) (1.04 g, 7.50 mmol) in THF (20 mL) at −15 °C was added DIAD (590 μL, 3.75 mmol) dropwise. The mixture was warmed to rt for 1 h and was then evaporated in vacuo. The residue was taken up in MeOH, evaporated onto silica (20 g), and purified by flash column chromatography (SiO<sub>2</sub>, 80 g, EtOAc in isohexane, 50–100%, gradient elution, then 5% MeOH in EtOAc, isocratic elution) to give the title compound (<b>46c</b>) as a yellow solid (1.40 g, 88%). LC-MS: <i>m</i>/<i>z</i> 310 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 3.14 (2H, t), 4.50 (2H, t), 5.31 (2H, bs), 7.10 (1H, d), 7.15 (1H, d), 7.68 (1H, m), 7.72 (1H, d), 7.81 (1H, m), 7.96 (1H, s), 8.32 (1H, dd), 4.43 (1H, d), 8.57 (1H, d).</div></div><div id="sec5_7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4-(2-((4-Aminonaphthalen-1-yl)oxy)ethyl)pyridin-3-amine (<b>47c</b>)</h3><div class="NLM_p last">A solution of 4-(2-((4-nitronaphthalen-1-yl)oxy)ethyl)pyridin-3-amine (<b>46c</b>) (700 mg, 2.26 mmol) in a mixture of MeOH (50 mL), EtOAc (25 mL), and DCM (25 mL) was passed through a ThalesNano H-cube (10% Pt/C, 30 mm, CatCart, 1.0 mL min<sup>–1</sup>, at 40 °C in full hydrogen mode). The volatiles were evaporated in vacuo to give the title compound (<b>47c</b>) as a brown solid (612 mg, 95%). LC-MS: <i>m</i>/<i>z</i> 280 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 3.02 (2H, t), 3.17 (2H, d), 4.21 (2H, t), 5.23 (2H, bs), 6.58 (1H, d), 6.75 (1H, d), 7.08 (1H, d), 7.38–7.41 (2H, overlapping m), 7.72 (1H, d), 7.95 (1H, s), 7.98–8.02 (2H, overlapping m).</div></div><div id="sec5_7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Methyl 4-(2-((4-Nitronaphthalen-1-yl)oxy)ethyl)picolinate (<b>46b</b>)</h3><div class="NLM_p last">To a solution of methyl 4-(2-hydroxyethyl)picolinate<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (<b>44</b>) (1.04 g, 5.74 mmol) in THF (10 mL) at 0 °C were added 4-nitronaphthalen-1-ol (0.72 g, 3.80 mmol), PPh<sub>3</sub> (1.31 g, 4.97 mmol), and DIAD (0.93 mL, 4.80 mmol). The reaction was warmed to rt for 18 h. The reaction mixture was diluted with EtOAc (100 mL), washed with saturated aq. NaHCO<sub>3</sub> (2 × 50 mL), and then dried and concentrated in vacuo. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 40 g, EtOAc in isohexane, 10–100%, gradient elution) followed by trituration from MeOH to give the title compound (<b>46b</b>) as a yellow solid (0.71 g, 53%). LC-MS: <i>m</i>/<i>z</i> 353 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR δ 3.38 (2H, t), 3.88 (3H, s), 4.65 (2H, t), 7.21 (1H, d), 7.67 (1H, td), 7.71 (1H, dd), 7.83 (1H, m), 8.16 (1H, s), 8.25 (1H, d), 8.45 (1H, d), 8.58 (1H, d), 8.67 (1H, dd).</div></div><div id="sec5_7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Methyl 4-(2-((4-Aminonaphthalen-1-yl)oxy)ethyl)picolinate (<b>47b</b>)</h3><div class="NLM_p last">A solution of methyl 4-(2-((4-nitronaphthalen-1-yl)oxy)ethyl)picolinate (<b>46b</b>) (1.2 g, 3.4 mmol) in a mixture of MeOH (60 mL) and DCM (20 mL) was passed through a ThalesNano H-cube (10% Pt/C 30 mm CatCart, 1.0 mL min<sup>–1</sup>, at rt, in full hydrogen mode). Evaporation of the volatiles in vacuo gave the title compound (<b>57b</b>) as a brown oil (1.10 g, 98%). LC-MS: <i>m</i>/<i>z</i> 323 (M + H)<sup>+</sup> (ES<sup>+</sup>).</div></div><div id="sec5_7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 4-(2-((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)picolinic Acid (<b>38</b>)</h3><div class="NLM_p">To a solution of CDI (0.85 g, 5.2 mmol) in DCM (1.0 mL) was added a solution of 3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-amine<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>34</b>) (1.20 g, 5.21 mmol) in DCM (2.0 mL) dropwise over 1 h. After an additional 2 h, a solution of methyl 4-(2-((4-aminonaphthalen-1-yl)oxy)ethyl)picolinate (<b>47b</b>) (1.12 g, 3.47 mmol) in DCM (3.0 mL) was added over 5 min. After an additional 2 h, the mixture was diluted with MeOH and was evaporated directly onto silica gel. The mixture was purified by flash column chromatography (SiO<sub>2</sub>, 80 g, EtOAc in isohexane, 30–100%, gradient elution) to give methyl 4-(2-((4-(3-(3-(<i>tert-</i>butyl)-1-(<i>p</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)picolinate (<b>49</b>) as a chalky solid (1.28 g, 63%). LC-MS: <i>m</i>/<i>z</i> 578 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR δ 1.25 (9H, s), 2.37 (3H, s), 3.30 (2H, t), 3.85 (3H, s), 4.43 (2H, t), 6.33 (1H, s), 6.97 (1H, d), 7.30–7.35 (2H, overlapping m), 7.40–7.45 (2H, overlapping m), 7.47 (1H, m), 7.55 (1H, m), 7.60 (1H, d), 7.70 (1H, dd), 7.87 (1H, d), 8.05 (1H, dd), 8.15 (1H, dd), 8.55 (1H, bs), 8.63 (1H, dd), 8.75 (1H, bs).</div><div class="NLM_p last">To a suspension of methyl ester (550 mg, 0.95 mmol), prepared above, in THF (10 mL) was added an aqueous solution of lithium hydroxide (1M, 1.90 mL, 1.90 mmol). After 15 min, AcOH (1.0 mL) was added and the reaction mixture was extracted into DCM. The combined organic extracts were washed with water and brine and then evaporated in vacuo to give the title compound (<b>38</b>) as a white solid (440 mg, 81%). LC-MS: <i>m</i>/<i>z</i> 564 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.30 (3H, s), 3.25 (2H, t), 4.37 (2H, t), 6.32 (1H, s), 6.93 (1H, d), 7.28–7.36 (3H, overlapping m), 7.38–7.48 (4H, overlapping m), 7.56 (1H, d), 7.87 (1H, d), 8.01 (1H, s), 8.03 (1H, d), 8.45 (1H, d), 9.17–9.23 (2H, overlapping m).</div></div><div id="sec5_7_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 1-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-3-(4-(2-(2-nitro-1<i>H</i>-imidazol-1-yl)ethoxy)naphthalen-1-yl)urea (<b>51</b>)</h3><div class="NLM_p last">A mixture of 1-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-3-(4-(2-iodoethoxy)naphthalen-1-yl)urea<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (<b>50</b>) (200 mg, 0.35 mmol), 2-nitroimidazole (44 mg, 0.39 mmol), and K<sub>2</sub>CO<sub>3</sub> (146 mg, 1.06 mmol) in DMF (2.0 mL) was heated at 50 °C for 3 h. The resulting mixture was cooled to rt, poured onto water, and extracted with EtOAc. The combined organic extracts were dried and evaporated in vacuo. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 12 g, EtOAc in isohexane, 10–80%, gradient elution) to give the title compound (<b>51</b>) as a yellow solid (41 mg, 21%). LC-MS: <i>m</i>/<i>z</i> 554 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.26 (9H, s), 2.37 (3H, s), 4.52 (2H, t), 4.96 (2H, t), 6.33 (1H, s), 6.93 (1H, d), 7.21 (1H, d), 7.32 (2H, m), 7.42 (2H, m), 7.46–7.57 (2H, overlapping m), 7.60 (1H, dd), 7.86–7.90 (2H, overlapping m), 8.07 (1H, dd), 8.55 (1H, bs), 8.75 (1H, bs).</div></div><div id="sec5_7_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Methyl 4-(((4-Nitronaphthalen-1-yl)oxy)methyl)picolinate (<b>54a</b>)</h3><div class="NLM_p last">To a mixture of methyl 4-(hydroxymethyl)picolinate (<b>52</b>) (374 mg, 2.06 mmol), 4-nitronaphthalen-1-ol (389 mg, 2.06 mmol), and PPh<sub>3</sub> (648 mg, 2.47 mmol) in THF (15 mL) at −50 °C was added DIAD (490 μL, 2.47 mmol) dropwise over 10 min. The resulting mixture was warmed to rt for 1.5 h, and then the volatiles were evaporated in vacuo. The residue was triturated with MeOH (8.0 mL) to give the title compound (<b>54a</b>) as a yellow solid (0.60 g, 82%). LC-MS: <i>m</i>/<i>z</i> 339 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 3.89 (3H, s), 5.65 (2H, s), 7.21 (1H, d), 7.75 (1H, m), 7.83–7.88 (2H, overlapping m), 8.22 (1H, d), 8.44–8.48 (2H, overlapping m), 8.59 (1H, d), 8.77 (1H, d).</div></div><div id="sec5_7_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Methyl 4-(((4-Aminonaphthalen-1-yl)oxy)methyl)picolinate (<b>56a</b>)</h3><div class="NLM_p last">A solution of methyl 4-(((4-nitronaphthalen-1-yl)oxy)methyl)picolinate (<b>54a</b>) (796 mg, 2.35 mmol) in a mixture of MeOH (150 mL) and DCM (150 mL) was passed through a ThalesNano H-cube (10% Pt/C, 30 mm, CatCart, 1.0 mL min<sup>–1</sup>, at rt in full hydrogen mode). The volatiles were evaporated in vacuo to give the title compound (<b>56a</b>) as a purple solid (710 mg, 88%, 90% purity). LC-MS: <i>m</i>/<i>z</i> 309 (M + H)<sup>+</sup> (ES<sup>+</sup>).</div></div><div id="sec5_7_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Methyl 4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)picolinate (<b>57</b>)</h3><div class="NLM_p last">A solution of 3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H-</i>pyrazol-5-amine<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>34</b>) (713 mg, 3.11 mmol) in DCM (3.0 mL) was added dropwise over 1 h to a suspension of CDI (504 mg, 3.11 mmol) in DCM (3.0 mL). The mixture was kept at rt for 2 h and was then treated dropwise with a solution of methyl 4-(((4-aminonaphthalen-1-yl)oxy)methyl)picolinate (<b>56a</b>) (366 mg, 1.41 mmol) in DCM (4.0 mL). After 30 min at rt, MeOH (20 mL) was added to the reaction mixture, which gave a precipitate. The mixture was reduced in volume to ca. 20 mL by evaporation in vacuo, and the precipitate was collected by filtration and washed with MeOH and diethyl ether to give the title compound (<b>57</b>) as a beige solid (0.92 g, 71%, 91% purity). LC-MS: <i>m</i>/<i>z</i> 564 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.39 (3H, s), 3.89 (3H, s), 5.47 (2H, s), 6.35 (1H, s), 7.01 (1H, d), 7.35 (2H, m), 7.43 (2H, m), 7.56–7.64 (3H, overlapping m), 7.81 (1H, dd), 7.93 (1H, m), 8.20 (1H, m), 8.31 (1H, m), 8.58 (1H, bs), 8.75 (1H, d), 8.79 (1H, bs).</div></div><div id="sec5_7_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)picolinic Acid (<b>39</b>)</h3><div class="NLM_p last">A suspension of methyl 4-(((4-(3-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)picolinate (<b>57</b>) (100 mg, 0.16 mmol) in a mixture of THF (3.0 mL) and water (2.0 mL) was treated with lithium hydroxide (17 mg, 0.71 mmol), and the mixture was maintained at rt for 3 h. Acetic acid (3.0 mL) was added, and the mixture was purified by SCX capture and release. The resultant solid was triturated with diethyl ether to afford the title compound (<b>39</b>) as a white solid (55 mg, 62%). LC-MS: <i>m</i>/<i>z</i> 550 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.35 (3H, s), 5.40 (3H, s), 6.31 (1H, s), 6.99 (1H, d), 7.31 (2H, m), 7.45 (2H, m), 7.53–7.60 (3H, overlapping m), 7.95 (1H, m), 8.05 (1H, s), 8.27 (1H, m), 8.55 (1H, d), 9.06 (1H, bs), 9.18 (1H, bs).</div></div><div id="sec5_7_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 2-Amino-4-((4-nitronaphthalen-1-yloxy)methyl)pyridine (<b>54b</b>)</h3><div class="NLM_p last">To a solution of 4-nitronaphthol (5.17 g, 27.3 mmol), PPh<sub>3</sub> (10.8 g, 41.0 mmol), and 2-aminopyridine-4-methanol (<b>53</b>) (5.09 g, 41.0 mmol) in THF (50 mL) at −15 °C was added DIAD (8.07 mL, 41.0 mmol) dropwise. The reaction mixture was warmed to rt for 18 h and was then evaporated in vacuo. The residue was triturated with EtOAc (150 mL), and the solids were collected by filtration and washed with EtOAc (100 mL). A second trituration with MeOH (100 mL) gave the title compound (<b>54b</b>) (4.54 g, 56%) as a yellow solid. LC-MS: <i>m</i>/<i>z</i> 296 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 5.35 (2H, s), 6.00 (2H, bs), 6.60 (2H, overlapping m), 7.15 (1H, d), 7.72 (1H, m), 7.85 (1H, m), 7.97 (1H, dd), 8.42 (2H, d), 8.60 (1H, d).</div></div><div id="sec5_7_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 2-Amino-4-((4-aminonaphthalen-1-yloxy)methyl)pyridine (<b>56b</b>)</h3><div class="NLM_p last">A solution of 2-amino-4-((4-nitronaphthalen-1-yloxy)methyl)pyridine (<b>54b</b>) (4.50 g, 15.24 mmol) in a mixture of MeOH (200 mL) and AcOH (200 mL) was passed through a ThalesNano H-cube (2.0 mL min<sup>–1</sup>, 40 °C, 55 mm, 10% Pt/C Cat-Cart, full hydrogen mode). The volatiles were removed in vacuo, and the crude product was subjected to SCX capture and release to give the title compound (<b>56b</b>) as a purple solid (3.82 g, 94%). LC-MS: <i>m</i>/<i>z</i> 266 (M + H)<sup>+</sup> (ES<sup>+</sup>).</div></div><div id="sec5_7_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-(4-((2-Aminopyridin-4-yl)methoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>37</b>)</h3><div class="NLM_p last">To a solution of CDI (4.18 g, 25.8 mmol) in DCM (15 mL) was added a solution of 3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-amine<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>34</b>) (5.91 g, 25.8 mmol) in DCM (15 mL) dropwise over 40 min. The resulting solution was stirred at rt for 1 h and was then added dropwise to a solution of 2-amino-4-((4-aminonaphthalen-1-yloxy)methyl)pyridine (<b>56b</b>) (3.80 g, 12.9 mmol) in DCM (25 mL). The mixture was maintained at rt for 18 h. The volatiles were removed in vacuo, and the crude product was purified by flash column chromatography (SiO<sub>2</sub>, 120 g, MeOH in EtOAc, 0–6%, gradient elution) to give the title compound (<b>37</b>) as an off-white solid (4.27 g, 63%). LC-MS: <i>m</i>/<i>z</i> 521 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.24 (9H, s), 2.38 (3H, s), 5.17 (2H, s), 5.95 (2H, bs), 6.35 (1H, s), 6.58–6.63 (2H, overlapping), 6.97 (1H, d), 7.35 (2H, m), 7.43 (2H, m), 7.54–7.63 (3H, overlapping m), 7.88–7.93 (2H, overlapping m), 8.30 (1H, dd), 8.57 (1H, bs), 8.77 (1H, bs).</div></div><div id="sec5_7_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(4-((4-(3-(3-<i>tert</i>-Butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl) pyridin-2-yl)-2-chloroacetamide (<b>36</b>)</h3><div class="NLM_p last">To a solution of 1-(4-((2-aminopyridin-4-yl)methoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>37</b>) (2.00 g, 3.84 mmol) in a mixture of DCM (40 mL) and DMF (8.0 mL) were added DIPEA (1.37 mL, 7.68 mmol) and chloroacetyl chloride (0.61 mL, 7.70 mmol). The reaction mixture was maintained at rt for 1 h and was then treated with a second aliquot of chloracetyl chloride (100 μL, 1.25 mmol). After 1 h at rt, the resulting mixture was partitioned between DCM (40 mL) and saturated aq. NaHCO<sub>3</sub> (40 mL). The organic phase was separated and concentrated in vacuo. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 80 g, MeOH in DCM, 0–10%, gradient elution). The crude product so obtained was triturated with a mixture of diethyl ether (20 mL) and isohexane (20 mL) to afford the title compound (<b>36</b>) as a light purple solid (1.07 g, 42%). LC-MS: <i>m</i>/<i>z</i> 597, 599 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.38 (3H, s), 4.35 (2H, s), 5.38 (2H, s), 6.35 (1H, s), 7.00 (1H, d), 7.29 (1H, dd), 7.35 (2H, m), 7.43 (2H, m), 7.55–7.63 (3H, overlapping m), 7.92 (1H, m), 8.28–8.34 (2H, overlapping m), 8.36 (1H, dd), 8.57 (1H, bs), 8.78 (1H, bs), 10.85 (1H, bs).</div></div><div id="sec5_7_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-Methoxy-<i>N</i>-(4-(((4-nitronaphthalen-1-yl)oxy)methyl)pyridin-2-yl)acetamide (<b>55a</b>)</h3><div class="NLM_p last">To a suspension of 2-amino-4-((4-nitronaphthalen-1-yloxy)methyl)pyridine (<b>54b</b>) (20.0 g, 68.0 mmol) in a mixture of DCM (100 mL) and THF (150 mL) at −5 °C was added DIPEA (17.7 mL, 102 mmol) followed by methoxyacetyl chloride (8.1 mL, 88 mmol) dropwise over 10 min. After 10 min, the reaction mixture was warmed to rt for an additional 30 min and was then treated with methanolic NH<sub>3</sub> (7 M, 30 mL). After 1 h, the volatiles were removed by evaporation in vacuo, and the residue was triturated with water (500 mL). The solids were collected by filtration and washed with water (300 mL) and diethyl ether (500 mL) to give the title compound (<b>55a</b>) as a yellow solid (24.0 g, 95%). LC-MS: <i>m</i>/<i>z</i> 368 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 3.37 (3H, s), 4.07 (2H, s), 5.57 (2H, s), 7.21 (1H, s), 7.30 (2H, dd), 7.75 (1H, m), 7.85 (1H, m), 8.32 (1H, s), 8.36 (1H, d), 8.44–8.47 (2H, overlapping m), 8.59 (1H, d), 10.10 (1H, bs).</div></div><div id="sec5_7_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 2-Methoxy-<i>N</i>-methyl-<i>N</i>-(4-(((4-nitronaphthalen-1-yl)oxy)methyl)pyridin-2-yl)acetamide (<b>55b</b>)</h3><div class="NLM_p last">To a solution of 2-methoxy-<i>N</i>-(4-(((4-nitronaphthalen-1-yl)oxy)methyl)pyridin-2-yl)acetamide (<b>55a</b>) (300 mg, 0.82 mmol) in THF at 0 °C was added sodium hydride (74 mg, 60 wt % dispersion in mineral oil, 1.20 mmol). After 30 min at rt, the mixture was treated with iodomethane (76 μL, 1.22 mmol), kept at rt for 1 h, and then heated at 50 °C. An additional aliquot of iodomethane (380 μL, 6.10 mmol) was added. After 1 h at 50 °C, the reaction mixture was cooled to rt and was poured into water. The mixture was extracted with EtOAc. The organic layer was separated and evaporated in vacuo. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 40 g, EtOAc in isohexane, 0–100%, gradient elution then MeOH in EtOAc, 0–10%, gradient elution) to furnish the title compound (<b>55b</b>) as a yellow solid (155 mg, 49%). LC-MS: <i>m</i>/<i>z</i> 382 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.40 (3H, s), 3.45 (3H, s), 4.24 (2H, s), 5.40 (2H, s), 6.85 (2H, d), 7.32 (1H, dd), 7.58 (1H, bs), 7.67 (1H, m), 7.80 (1H, m), 8.37 (1H, d), 8.46 (1H, dq), 8.51 (1H, dd), 8.78 (1H, d).</div></div><div id="sec5_7_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(4-(((4-Aminonaphthalen-1-yl)oxy)methyl)pyridin-2-yl)-2-methoxy-<i>N</i>-methylacetamide (<b>35</b>)</h3><div class="NLM_p last">The title compound was obtained in a similar manner as that for <b>56b</b> to provide <b>37</b> as a purple solid (130 mg, 90%). LC-MS: <i>m</i>/<i>z</i> 352 (M + H)<sup>+</sup> (ES<sup>+</sup>).</div></div><div id="sec5_7_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-(2-Aminopyridin-4-yl)ethanone (<b>58</b>)</h3><div class="NLM_p last">To a stirred solution of methyl-2-aminopyridine-4-carboxylate (1.00 g, 6.57 mmol) in THF (100 mL) at −78 °C under nitrogen was added methyllithium (1.6 M in diethyl ether, 16.4 mL, 26.3 mmol) over 10 min. After a further 30 min at −78 °C, the viscous reaction mixture was warmed to 0 °C. After a further 3 h, the reaction was quenched at 0 °C by the cautious addition of isopropanol (8.0 mL). The mixture was warmed to rt. Brine (200 mL) and EtOAc (150 mL) were added, and the layers were separated. The aqueous layer was extracted with EtOAc (3 × 100 mL). The combined organic extracts were dried, and the solvents were removed in vacuo. The crude residue was purified by column chromatography (SiO<sub>2</sub>, 80 g, MeOH in EtOAc, 0–8%, gradient elution) to give 1-(2-aminopyridin-4-yl)ethanone (<b>58</b>) as a yellow powder (176 mg, 20%). LC-MS: <i>m</i>/<i>z</i> 137 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR (MeOH-<i>d</i><sub>4</sub>): δ 2.54 (3H, s), 7.01 (1H, dd), 7.03 (1H, m), 8.03 (1H, dd).</div></div><div id="sec5_7_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2-(2-Aminopyridin-4-yl)propan-2-ol (<b>59a</b>)</h3><div class="NLM_p last">To a stirred solution of methyl-2-aminopyridine-4-carboxylate (2.00 g, 13.0 mmol) in THF (200 mL) at −78 °C under nitrogen was added methyllithium (1.6 M in diethyl ether, 33 mL, 53.0 mmol) over 10 min. After 30 min, the viscous reaction mixture was warmed to 0 °C for 3.5 h and was quenched at 0 °C by the cautious addition of isopropanol (15 mL). The mixture was warmed to rt, and brine (400 mL) and EtOAc (300 mL) were added. The aqueous layer was separated and extracted with EtOAc (3 × 200 mL). The combined organic extracts were evaporated in vacuo. The crude residue was purified by flash column chromatography (SiO<sub>2</sub>, 120 g, MeOH in EtOAc, 0–10%, gradient elution) to afford the title compound (<b>59a</b>) (1.27 g, 63%) as a yellow amorphous solid. <sup>1</sup>H NMR (MeOH-<i>d</i><sub>4</sub>): δ 1.47 (6H, s), 6.68–6.71 (2H, overlapping m), 7.80–7.81 (1H, dd).</div></div><div id="sec5_7_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-(2-(4-Nitronaphthalen-1-yloxy)propan-2-yl)pyridin-2-amine (<b>60a</b>)</h3><div class="NLM_p last">To a stirred solution of 2-(2-aminopyridin-4-yl)propan-2-ol (<b>59a</b>) (1.55 g, 10.0 mmol) in DMF (30 mL) under nitrogen at 0 °C was added sodium hydride (60 wt %, 0.61 g, 15.0 mmol). The resulting mixture was stirred at 0 °C for 5 min. A solution of 1-fluoro-4-nitronaphthalene (1.95 g, 10.0 mmol) in DMF (30 mL) was added dropwise, and the resulting dark-red mixture was stirred at 0 °C for a further 5 min and then at rt for 2 h. The reaction mixture was quenched by the addition of a saturated aq. NH<sub>4</sub>Cl solution (10 mL). Water (150 mL) and EtOAc (150 mL) were added, and the aqueous layer was separated and extracted with EtOAc (3 × 100 mL). The combined organic extracts were washed with brine, dried, and evaporated in vacuo. The crude residue was purified by column chromatography (SiO<sub>2</sub>, 80 g, EtOAc in isohexane, 0–60%, gradient elution) to afford the title compound (<b>60a</b>) (282 mg, 8%) as a red oil. LC-MS <i>m</i>/<i>z</i> 324 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.52 (6H, s), 5.92 (2H, br s), 6.45 (1H, s), 6.55 (1H, dd), 6.93 (1H, d), 7.75 (1H, m), 7.84–7.90 (2H, overlapping m), 8.35 (1H, d), 8.49 (1H, dd), 8.58 (1H, d).</div></div><div id="sec5_7_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-(2-(4-Aminonaphthalen-1-yloxy)propan-2-yl)pyridin-2-amine (<b>61a</b>)</h3><div class="NLM_p last">A solution of 4-(2-(4-nitronaphthalen-1-yloxy)propan-2-yl)pyridin-2-amine (<b>60a</b>) (282 mg, 0.87 mmol) in MeOH (45 mL) was passed through a ThalesNano H-cube (1.0 mL min<sup>–1</sup>, 30 °C, 55 mm 10% Pt/C Cat-Cart, full hydrogen mode). The reaction mixture was evaporated in vacuo to afford the title compound (<b>61a</b>) (253 mg, 89%) as a brown foam. LC-MS <i>m</i>/<i>z</i> 294 (M + H)<sup>+</sup> (ES<sup>+</sup>).</div></div><div id="sec5_7_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-(4-(2-(2-Aminopyridin-4-yl)propan-2-yloxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>40</b>)</h3><div class="NLM_p last">A solution of 3-(<i>tert</i>-butyl)-5-isocyanato-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazole (see compound <b>10</b>) (447 mg, 1.75 mmol) in THF (15 mL) was added to a solution of 4-(2-(4-aminonaphthalen-1-yloxy)propan-2-yl)pyridin-2-amine (<b>61a</b>) (253 mg, 0.86 mmol) in THF (2.0 mL). DIPEA (451 μL, 2.59 mmol) was added, and the reaction mixture was stirred at rt for 2 h. Water (30 mL) and EtOAc (20 mL) were added, and the aqueous layer was separated and extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine (40 mL) and evaporated in vacuo. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 40 g, MeOH in DCM, 0–10%, gradient elution) to afford the title compound (<b>40</b>) (249 mg, 51%) as a purple amorphous solid. LC-MS: <i>m</i>/<i>z</i> 549 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 1.37 (6H, s), 2.38 (3H, s), 6.37 (1H, s), 6.97 (1H, dd), 7.36 (2H, m), 7.45 (2H, m), 7.47–7.55 (2H, overlapping m), 7.72 (2H, m), 7.92 (1H, d), 7.97 (1H, dd), 8.12 (1H, dd), 8.66–8.71 (2H, overlapping m), 8.93 (1H, bs).</div></div><div id="sec5_7_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 1-(2-Aminopyridin-4-yl)ethanol (<b>59b</b>)</h3><div class="NLM_p last">To a mixture of 1-(2-aminopyridin-4-yl)ethanone (<b>58</b>) (168 mg, 1.23 mmol) in MeOH (10 mL) under nitrogen at 0 °C was added sodium borohydride (47 mg, 1.23 mmol). The resulting reaction mixture was stirred at rt for 2 h, and then the solvents were removed in vacuo. The residue was taken up into EtOAc (25 mL) and washed with a saturated aq. NaHCO<sub>3</sub> solution (30 mL), and the layers were separated. The aqueous layer was extracted with EtOAc (2 × 20 mL). The combined organic extracts were washed with brine (30 mL) and dried, and the solvents were removed in vacuo to give 1-(2-aminopyridin-4-yl)ethanol (<b>59b</b>) (77 mg, 45%) as a yellow oil. LC-MS: <i>m</i>/<i>z</i> 139 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.23 (3H, d), 4.50 (1H, m), 5.13 (1H, d), 5.75 (2H, br s), 6.40–6.43 (2H, overlapping m), 7.78 (1H, d).</div></div><div id="sec5_7_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-(1-(4-Nitronaphthalen-1-yloxy)ethyl)pyridin-2-amine (<b>60b</b>)</h3><div class="NLM_p last">To a stirred solution of 1-(2-aminopyridin-4-yl)ethanol (<b>59b</b>) (73 mg, 0.53 mmol) in DMF (1.5 mL) under nitrogen at 0 °C was added sodium hydride (32 mg, 0.79 mmol, 60 wt % in mineral oil). The resulting mixture was stirred at 0 °C for 40 min before a solution of 1-fluoro-4-nitronaphthalene (101 mg, 0.53 mmol) in DMF (1.5 mL) was added dropwise. The resulting dark-red mixture was stirred at 0 °C for a further 5 min and warmed to rt. After a further 40 min, the reaction was quenched by the addition of a saturated aq. NH<sub>4</sub>Cl solution (1.0 mL). Water (20 mL) and EtOAc (20 mL) were added, and the aqueous layer was separated and extracted with EtOAc (3 × 15 mL). The combined organic extracts were washed with brine and dried, and the solvents were removed in vacuo. The crude material was purified by column chromatography (SiO<sub>2</sub>, 12 g, EtOAc in isohexane, 0–80%, gradient elution) to give 4-(1-(4-nitronaphthalen-1-yloxy)ethyl)pyridin-2-amine (<b>60b</b>) (94.6 mg, 57%) as an orange gum. LC-MS: <i>m</i>/<i>z</i> 310 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.69 (3H, d), 5.75 (1H, q), 5.93 (2H, bs), 6.45 (1H, s), 6.55 (1H, dd), 6.93 (1H, d), 7.75 (1H, m), 7.84–7.89 (2H, overlapping m), 8.35 (1H, d), 8.50 (1H, dd), 8.58 (1H, d).</div></div><div id="sec5_7_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-(1-(4-Aminonaphthalen-1-yloxy)ethyl)pyridin-2-amine (<b>61b</b>)</h3><div class="NLM_p last">4-(1-(4-Nitronaphthalen-1-yloxy)ethyl)pyridin-2-amine (<b>60b</b>) (91 mg, 0.29 mmol) in MeOH (15 mL) and AcOH (3.0 mL) was passed through a ThalesNano H-cube (1.0 mL min<sup>–1</sup>, 30 °C, 55 mm 10% Pt/C Cat-Cart, full hydrogen mode). The volatiles were removed in vacuo, and the residue was subjected to SCX capture and release to give 4-(1-(4-aminonaphthalen-1-yloxy)ethyl)pyridin-2-amine (<b>61b</b>) (81 mg, 99%) as a purple oil. LC-MS: <i>m</i>/<i>z</i> 280 (M + H)<sup>+</sup> (ES<sup>+</sup>).</div></div><div id="sec5_7_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 1-(4-(1-(2-Aminopyridin-4-yl)ethoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>41</b>)</h3><div class="NLM_p last">The title compound was prepared in a similar manner as that for <b>40</b> from 4-(1-(4-aminonaphthalen-1-yloxy)ethyl)pyridin-2-amine (<b>61b</b>) to give <b>41</b> as a beige powder (63 mg, 38%). LC-MS: <i>m</i>/<i>z</i> 535 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.24 (9H, s), 1.63 (3H, d), 2.37 (3H, s), 5.50 (1H, q), 5.80 (2H, bs), 6.31 (1H, s), 6.48 (1H, s), 6.55 (1H, dd), 6.75 (1H, d), 7.34 (2H, m), 7.42 (2H, m), 7.47 (1H, d), 7.55 (1H, m), 7.82 (1H, dd), 7.87 (1H, m), 8.32 (1H, m), 8.60 (1H, bs), 8.76 (1H, bs).</div></div><div id="sec5_7_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 1-(4-(2-(2-Aminopyridin-4-yl)ethoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>9</b>)</h3><div class="NLM_p">To a suspension of CDI (3.00 g, 18.2 mmol) in DCM (15 mL) was added a solution of 3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-amine<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>34</b>) (4.17 g, 18.2 mmol) in DCM (40 mL) over 1.5 h. After 2 h at rt, a solution of <i>tert</i>-butyl 4-(2-(4-aminonaphthalen-1-yloxy)ethyl)pyridin-2-ylcarbamate (<b>48a</b>) (3.00 g, 7.91 mmol) in DCM (15 mL) was added. After 18 h, the solution was diluted with MeOH (10 mL), evaporated onto silica gel (30 g), and subjected to column chromatography (SiO<sub>2</sub>, 330 g, EtOAc in isohexane, 30–100%, gradient elution then MeOH in EtOAc, 0–6%, gradient elution) to give <i>tert</i>-butyl (4-(2-((4-(3-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)pyridin-2-yl)carbamate as a beige solid (4.2 g, 80%).</div><div class="NLM_p last">A portion of the above material (1.35 g, 2.20 mmol) was suspended in DCM (10 mL) and was treated with TFA (10 mL). The reaction mixture was kept at rt for 2 h and was then evaporated in vacuo. The residue was taken up in EtOAc (50 mL), washed with saturated aq. NaHCO<sub>3</sub> (50 mL) and brine (50 mL), and then dried and evaporated in vacuo to give the title compound (<b>9</b>) as a pale pink solid (1.20 g, 80% over two steps). LC-MS: <i>m</i>/<i>z</i> 535 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.26 (9H, s), 2.37 (3H, s), 3.00 (2H, t), 4.32 (2H, t), 5.80 (2H, s), 6.34 (1H, s), 6.45 (1H, s), 6.52 (1H, dd), 6.95 (1H, d), 7.32–7.36 (2H, overlapping m), 7.40–7.45 (2H, overlapping m), 7.50–7.55 (2H, overlapping m), 7.60 (1H, d), 7.81 (1H, dd), 7.87 (1H, m), 8.11 (1H, dd), 8.54 (1H, s), 8.74 (1H, s).</div></div><div id="sec5_7_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 1-(4-(2-(3-Aminopyridin-4-yl)ethoxy)naphthalen-1-yl)-3-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)urea (<b>10</b>)</h3><div class="NLM_p">To a solution of 3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-amine<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>34</b>) (1.00 g, 4.36 mmol) in DCM (90 mL) was added a saturated aq. NaHCO<sub>3</sub> solution (60 mL). The heterogeneous mixture was stirred vigorously at 0 °C, treated with diphosgene (2.10 mL, 17.4 mmol) in a single portion, and then warmed to rt for 1 h. The organic layer was separated, dried, and evaporated in vacuo to give a brown oil, which was triturated from isohexane (5.0 mL) and filtered. The filtrate was concentrated in vacuo to give 3-<i>tert-</i>butyl-5-isocyanato-1-<i>p</i>-tolyl-1<i>H</i>-pyrazole as a light brown oil (1.00 g, 3.92 mmol, 90%). LC-MS: <i>m</i>/<i>z</i> 288 (in MeOH) (M + H+MeOH)<sup>+</sup> (ES<sup>+</sup>).</div><div class="NLM_p last">A solution of 3-<i>tert-</i>butyl-5-isocyanato-1-<i>p</i>-tolyl-1<i>H</i>-pyrazole (530 mg, 2.10 mmol) in THF (2.0 mL) was added to a solution of 4-(2-(4-aminonaphthalen-1-yloxy)ethyl)pyridin-3-amine (<b>47c</b>) (580 mg, 2.10 mmol) and DIPEA (1.1 mL, 6.20 mmol) in a mixture of THF (10 mL) and MeCN (1.0 mL). The reaction mixture was stirred at rt for 18 h, poured into brine (25 mL), and extracted with EtOAc (2 × 25 mL). The combined organics were dried, and the volatiles were removed in vacuo. The residue was taken up in MeOH, evaporated onto Hyflo Super Cel (10 g), and purified by reverse-phase flash column chromatography (C18 reverse-phase silica gel, 40 g, MeCN in H<sub>2</sub>O, 0–100%, gradient elution) to afford the title compound (<b>10</b>) as an off-white solid (410 mg, 36%). LC-MS: <i>m</i>/<i>z</i> 535 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.26 (9H, s), 2.38 (3H, s), 3.06 (2H, t), 4.34 (2H, t), 5.25 (2H, bs), 6.34 (1H, s), 6.95 (1H, d), 7.07 (1H, d), 7.35 (2H, m), 7.42 (2H, m), 7.45–7.57 (2H, overlapping m), 7.60 (1H, d), 7.71 (1H, dd), 7.87 (2H, d), 7.95 (1H, s), 8.15 (1H, dd), 8.55 (1H, bs), 8.75 (1H, bs).</div></div><div id="sec5_7_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(4-(2-((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)pyridin-2-yl)acetamide (<b>11</b>)</h3><div class="NLM_p last">The title compound was prepared using the process described to make <b>14</b> by replacing methoxyacetyl chloride with acetyl chloride to give <b>11</b> as a white solid (41 mg, 77%). LC-MS: <i>m</i>/<i>z</i> 577 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.26 (9H, s), 2.08 (3H, m), 2.38 (3H, s), 3.20 (2H, t), 4.37 (2H, t), 6.34 (1H, s), 6.95 (1H, d), 7.15 (1H, dd), 7.35 (2H, m), 7.40–7.50 (3H, overlapping m), 7.55 (1H, m), 7.60 (1H, m), 7.90 (1H, d), 8.15–8.23 (3H, overlapping m), 8.57 (1H, s), 8.77 (1H, bs), 10.40 (1H, s).</div></div><div id="sec5_7_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-(4-(2-((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)pyridin-3-yl)acetamide (<b>12</b>)</h3><div class="NLM_p last">The title compound was prepared in the same manner as that for <b>14</b> from 1-(4-(2-(3-aminopyridin-4-yl)ethoxy)naphthalen-1-yl)-3-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)urea (<b>10</b>) as the amine substrate by reaction with acetyl chloride to provide <b>12</b> as a white solid (20 mg, 46%). LC-MS: <i>m</i>/<i>z</i> 577 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.24 (9H, s), 2.10 (3H, s), 2.38 (3H, s), 3.20 (2H, t), 4.38 (2H, t), 6.34 (1H, s), 6.95 (1H, d), 7.35 (2H, m), 7.42 (2H, m), 7.45–7.50 (2H, overlapping m), 7.55 (1H, m), 7.61 (1H, d), 7.87 (1H, d), 8.07 (1H, dd), 8.31 (1H, d), 8.52–8.56 (2H, overlapping m), 8.75 (1H, bs).</div></div><div id="sec5_7_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(4-(2-((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl) pyridin-3-yl)-2-methoxyacetamide (<b>13</b>)</h3><div class="NLM_p last">The title compound was prepared in the same manner as that for <b>12</b> from <b>10</b> by reaction with methoxyacetyl chloride to provide <b>13</b> as a pale pink solid (45 mg, 77%). LC-MS: <i>m</i>/<i>z</i> 607 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.38 (3H, s), 3.16 (3H, s), 4.07 (2H, s), 4.37 (2H, t), 6.34 (1H, s), 6.95 (2H, s), 7.33 (2H, m), 7.43 (2H, m), 7.46–7.55 (3H, overlapping m), 7.60 (1H, d), 7.88 (1H, d), 8.07 (1H, dd), 8.35 (1H, d), 8.51 (1H, s), 8.55 (1H, bs), 8.75 (1H, bs), 9.65 (1H, bs).</div></div><div id="sec5_7_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(4-(2-(4-(3-(3-<i>tert</i>-Butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy)ethyl)pyridin-2-yl)-2-methoxyacetamide (<b>14</b>)</h3><div class="NLM_p last">To a suspension of 1-(4-(2-(2-aminopyridin-4-yl)ethoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>9</b>) (35 mg, 0.07 mmol) in DCM (0.5 mL) were added DIPEA (23 μL, 0.13 mmol) and methoxyacetyl chloride (7.0 μL, 0.07 mmol). The mixture was maintained at rt for 2 h and was then diluted with saturated aq. NaHCO<sub>3</sub> (1.5 mL). The organic layer was collected and evaporated in vacuo, and the residue was subjected to SCX capture and release. The resulting crude product was purified by preparative RP HPLC to give the title compound (<b>14</b>) as a white solid (5 mg, 13%). LC-MS: <i>m</i>/<i>z</i> 607 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.26 (9H, s), 2.37 (3H, s), 3.20 (2H, t), 3.37 (3H, s), 4.06 (2H, s), 4.38 (2H, t), 6.33 (1H, s), 6.95 (1H, d), 7.19 (1H, dd), 7.33 (2H, m), 7.42–7.47 (3H, overlapping m), 7.54 (1H, m), 7.59 (1H, d), 7.87 (1H, d), 8.12 (1H, d), 8.18 (1H, bs), 8.23 (1H, d), 8.67 (1H, s), 8.84 (1H, s), 9.89 (1H, s).</div></div><div id="sec5_7_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 4-(2-((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)-<i>N</i>-methylpicolinamide (<b>15</b>)</h3><div class="NLM_p last">To a mixture of 4-(2-((4-(3-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)picolinic acid (<b>38</b>) (100 mg, 0.18 mmol), HOBt (36 mg, 0.27 mmol), and EDC (51 mg, 0.27 mmol) in THF was added methylamine (2 M in THF, 890 μL, 1.8 mmol). The reaction was maintained at 45 °C for 2 h and then at rt for 18 h. The resulting mixture was diluted with saturated aq. NaHCO<sub>3</sub> and extracted with DCM. The organic extracts were evaporated in vacuo, and the residue was purified by flash column chromatography (SiO<sub>2</sub>, 12 g, MeOH in DCM, 0–5%, gradient elution) to provide the title compound (<b>16</b>) (24 mg, 24%). LC-MS: <i>m</i>/<i>z</i> 577 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.37 (3H, s), 2.80 (3H, d), 3.30 (2H, obscured by DOH), 4.41 (2H, t), 6.32 (1H, s), 6.97 (1H, d), 7.32 (2H, m), 7.42 (2H, m), 7.46 (1H, m), 7.54 (1H, m), 7.60 (2H, d), 7.63 (1H, dd), 7.87 (1H, d), 8.05 (1H, dd), 8.10 (1H, d), 8.53–8.57 (2H, overlapping m), 8.70–8.76 (2H, overlapping m).</div></div><div id="sec5_7_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 4-(2-((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)-<i>N</i>-(2-methoxyethyl)picolinamide (<b>16</b>)</h3><div class="NLM_p last">The title compound was prepared by a similar procedure as that used for <b>15</b> by substituting methylamine with 2-methoxyethanamine to give <b>16</b> (58 mg, 53%). LC-MS: <i>m</i>/<i>z</i> 621 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.38 (3H, s), 3.25 (3H, s), 3.30 (2H, obscured by DOH), 3.45–3.48 (4H, overlapping m), 4.42 (2H, t), 6.33 (1H, s), 6.97 (1H, d), 7.33 (2H, m), 7.42 (2H, m), 7.45 (1H, m), 7.53 (1H, m), 7.60 (1H, d), 7.65 (1H, dd), 7.86 (1H, d), 8.05 (1H, dd), 8.12 (1H, d), 8.52–8.58 (2H, overlapping m), 8.65 (1H, m), 8.75 (1H, bs).</div></div><div id="sec5_7_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(1-(2-((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)-1H-imidazol-2-yl)acetamide (<b>17</b>)</h3><div class="NLM_p last">To a suspension of 1-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-3-(4-(2-(2-nitro-1<i>H</i>-imidazol-1-yl)ethoxy)naphthalen-1-yl)urea (<b>51</b>) (80 mg, 0.15 mmol) in a mixture of EtOH and AcOH (2:1v/v, 3.0 mL) was added iron mesh (48 mg, 0.87 mmol). The mixture was heated at 60 °C for 1 h, cooled to rt, and adjusted to pH 9 by the addition of a saturated aq. Na<sub>2</sub>CO<sub>3</sub> solution, which resulted in the formation of a thick suspension. The volatiles were evaporated in vacuo, and the residue was subjected to SCX capture and release to afford a crude sample of 1-(4-(2-(2-amino-1<i>H</i>-imidazol-1-yl)ethoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (80 mg). A portion of this material (53 mg, ∼0.10 mmol) in DCM (2.0 mL) was treated with DIPEA (35 μL, 0.20 mmol) and acetyl chloride (8 μL, 0.11 mmol). After 18 h at rt, the mixture was diluted with a saturated aq. NaHCO<sub>3</sub> solution (1.0 mL) and the layers were separated. The organic layer was evaporated in vacuo, and the residue was purified by flash column chromatography (SiO<sub>2</sub>, 12 g, MeOH in EtOAc, 0–5%, gradient elution). The material so obtained was triturated from a mixture of diethyl ether and isohexane and was then subjected to SCX capture and release to give the title compound (<b>17</b>) as pale yellow solid (7 mg, 9%, 87% purity). LC-MS: <i>m</i>/<i>z</i> 566 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.24 (9H, s), 2.05 (3H, s), 2.37 (3H, s), 4.25 (2H, m), 4.35 (2H, t), 6.35 (1H, s), 6.79 (1H, s), 6.90 (1H, d), 7.29–7.39 (3H, overlapping m), 7.42 (2H, m), 7.50–7.60 (2H, overlapping m), 7.61 (1H, d), 7.88 (1H, d), 8.15 (1H, d), 8.55 (1H, bs), 8.76 (1H, bs), 10.05 (1H, bs).</div></div><div id="sec5_7_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)-<i>N</i>-(2-methoxyethyl)picolinamide (<b>18</b>)</h3><div class="NLM_p last">A mixture of 4-(((4-(3-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy) ethyl)picolinic acid (<b>39</b>) (35 mg, 0.06 mmol), 2-methoxyethylamine (6.0 μL, 0.07 mmol), DMAP (7.8 mg, 0.06 mmol), and EDC·HCl (16 mg, 0.08 mmol) in a mixture of DCM (1.0 mL) and DMF (1.0 mL) was kept at rt for 72 h. The neat reaction mixture was purified by flash column chromatography (SiO<sub>2</sub>, 12 g, MeOH in DCM, 0–20%, gradient elution). The crude product so obtained was purified further by SCX capture and release to afford the title compound (<b>18</b>) as a light brown solid (7 mg, 17%). LC-MS: <i>m</i>/<i>z</i> 607 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.37 (3H, s), 3.27 (3H, s), 3.47 (4H, overlapping m), 5.48 (2H, s), 6.35 (1H, s), 7.00 (1H, s), 7.35 (2H, m), 7.43 (2H, m), 7.57–7.63 (3H, overlapping m), 7.75 (1H, dd), 7.92 (1H, m), 8.18 (1H, d), 8.31 (1H, m), 8.58 (1H, bs), 8.67 (1H, d), 8.72 (1H, m), 8.78 (1H, bs).</div></div><div id="sec5_7_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)-<i>N</i>-(2-morpholinoethyl)picolinamide (<b>19</b>)</h3><div class="NLM_p last">The title compound was prepared in the same manner as that described for <b>18</b> by replacing 2-methoxyethanamine with 2-morpholinoethanamine to furnish <b>19</b> as an off-white solid (10 mg, 16%). LC-MS: <i>m</i>/<i>z</i> 662 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.35–2.45 (7H, overlapping s), 2.45 (2H, obscured by DOH), 3.45 (2H, t), 3.55 (4H, t), 5.44 (2H, s), 6.35 (1H, s), 7.00 (1H, d), 7.35 (2H, m), 7.43 (2H, m), 7.58–7.62 (3H, overlapping, m), 7.75 (1H, dd), 7.93 (1H, m), 8.17 (1H, d), 8.31 (1H, m), 8.58 (1H, bs), 8.67 (1H, dd), 8.74 (1H, t), 8.79 (1H, bs).</div></div><div id="sec5_7_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Methyl (4-(((4-(3-(3-(<i>tert-</i>Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)pyridin-2-yl)carbamate (<b>20</b>)</h3><div class="NLM_p last">To a solution of 1-(4-((2-aminopyridin-4-yl)methoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>37</b>) (40 mg, 0.08 mmol) in a mixture of DCM (0.9 mL) and DMF (0.1 mL) were added DIPEA (15 μL, 0.09 mmol) and methyl chloroformate (6.5 μL, 0.09 mmol). After 1 h, an additional aliquot of methyl chloroformate (6.5 μL, 0.09 mmol) was added. The mixture was maintained at rt for 1 h and was then evaporated in vacuo. The residue was triturated with methanol (2.0 mL). The resulting solid was collected by filtration and washed with MeOH (1.0 mL) and diethyl ether (2.0 mL) to give the title compound (<b>20</b>) as a beige powder (15 mg, 33%). LC-MS: <i>m</i>/<i>z</i> 579 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.38 (3H, s), 3.67 (3H, s), 5.35 (2H, s), 6.35 (1H, s), 6.99 (1H, d), 7.19 (1H, dd), 7.35 (2H, m), 7.43 (2H, m), 7.56–7.63 (2H, overlapping m), 7.92 (1H, m), 8.05 (1H, s), 8.26–8.32 (2H, overlapping m), 8.58 (1H, bs), 8.79 (1H, bs), 10.25 (1H, bs).</div></div><div id="sec5_7_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>N</i>-(4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)yridin-2-yl)methanesulfonamide (<b>21</b>)</h3><div class="NLM_p last">To a solution of 1-(4-((2-aminopyridin-4-yl)methoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>39</b>) (100 mg, 0.19 mmol) in pyridine (1.0 mL) was added methanesulfonyl chloride (59 μL, 0.76 mmol), and the resulting yellow solution was kept at rt for 72 h. The mixture was treated with 1% NH<sub>3</sub> in MeOH (2.0 mL), and after 30 min, it was preabsorbed onto silica gel and purified by flash column chromatography (SiO<sub>2</sub>, 12 g, MeOH in DCM, 0–5%, gradient elution) to furnish the title compound (<b>23</b>) as a light orange solid (49 mg, 50%). LC-MS: <i>m</i>/<i>z</i> 599 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.39 (3H, s), 3.25 (3H, s), 5.32 (2H, s), 6.35 (1H, s), 7.00 (1H, d), 7.10 (1H, m), 7.21 (1H, m), 7.35 (2H, m), 7.43 (2H, m), 7.55–7.63 (3H, overlapping m), 7.92 (1H, dd), 8.21 (1H, m), 8.31 (1H, dd), 8.57 (1H, bs), 8.79 (1H, bs), 10.80 (1H, bs).</div></div><div id="sec5_7_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>N</i>-(4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)yridin-2-yl)acetamide (<b>22</b>)</h3><div class="NLM_p last">To a solution of 1-(4-((2-aminopyridin-4-yl)methoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>37</b>) (40 mg, 0.08 mmol) and DIPEA (15 μL, 0.09 mmol) in a mixture of DCM (1.0 mL) and DMF (0.1 mL) was added acetyl chloride (6 μL, 0.08 mmol). After 40 min at rt, additional aliquots of acetyl chloride (4 μL, 0.05 mmol) and DIPEA (10 μL, 0.06 mmol) were added. The resulting mixture was kept at rt for an additional 30 min, treated with acetic acid (0.5 mL), and subjected to SCX capture and release. The crude material so obtained was triturated with DCM to afford the title compound (<b>22</b>) as a pale orange solid (30 mg, 69%). LC-MS: <i>m</i>/<i>z</i> 563 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.26 (9H, s), 2.09 (3H, s), 2.35 (3H, s), 5.35 (2H, s), 6.35 (1H, s), 7.00 (1H, d), 7.22 (1H, m), 7.35 (2H, m), 7.42 (2H, m), 7.55–7.63 (3H, overlapping m), 7.92 (1H, dd), 8.28–8.33 (2H, overlapping m), 8.57 (1H, bs), 8.78 (1H, bs), 10.54 (1H, bs).</div></div><div id="sec5_7_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 1-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-3-(4-((2-(3-methylureido)pyridin-4-yl)ethoxy)naphthalen-1-yl)urea (<b>23</b>)</h3><div class="NLM_p last">To a solution of 1-(4-((2-aminopyridin-4-yl)methoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>37</b>) (70 mg, 0.13 mmol) in pyridine (1.5 mL) was added methyl isocyanate (14 μL, 0.24 mmol). The reaction mixture was kept at rt for 72 h. The reaction mixture was evaporated in vacuo, and the residue was triturated with DCM (3.0 mL) to afford the title compound (<b>23</b>) as an off-white powder (36 mg, 45%). LC-MS: <i>m</i>/<i>z</i> 578 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.39 (3H, s), 2.74 (3H, d), 5.30 (2H, s), 6.36 (1H, s), 6.99 (1H, d), 7.05 (1H, d), 7.35, (2H, m), 7.44 (2H, m), 7.54–7.64 (4H, overlapping m), 7.93 (1H, d), 8.19 (1H, d), 8.23 (1H, bs), 8.35 (1H, d), 8.58 (1H, bs), 8.79 (1H, bs), 9.36 (1H, bs).</div></div><div id="sec5_7_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>-(4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)yridin-2-yl)benzamide (<b>24</b>)</h3><div class="NLM_p last">The title compound was prepared by the procedure described for <b>22</b> using benzoyl chloride in place of acetyl chloride to give <b>24</b> as a beige powder (19 mg, 39%). LC-MS: <i>m</i>/<i>z</i> 625 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.39 (3H, s), 5.41 (2H, s), 6.35 (1H, s), 7.04 (1H, d), 7.31–7.37 (3H, overlapping m), 7.42 (2H, m), 7.50 (2H, m), 7.56–7.64 (4H, overlapping m), 7.93 (1H, m), 8.02 (2H, m), 8.32 (1H, m), 8.40–8.45 (2H, overlapping m), 8.58 (1H, bs), 8.79 (1H, bs), 10.90 (1H, bs).</div></div><div id="sec5_7_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-(4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)yridin-2-yl)-2-phenylacetamide (<b>25</b>)</h3><div class="NLM_p last">The title compound was obtained in a similar manner as that for <b>22</b> using phenylacetyl chloride in place of acetyl chloride to give <b>25</b> as a beige powder (7 mg, 13%). LC-MS: <i>m</i>/<i>z</i> 639 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.25 (9H, s), 2.37 (3H, s), 4.72 (2H, s), 5.34 (2H, s), 6.34 (1H, s), 6.97 (1H, d), 7.20–7.26 (2H, overlapping m), 7.27–7.37 (6H, overlapping m), 7.53–7.62 (3H, overlapping m), 7.92 (1H, m), 8.25–8.29 (2H, overlapping m), 8.33 (1H, dd), 8.57 (1H, bs), 8.78 (1H, bs), 10.77 (1H, bs).</div></div><div id="sec5_7_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>-(4-((4-(3-(3-<i>tert</i>-Butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)yridin-2-yl)-2-(dimethylamino)acetamide (<b>26</b>)</h3><div class="NLM_p last">To a solution of <i>N</i>-(4-((4-(3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy) ethyl) pyridin-2-yl)-2-chloroacetamide (<b>36</b>) (50 mg, 0.08 mmol) in a mixture of DCM (1.0 mL), DMF (0.1 mL), and DIPEA (17 μL, 0.10 mmol) was added a solution of dimethylamine (2.0 M in THF, 41 μL, 0.08 mmol). The reaction mixture was heated at 40 °C for 12 h. The resulting mixture was purified by flash column chromatography (12 g SiO<sub>2</sub>, MeOH in DCM, 0–10%, gradient elution). The product obtained was triturated with a mixture of diethyl ether, DCM, and isohexane (2:1:2, 5.0 mL) to afford the title compound (<b>26</b>) as an orange solid (18 mg, 35%). LC-MS: <i>m</i>/<i>z</i> 607 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.31 (6H, s), 2.39 (3H, s), 3.14 (2H, s), 5.39 (2H, s), 6.35 (1H, s), 7.01 (1H, d), 7.29 (1H, d), 7.35 (2H, d), 7.44 (2H, d), 7.65–7.55 (3H, overlapping m), 7.94 (1H, m), 8.38–8.28 (3H, overlapping m), 8.59 (1H, bs), 8.79 (1H, bs), 9.93 (1H, bs).</div></div><div id="sec5_7_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>N</i>-(4-((4-(3-(3-<i>tert</i>-Butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)yridin-2-yl)-2-morpholinoacetamide (<b>27</b>)</h3><div class="NLM_p last">To a solution of <i>N</i>-(4-((4-(3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy)ethyl)pyridin-2-yl)-2-chloroacetamide (<b>36</b>) (50 mg, 0.08 mmol) in a mixture of DCM (1.0 mL), DMF (0.1 mL), and DIPEA (21.9 μL, 0.13 mmol) was added morpholine (11.0 μL, 0.13 mmol). The reaction mixture was kept at rt for 3 h, heated at 40 °C for 12 h, and then treated with a second aliquot of morpholine (11.0 μL, 0.13 mmol). After an additional 5 h at 40 °C, the crude reaction mixture was purified by flash column chromatography (12 g, SiO<sub>2</sub>, MeOH in DCM, 0–10%, gradient elution). The impure product obtained was triturated with MeOH (5.0 mL), and the solid was collected by filtration to provide the title compound (<b>27</b>) as a light yellow solid (11 mg, 20%). LC-MS: <i>m</i>/<i>z</i> 648 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.39 (3H, s), 2.54 (4H, m), 3.20 (2H, s), 3.63 (4H, m), 5.39 (2H, s), 6.35 (1H, s), 7.01 (1H, d), 7.28 (1H, d), 7.35 (2H, d), 7.43 (2H, d), 7.56–7.62 (3H, overlapping m), 7.92 (1H, d), 8.29–8.37 (3H, overlapping m), 8.58 (1H, bs), 8.90 (1H, bs), 10.01 (1H, bs).</div></div><div id="sec5_7_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>N</i>-(4-((4-(3-(3-<i>tert</i>-Butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)yridin-2-yl)-2-(methylthio)acetamide (<b>28</b>)</h3><div class="NLM_p last">To a stirred suspension of sodium thiomethoxide (35 mg, 0.50 mmol) in MeOH (5.0 mL) at rt was added portionwise <i>N</i>-(4-((4-(3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)pyridin-2-yl)-2-chloroacetamide (<b>36</b>) (100 mg, 0.17 mmol). After 1 h at rt, the resulting mixture was evaporated in vacuo and the residue was partitioned between brine (20 mL) and DCM (30 mL). The organic layer was separated and concentrated in vacuo. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 12 g, EtOAc in isohexane, 10–100%, gradient elution) to give the title compound (<b>28</b>) as a light yellow solid (28 mg, 26%). LC-MS: <i>m</i>/<i>z</i> 610 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.16 (3H, s), 2.39 (3H, s), 3.53 (2H, s), 5.37 (2H, s), 6.35 (1H, s), 7.01 (1H, d), 7.26 (1H, dd), 7.35 (2H, m), 7.44 (2H, m), 7.55–7.64 (3H, m), 7.92 (1H, m), 8.30–8.35 (3H, overlapping m), 8.58 (1H, s), 8.78 (1H, s), 10.60 (1H, s).</div></div><div id="sec5_7_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N</i>-(4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl)yridin-2-yl)-2-(methylsulfonyl)acetamide (<b>29</b>)</h3><div class="NLM_p last">To a suspension of methanesulfonylacetic acid (40 mg, 0.29 mmol) and oxalyl chloride (29 μL, 0.34 mmol) in DCM (1.0 mL) was added DMF (1 drop). The reaction mixture was stirred at rt for 1 h. The resulting solution was added dropwise to a mixture of 1-(4-((2-aminopyridin-4-yl)methoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>37</b>) (50 mg, 0.10 mmol) and DIPEA (167 μL, 1.00 mmol) in DCM/DMF (10:1 v/v, 1.1 mL). After 18 h, the reaction mixture was treated with 1% NH<sub>3</sub> in MeOH (2.0 mL) and was then evaporated in vacuo. The residue was subjected to SCX capture and release to afford the title compound (<b>29</b>) as a pale pink solid (11 mg, 18%). LC-MS: <i>m</i>/<i>z</i> 641 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.39 (3H, s), 3.17 (3H, s), 4.44 (2H, s), 5.40 (2H, s), 6.35 (1H, s), 7.02 (1H, d), 7.33 (1H, dd), 7.36 (2H, m), 7.44 (2H, m), 7.56–7.64 (3H, overlapping m), 7.93 (1H, m), 8.30–8.33 (2H, overlapping m), 8.39 (1H, dd), 8.59 (1H, bs), 8.79 (1H, bs), 10.98 (1H, bs).</div></div><div id="sec5_7_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>N</i>-(4-((4-(3-(3-<i>tert</i>-Butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)yridin-2-yl)-2-methoxyacetamide (<b>30</b>)</h3><div class="NLM_p last">To a solution of 1-(4-((2-aminopyridin-4-yl)methoxy)naphthalen-1-yl)-3-(3-<i>tert</i>-butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>37</b>) (526 mg, 0.96 mmol) and DIPEA (184 μL, 1.06 mmol) in a mixture of DCM and DMF (10:1, 11 mL) was added methoxyacetyl chloride (92 μL, 1.01 mmol). After 1 h at rt, additional aliquots of DIPEA (184 μL, 1.06 mmol) and methoxyacetyl chloride (92 μL, 1.01 mmol) were added sequentially. Stirring was continued for 1 h. A solution of 1% NH<sub>3</sub> in MeOH (40 mL) was added, and after 15 min, the mixture was evaporated in vacuo. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 40 g, MeOH in DCM, 0–6%, gradient elution) to furnish the title compound (<b>30</b>) as a white solid (286 mg, 49%). LC-MS: <i>m</i>/<i>z</i> 593 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.39 (3H, s), 3.32 (3H, s), 4.08 (2H, s), 5.39 (2H, s), 6.36 (1H, s), 7.03 (1H, d), 7.28 (1H, dd), 7.36 (2H, m), 7.44 (2H, m), 7.56–7.64 (3H, overlapping m), 7.93 (1H, m), 8.30–8.35 (3H, overlapping m), 8.58 (1H, bs), 8.79 (1H, bs), 10.02 (1H, bs).</div></div><div id="sec5_7_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N</i>-(4-(((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)methyl) yridin-2-yl)-2-methoxy-<i>N</i>-methylacetamide (<b>31</b>)</h3><div class="NLM_p last">The title compound was prepared in a similar manner as that for <b>37</b> from <i>N</i>-(4-(((4-aminonaphthalen-1-yl)oxy)methyl)pyridin-2-yl)-2-methoxy-<i>N</i>-methylacetamide (<b>35</b>) to give <b>31</b> as a light beige solid (60 mg, 27%). LC-MS: <i>m</i>/<i>z</i> 607 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.27 (9H, s), 2.38 (3H, s), 3.20 (3H, s), 3.29 (3H, s), 4.13 (2H, s), 5.39 (2H, s), 6.34 (1H, s), 7.02 (1H, d), 7.35 (2H, m), 7.41–7.45 (3H, overlapping m), 7.55–7.65 (3H, overlapping m), 7.70 (1H, s), 7.92 (1H, m), 8.31 (1H, m), 8.46 (1H, d), 8.57 (1H, bs), 8.78 (1H, bs).</div></div><div id="sec5_7_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> <i>N</i>-(4-(1-((4-(3-(3-(<i>tert-</i>Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)pyridin-2-yl)-2-methoxyacetamide (<b>32</b>)</h3><div class="NLM_p last">The title compound (<b>32</b>) was prepared in a similar manner as that for <b>30</b> from 1-(4-(1-(2-aminopyridin-4-yl)ethoxy)naphthalen-1-yl)-3-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)urea (<b>41</b>) as a beige solid (24 mg, 51%). LC-MS <i>m</i>/<i>z</i> 607 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.26 (9H, s), 1.67 (3H, d), 2.38 (3H, s), 4.03 (2H, s), 5.75 (1H, q), 6.32 (1H, s), 6.81 (1H, d), 7.22 (1H, dd), 7.35 (2H, m), 7.42 (2H, m), 7.48 (1H, s), 7.59 (2H, m), 7.88 (1H, m), 8.24 (1H, bs), 8.27 (1H, d), 8.36 (1H, m), 8.59 (1H, bs), 8.76 (1H, bs), 9.99 (1H, bs).</div></div><div id="sec5_7_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>N</i>-(4-(2-((4-(3-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)propan-2-yl)pyridin-2-yl)-2-methoxyacetamide (<b>33</b>)</h3><div class="NLM_p last">The title compound (<b>33</b>) was prepared in a similar manner as that for <b>30</b> from 1-(4-(2-(2-aminopyridin-4-yl)propan-2-yloxy)naphthalen-1-yl)-3-(3-<i>tert-</i>butyl-1-<i>p</i>-tolyl-1<i>H</i>-pyrazol-5-yl)urea (<b>42</b>) as a white solid (18 mg, 24%). LC-MS <i>m</i>/<i>z</i> 621 (M + H)<sup>+</sup> (ES<sup>+</sup>). <sup>1</sup>H NMR: δ 1.28 (9H, s), 1.39 (6H, s), 2.39 (3H, s), 3.22 (3H, s), 3.80 (1H, d), 4.16 (1H, d), 5.27 (1H, s), 6.41 (1H, s), 7.26 (1H, dd), 7.37 (2H, m), 7.46 (2H, m), 7.56 (1H, d), 7.60 (2H, overlapping m), 7.76 (1H, br s), 7.95 (1H, m), 8.01 (1H, d), 8.09 (1H, m), 8.22 (1H, d), 8.94 (1H, bs), 9.28 (1H, bs).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01029" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stuart T. Onions</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#04772a6b6a6d6b6a7744777d636a6570717661606d77676b7261767d2a676b69"><span class="__cf_email__" data-cfemail="52217c3d3c3b3d3c2112212b353c3326272037363b21313d2437202b7c313d3f">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine E. Charron</span> - <span class="hlFld-Affiliation affiliation">RespiVert
Limited, 2 Royal College
Street, The London Bioscience Innovation Centre, London NW1 0NH, United
Kingdom</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7e1d1f0a161b0c17101b3e0c1b0d0e17081b0c0a501d1113"><span class="__cf_email__" data-cfemail="70131104181502191e15300215030019061502045e131f1d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kazuhiro Ito</span> - <span class="hlFld-Affiliation affiliation">RespiVert
Limited, 2 Royal College
Street, The London Bioscience Innovation Centre, London NW1 0NH, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard J. Brown</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie Colucci</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fritz Frickel</span> - <span class="hlFld-Affiliation affiliation">RespiVert
Limited, 2 Royal College
Street, The London Bioscience Innovation Centre, London NW1 0NH, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Hardy</span> - <span class="hlFld-Affiliation affiliation">RespiVert
Limited, 2 Royal College
Street, The London Bioscience Innovation Centre, London NW1 0NH, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Joly</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John King-Underwood</span> - <span class="hlFld-Affiliation affiliation">CompChem
Resource, Old Cottage
Hospital, Homend, Ledbury, Herefordshire HR8 1ED, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasuo Kizawa</span> - <span class="hlFld-Affiliation affiliation">Department
of Physiology and Anatomy, Nihon University
School of Pharmacy, 7-7-1,
Narashinodai, Funabashi, Chiba 274-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian Knowles</span> - <span class="hlFld-Affiliation affiliation">Pneumolabs
UK Limited, Harrow, Middlesex HA1 3UJ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">P. John Murray</span> - <span class="hlFld-Affiliation affiliation">RespiVert
Limited, 2 Royal College
Street, The London Bioscience Innovation Centre, London NW1 0NH, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Novak</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anjna Rani</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Garth Rapeport</span> - <span class="hlFld-Affiliation affiliation">RespiVert
Limited, 2 Royal College
Street, The London Bioscience Innovation Centre, London NW1 0NH, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alun Smith</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Strong</span> - <span class="hlFld-Affiliation affiliation">RespiVert
Limited, 2 Royal College
Street, The London Bioscience Innovation Centre, London NW1 0NH, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David M. Taddei</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan G. Williams</span> - <span class="hlFld-Affiliation affiliation">Sygnature
Discovery Limited, Biocity, Nottingham NG1 1GF, United Kingdom</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Stuart T. Onions, Richard J. Brown, Marie Colucci, Kevin Joly, Andrew Novak, Anjna Rani, Alun Smith, David M. Taddei, and Jonathan G. Williams were full-time employees of Sygnature Discovery Limited at the time this work was completed. Kazuhiro Ito, Catherine E. Charron, P. John Murray, Garth Rapeport,  and Peter Strong were full-time employees of RespiVert Ltd at the time this work was completed.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i75" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i75"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i76" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i76"> Abbreviations Used</h2><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">glacial acetic acid</p></td></tr><tr><td class="NLM_term">BALF</td><td class="NLM_def"><p class="first last">bronchoalveolar lavage fluid</p></td></tr><tr><td class="NLM_term">b</td><td class="NLM_def"><p class="first last">broad</p></td></tr><tr><td class="NLM_term">CatCart</td><td class="NLM_def"><p class="first last">catalytic cartridge</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1-carbonyl-diimidazole</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">CS</td><td class="NLM_def"><p class="first last">cigarette smoke</p></td></tr><tr><td class="NLM_term">Cs<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">cesium carbonate</p></td></tr><tr><td class="NLM_term">CXCL8</td><td class="NLM_def"><p class="first last">interleukin 8</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">d-</td><td class="NLM_def"><p class="first last">differentiated</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">aspartic acid–phenylalanine–glycine</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropylazadicarboxylate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">(ES<sup>+</sup>)</td><td class="NLM_def"><p class="first last">electrospray ionization, positive mode</p></td></tr><tr><td class="NLM_term">FACS</td><td class="NLM_def"><p class="first last">fluorescence-activated cell sorting</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine sample</p></td></tr><tr><td class="NLM_term">FEV1</td><td class="NLM_def"><p class="first last">forced expiratory volume in 1 s</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluticasone propionate</p></td></tr><tr><td class="NLM_term">FRET</td><td class="NLM_def"><p class="first last">fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte-macrophage colony-stimulating factor</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>O<sub>2</sub></td><td class="NLM_def"><p class="first last">hydrogen peroxide</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HCK</td><td class="NLM_def"><p class="first last">hematopoietic kinase</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">inflammatory bowel disease</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IT</td><td class="NLM_def"><p class="first last">intratracheal</p></td></tr><tr><td class="NLM_term">LiOH</td><td class="NLM_def"><p class="first last">lithium hydroxide</p></td></tr><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">mitogen activated protein</p></td></tr><tr><td class="NLM_term">MAPKAP-K2</td><td class="NLM_def"><p class="first last">mitogen activated protein kinase-activated protein kinase 2</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MeI</td><td class="NLM_def"><p class="first last">methyl iodide</p></td></tr><tr><td class="NLM_term">MeLi</td><td class="NLM_def"><p class="first last">methyllithium</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">(M + H)<sup>+</sup></td><td class="NLM_def"><p class="first last">protonated molecule</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute(s)</p></td></tr><tr><td class="NLM_term">MOMA2</td><td class="NLM_def"><p class="first last">monocyte/macrophage marker antibody</p></td></tr><tr><td class="NLM_term"><i>m</i>/<i>z</i></td><td class="NLM_def"><p class="first last">mass-to-charge ratio</p></td></tr><tr><td class="NLM_term">MgSO<sub>4</sub></td><td class="NLM_def"><p class="first last">magnesium sulfate</p></td></tr><tr><td class="NLM_term">NaBH<sub>4</sub></td><td class="NLM_def"><p class="first last">sodium borohydride</p></td></tr><tr><td class="NLM_term">NaCl</td><td class="NLM_def"><p class="first last">sodium chloride</p></td></tr><tr><td class="NLM_term">NaHCO<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium bicarbonate</p></td></tr><tr><td class="NLM_term">NaOH</td><td class="NLM_def"><p class="first last">sodium hydroxide</p></td></tr><tr><td class="NLM_term">NH<sub>3</sub></td><td class="NLM_def"><p class="first last">ammonia</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>Cl</td><td class="NLM_def"><p class="first last">ammonium chloride</p></td></tr><tr><td class="NLM_term">NSKI</td><td class="NLM_def"><p class="first last">narrow spectrum kinase inhibitor</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononucleated cell</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last">tris(dibenzylideneacetone)dipalladium(0)</p></td></tr><tr><td class="NLM_term">PMA</td><td class="NLM_def"><p class="first last">phorbol myristate acetate</p></td></tr><tr><td class="NLM_term">PPh<sub>3</sub></td><td class="NLM_def"><p class="first last">triphenylphosphine</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RP</td><td class="NLM_def"><p class="first last">reverse phase</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SCX</td><td class="NLM_def"><p class="first last">strong cation exchange (resin)</p></td></tr><tr><td class="NLM_term">SiO<sub>2</sub></td><td class="NLM_def"><p class="first last">silica</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">TBDMSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl chloride</p></td></tr><tr><td class="NLM_term">TMS-CN</td><td class="NLM_def"><p class="first last">trimethylsilyl cyanide</p></td></tr><tr><td class="NLM_term">Xantphos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Corticosteroid Resistance in Airway Disease</span> <span class="citation_source-journal">Proc. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span><span class="refDoi"> DOI: 10.1513/pats.200402-014MS</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1513%2Fpats.200402-014MS" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16113444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFGis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=264-268&author=P.+J.+Barnes&title=Corticosteroid+Resistance+in+Airway+Disease&doi=10.1513%2Fpats.200402-014MS"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Corticosteroid resistance in airway disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-268</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Resistance to the antiinflammatory effects of corticosteroids is very uncommon in asthma but common in chronic obstructive pulmonary disease.  Recent understanding of the mol. mechanisms involved in the antiinflammatory actions of corticosteroids has revealed that there are several possible mechanisms for corticosteroid resistance.  Certain cytokines activate p38 mitogen-activated protein kinase, which may interfere with the nuclear localization of glucocorticoid receptors (GRs).  In other patients, nuclear localization of GR is normal but there is a redn. in acetylation of a lysine residue in histone-4, thus leading to impaired activation of certain antiinflammatory genes.  In chronic obstructive pulmonary disease and severe asthma, oxidative stress may reduce the activity and expression of certain histone deacetylases and therefore interfere with the antiinflammatory action of corticosteroids.  These mechanisms suggest that there may be several therapeutic approaches to treating corticosteroid resistance in the future, including antioxidants, p38 mitogen-activated protein kinase inhibitors, and theophylline, which activates histone deacetylases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6nBRWXvawEbVg90H21EOLACvtfcHk0ljR17SQvRC6lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFGis74%253D&md5=594dd4af104bf0d61a0b992093e9a3d6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1513%2Fpats.200402-014MS&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.200402-014MS%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DCorticosteroid%2520Resistance%2520in%2520Airway%2520Disease%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2004%26volume%3D1%26spage%3D264%26epage%3D268%26doi%3D10.1513%2Fpats.200402-014MS" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Creed, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probert, C. S. J.</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1111/j.1365-2036.2006.03156.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1111%2Fj.1365-2036.2006.03156.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=17229236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVCqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Creed%2C+T.+J.%3B+Probert%2C+C.+S.+J.Aliment.+Pharmacol.+Ther.+2007%2C+25%2C+111%E2%80%93122+10.1111%2Fj.1365-2036.2006.03156.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies</span></div><div class="casAuthors">Creed, T. J.; Probert, C. S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Steroid resistance in inflammatory bowel disease presents a difficult clin. challenge.  The advent of biol. therapies coupled with an increasing understanding of the pathogenesis of inflammatory bowel disease has provided new therapeutic options.  Methods: We review the available literature of the mechanisms behind steroid resistance.  In addn., we outline some of the options available for treating those patients who fail to respond adequately to glucocorticoids.  Results: Approx. 30% of patients prescribed glucocorticoids will not achieve clin. remission.  Many such patients are offered immunosuppressive or, recently, biol. agents.  However, these agents are ineffective in a large proportion of patients.  Immunosuppressive agents only bring 40-60% of patients into remission, and biol. agents typically induce remission in just 40% of patients.  In this review, the possible explanations for glucocorticoid resistance are discussed.  Recent evidence suggests that in many patients it is mediated by interleukin-2.  Basiliximab, a biol. agent that interrupts interleukin-2 signalling, has shown significant benefit in early clin. studies.  Conclusions: Patients who fail to respond to steroid therapy should have alternative agents introduced in a timely fashion.  Steroid refractory inflammatory bowel disease remains a difficult condition to treat, but new therapies and managements are emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraCvpI3aTsX7Vg90H21EOLACvtfcHk0lh-X-Vd7-pUKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVCqt7o%253D&md5=48640f3485441178c8efa129a56923ed</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2006.03156.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2006.03156.x%26sid%3Dliteratum%253Aachs%26aulast%3DCreed%26aufirst%3DT.%2BJ.%26aulast%3DProbert%26aufirst%3DC.%2BS.%2BJ.%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2007%26volume%3D25%26spage%3D111%26epage%3D122%26doi%3D10.1111%2Fj.1365-2036.2006.03156.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Hogg, J.</span><span> </span><span class="NLM_article-title">Role of Latent Viral Infections in Chronic Obstructive Pulmonary Disease and Asthma</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span><span class="refDoi"> DOI: 10.1164/ajrccm.164.supplement_2.2106063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1164%2Fajrccm.164.supplement_2.2106063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=11734471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BD3MnovVSjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2001&pages=71-75&author=J.+Hogg&title=Role+of+Latent+Viral+Infections+in+Chronic+Obstructive+Pulmonary+Disease+and+Asthma&doi=10.1164%2Fajrccm.164.supplement_2.2106063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Role of latent viral infections in chronic obstructive pulmonary disease and asthma</span></div><div class="casAuthors">Hogg J C</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">10 Pt 2</span>),
    <span class="NLM_cas:pages">S71-5</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Acute viral respiratory tract infections are well known to precipitate asthma attacks and acute exacerbations of chronic obstructive pulmonary disease, but their role in the pathogenesis of chronic disease is poorly defined.  Double-stranded DNA viruses have the ability to persist in airway epithelial cells long after the acute infection has cleared.  During these latent infections, viral genes are expressed at the protein level without replication of a complete virus.  The expression of the adenoviral trans-activating protein has been demonstrated in the airway epithelium of both human and animal lungs and is associated with an amplification of the cigarette smoke-induced inflammatory response.  Studies of cultured human airway epithelial cells have also shown that transfection with this viral gene upregulates the expression of intercellular adhesion molecule 1 and interleukin 8 by these cells when they are challenged with endotoxin.  In guinea pigs, cigarette smoke-induced emphysema is amplified by latent adenoviral infection.  Furthermore, this infection independently increased the number of CD-8 cells, whereas the cigarette smoke independently increased the number of CD-4 cells in the inflammatory infiltrate.  On the other hand, allergen-induced lung inflammation was uninfluenced by latent adenoviral infection in the guinea pig, but the latent infection caused the eosinophilic component of this response to become steroid resistant.  These studies suggest that latent adenoviral infections may have a role in the pathogenesis of obstructive airway disease by amplifying the response to cigarette smoke and inducing steroid resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPhJKChJg9hZdYoSR9eyvsfW6udTcc2ea9XGcdoNZlZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnovVSjsw%253D%253D&md5=93b2a54c601fed2e4bfaf20e512cebea</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.164.supplement_2.2106063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.164.supplement_2.2106063%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%26atitle%3DRole%2520of%2520Latent%2520Viral%2520Infections%2520in%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%2520and%2520Asthma%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2001%26volume%3D164%26spage%3D71%26epage%3D75%26doi%3D10.1164%2Fajrccm.164.supplement_2.2106063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Pauwels, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurd, S. S.</span><span> </span><span class="NLM_article-title">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">1256</span><span class="refDoi"> DOI: 10.1164/ajrccm.163.5.2101039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1164%2Fajrccm.163.5.2101039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=11316667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BD3MzisFGqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2001&pages=1256&author=R.+A.+Pauwelsauthor=A.+S.+Buistauthor=P.+M.+A.+Calverleyauthor=C.+R.+Jenkinsauthor=S.+S.+Hurd&title=Global+strategy+for+the+diagnosis%2C+management%2C+and+prevention+of+chronic+obstructive+pulmonary+disease.+NHLBI%2FWHO+Global+Initiative+for+Chronic+Obstructive+Lung+Disease+%28GOLD%29+workshop+summary&doi=10.1164%2Fajrccm.163.5.2101039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary</span></div><div class="casAuthors">Pauwels R A; Buist A S; Calverley P M; Jenkins C R; Hurd S S</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1256-76</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS64ADS-aOebBwLZxei1HN8fW6udTcc2ea9XGcdoNZlZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MzisFGqtw%253D%253D&md5=880de2434feae4d24c905f9ea6d4c504</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.163.5.2101039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.163.5.2101039%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DR.%2BA.%26aulast%3DBuist%26aufirst%3DA.%2BS.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3DJenkins%26aufirst%3DC.%2BR.%26aulast%3DHurd%26aufirst%3DS.%2BS.%26atitle%3DGlobal%2520strategy%2520for%2520the%2520diagnosis%252C%2520management%252C%2520and%2520prevention%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease.%2520NHLBI%252FWHO%2520Global%2520Initiative%2520for%2520Chronic%2520Obstructive%2520Lung%2520Disease%2520%2528GOLD%2529%2520workshop%2520summary%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2001%26volume%3D163%26spage%3D1256%26doi%3D10.1164%2Fajrccm.163.5.2101039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Yang, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, K. M.</span><span> </span><span class="NLM_article-title">Inhaled corticosteroids for stable chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD002991</span><span class="refDoi"> DOI: 10.1002/14651858.CD002991.pub3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1002%2F14651858.CD002991.pub3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=CD002991&author=I.+A.+Yangauthor=M.+S.+Clarkeauthor=E.+H.+Simauthor=K.+M.+Fong&title=Inhaled+corticosteroids+for+stable+chronic+obstructive+pulmonary+disease&doi=10.1002%2F14651858.CD002991.pub3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD002991.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD002991.pub3%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DI.%2BA.%26aulast%3DClarke%26aufirst%3DM.%2BS.%26aulast%3DSim%26aufirst%3DE.%2BH.%26aulast%3DFong%26aufirst%3DK.%2BM.%26atitle%3DInhaled%2520corticosteroids%2520for%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2012%26volume%3D7%26spage%3DCD002991%26doi%3D10.1002%2F14651858.CD002991.pub3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Fuso, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mores, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malerba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montuschi, P.</span><span> </span><span class="NLM_article-title">Long-acting beta-agonists and their association with inhaled corticosteroids in COPD</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.2174/0929867311320120003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.2174%2F0929867311320120003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=23409722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1477-95&author=L.+Fusoauthor=N.+Moresauthor=S.+Valenteauthor=M.+Malerbaauthor=P.+Montuschi&title=Long-acting+beta-agonists+and+their+association+with+inhaled+corticosteroids+in+COPD&doi=10.2174%2F0929867311320120003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting beta-agonists and their association with inhaled corticosteroids in COPD</span></div><div class="casAuthors">Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1495</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD).  The short-acting beta2-agonists, including salbutamol, and fenoterol, have a rapid onset of action, a bronchodilating effect for 3-6 h and are used on demand.  The long-acting beta2-agonists (LABAs), including salmeterol and formoterol, have 12-h duration of action and are used with a twice-daily dosing regimen for long-term COPD treatment.  Unlike salmeterol, formoterol has a rapid onset of action.  Pharmacol. characteristics required by novel inhaled LABAs include 24 h bronchodilator effect in vivo which would make them suitable for once daily administration (ultra-LABA), high potency and selectivity for beta2-adrenoceptors, rapid onset of action, low oral bioavailability (< 5%) after inhalation, and high systemic clearance.  Indacaterol, which has been approved for long-term treatment of COPD in Europe and in the USA, has a 24-h duration of action and a once-daily dosing regimen.  Newer ultra-LABAs, including olodaterol, vilanterol, milveterol, carmoterol, and abediterol, are in development.  Combination with ICS (fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formoterol) appears to provide an addnl. benefit over the monocomponent therapy, although the extent of this benefit is variable and often not clin. significant in all the endpoints assessed.  In patients with COPD, treatment with ICS is assocd. with increased risk of pneumonia which should be carefully considered when assessing the risk/benefit ratio of ICS/LABA combinations.  Subphenotyping of patients with COPD (e.g., frequent exacerbations, sputum eosinophilia, mixed asthma/COPD phenotype) might help identify those patients who are most likely to benefit from addn. of ICS to bronchodilating treatment.  Ultra-LABA/ long-acting muscarinic receptor antagonist (LAMA) combination treatment is under development and is likely to become a std. pharmacol. strategy for COPD.  Dual-pharmacol. inhaled muscarinic antagonist-beta2 agonist (MABA) mols. provide a new approach to the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqtajjRd8d0LVg90H21EOLACvtfcHk0lg-CUZoU7lx3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLk%253D&md5=32add113b9bc1d3a8e68df8d1acb7fe8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120003%26sid%3Dliteratum%253Aachs%26aulast%3DFuso%26aufirst%3DL.%26aulast%3DMores%26aufirst%3DN.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DMalerba%26aufirst%3DM.%26aulast%3DMontuschi%26aufirst%3DP.%26atitle%3DLong-acting%2520beta-agonists%2520and%2520their%2520association%2520with%2520inhaled%2520corticosteroids%2520in%2520COPD%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1477%26epage%3D95%26doi%3D10.2174%2F0929867311320120003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Teo, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abisheganaden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lew, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, B. H.</span><span> </span><span class="NLM_article-title">Economic burden of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respirology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1111/j.1440-1843.2011.02073.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1111%2Fj.1440-1843.2011.02073.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=21954985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FptVOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=120-126&author=W.+S.+Teoauthor=W.+S.+Tanauthor=W.+F.+Chongauthor=J.+Abisheganadenauthor=Y.+J.+Lewauthor=T.+K.+Limauthor=B.+H.+Heng&title=Economic+burden+of+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1440-1843.2011.02073.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Economic burden of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Teo W-S Kelvin; Tan Woan-Shin; Chong Wai-Fung; Abisheganaden John; Lew Yii-Jen; Lim Tow-Keang; Heng Bee-Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND OBJECTIVE:  The aim of this study was to estimate the direct medical costs of COPD in two public health clusters in Singapore from 2005 to 2009.  METHODS:  Patients aged 40 years and over, who had been diagnosed with COPD, were identified in a Chronic Disease Management Data-mart.  Annual utilization of health services in inpatient, specialist outpatient, emergency department and primary care settings was extracted from the Chronic Disease Management Data-mart.  Trends in attributable costs, proportions of costs and health-care utilization were analyzed across each level of care.  A weighted attribution approach was used to allocate costs to each health-care utilization episode, depending on the relevance of co-morbidities.  RESULTS:  The mean total cost was approximately $9.9 million per year.  Inpatient admissions were the major cost driver, contributing an average of $7.2 million per year.  The proportion of hospitalization costs declined from 75% in 2005 to 68% in 2009.  Based on the 5-year average, attendances at primary care clinics, emergency department and specialist clinics contributed 3%, 5% and 17%, respectively, of overall COPD costs.  On average, 42% of the total cost burden was incurred for the medical management of COPD.  The share of cost incurred for the treatment of conditions related and unrelated to COPD were 29% and 26%, respectively, of the total average costs.  CONCLUSIONS:  COPD is likely to represent a significant burden to the public health system in most countries.  The findings are particularly relevant to understanding the allocation of health-care resources and informing appropriate cost containment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROsHOCQUWjJSCEBeYuoi7AfW6udTcc2eYDNadRyJnR-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FptVOqtQ%253D%253D&md5=9366bb24664acaa1af55a3ce9167fe63</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1843.2011.02073.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1843.2011.02073.x%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DW.%2BS.%26aulast%3DTan%26aufirst%3DW.%2BS.%26aulast%3DChong%26aufirst%3DW.%2BF.%26aulast%3DAbisheganaden%26aufirst%3DJ.%26aulast%3DLew%26aufirst%3DY.%2BJ.%26aulast%3DLim%26aufirst%3DT.%2BK.%26aulast%3DHeng%26aufirst%3DB.%2BH.%26atitle%3DEconomic%2520burden%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespirology%26date%3D2012%26volume%3D17%26spage%3D120%26epage%3D126%26doi%3D10.1111%2Fj.1440-1843.2011.02073.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span>Chronic Respiratory Diseases; <span class="NLM_publisher-name">WHO</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>. <a href="http://www.who.int/gard/publications/chronic_respiratory_diseases.pdf" class="extLink">http://www.who.int/gard/publications/chronic_respiratory_diseases.pdf</a> (accessed July, 2013).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chronic+Respiratory+Diseases%3B+WHO%3A+Geneva%2C+Switzerland.+http%3A%2F%2Fwww.who.int%2Fgard%2Fpublications%2Fchronic_respiratory_diseases.pdf+%28accessed+July%2C+2013%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DChronic%2520Respiratory%2520Diseases%26pub%3DWHO" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B. R.</span><span> </span><span class="NLM_article-title">Systemic manifestations and comorbidities of COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1185</span><span class="refDoi"> DOI: 10.1183/09031936.00128008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1183%2F09031936.00128008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=19407051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFahtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=1165-1185&author=P.+J.+Barnesauthor=B.+R.+Celli&title=Systemic+manifestations+and+comorbidities+of+COPD&doi=10.1183%2F09031936.00128008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic manifestations and comorbidities of COPD</span></div><div class="casAuthors">Barnes, P. J.; Celli, B. R.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1165-1185</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Increasing evidence indicates that chronic obstructive pulmonary disease (COPD) is a complex disease involving more than airflow obstruction.  Airflow obstruction has profound effects on cardiac function and gas exchange with systemic consequences.  In addn., as COPD results from inflammation and/or alterations in repair mechanisms, the "spill-over" of inflammatory mediators into the circulation may results in important systemic manifestations of the disease, such as skeletal muscle wasting and cachexia.  Systemic inflammation may also initiate or worsen comorbid diseases, such as ischemic heart disease, heart failure, osteoporosis, normocytic anemia, lung cancer, depression and diabetes.  Comorbid diseases potentiate the morbidity of COPD, leading to increased hospitalizations, mortality and healthcare costs.  Comorbidities complicate the management of COPD and need to be evaluated carefully.  Current therapies for comorbid diseases, such as statins and peroxisome proliferator-activated receptor-agonists, may provide unexpected benefits for COPD patients.  Treatment of COPD inflammation may concomitantly treat systemic inflammation and assocd. comorbidities.  However, new broad-spectrum anti-inflammatory treatments, such as phosphodiesterase 4 inhibitors, have significant side-effects so it may be necessary to develop inhaled drugs in the future.  Another approach is the reversal of corticosteroid resistance, for example with effective antioxidants.  More research is needed on COPD comorbidities and their treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Pa8nodQf1LVg90H21EOLACvtfcHk0lg-CUZoU7lx3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFahtbk%253D&md5=645e93d5c627e42dd0e1bbd0f25259cb</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1183%2F09031936.00128008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00128008%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DCelli%26aufirst%3DB.%2BR.%26atitle%3DSystemic%2520manifestations%2520and%2520comorbidities%2520of%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D33%26spage%3D1165%26epage%3D1185%26doi%3D10.1183%2F09031936.00128008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Montuschi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuso, L.</span><span> </span><span class="NLM_article-title">Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1464</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span><span class="refDoi"> DOI: 10.2174/0929867311320120002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.2174%2F0929867311320120002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=22963553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1464-76&author=P.+Montuschiauthor=F.+Macagnoauthor=S.+Valenteauthor=L.+Fuso&title=Inhaled+muscarinic+acetylcholine+receptor+antagonists+for+treatment+of+COPD&doi=10.2174%2F0929867311320120002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD</span></div><div class="casAuthors">Montuschi, P.; Macagno, F.; Valente, S.; Fuso, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1464-1476</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Bronchodilators, generally administered via metered dose or dry powder inhalers, are the mainstays of pharmacol. treatment of stable COPD.  Inhaled long-acting beta-agonists (LABA) and anticholinergics are the broncholidators primarily used in the chronic treatment of COPD.  Anticholinergics act as muscarinic acetylcholine receptor antagonists and are frequently preferred over beta-agonists for their minimal cardiac stimulatory effects and greater efficacy in most studies.  Their therapeutic efficacy is based on the fact that vagally mediated bronchoconstriction is the major reversible component of airflow obstruction in patients with COPD.  However, bronchodilators are effective only on the reversible component of airflow obstruction, which by definition is limited, as COPD is characterized by a fixed or poorly reversible airflow obstruction.  Inhaled anticholinergic antimuscarinic drugs approved for the treatment of COPD include ipratropium bromide, oxitropium bromide and tiotropium bromide.  Ipratropium bromide, the prototype of anticholinergic bronchodilators, is a short-acting agent.  Oxitropium bromide is administered twice a day.  Tiotropium bromide, the only long-acting antimuscarinic agent (LAMA) currently approved, is administered once a day.  Newer LAMAs including aclidinium bromide and glycopyrrolate bromide are currently in phase III development for treatment of COPD.  Some new LAMAs, including glycocpyrrolate, are suitable for once daily administration and, unlike tiotropium, have a rapid onset of action.  New LAMAs and their combination with ultra-LABA and, possibly, inhaled corticosteroids, seem to open new perspectives in the management of COPD.  Dual-pharmacol. muscarinic antagonist-beta2 agonist (MABA) mols. present a novel approach to the treatment of COPD by combining muscarinic antagonism and beta2 agonism in a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYOw4zXsYanrVg90H21EOLACvtfcHk0licbmKn6QVxCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLg%253D&md5=3e12b45f2c1c0bc03f7d54f62096b48f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120002%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DMacagno%26aufirst%3DF.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DFuso%26aufirst%3DL.%26atitle%3DInhaled%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%2520for%2520treatment%2520of%2520COPD%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1464%26epage%3D76%26doi%3D10.2174%2F0929867311320120002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Alveolar macrophages as orchestrators of COPD</span> <span class="citation_source-journal">COPD</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1081/COPD-120028701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1081%2FCOPD-120028701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16997739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BD28rmslWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=59-70&author=P.+J.+Barnes&title=Alveolar+macrophages+as+orchestrators+of+COPD&doi=10.1081%2FCOPD-120028701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Alveolar macrophages as orchestrators of COPD</span></div><div class="casAuthors">Barnes Peter J</div><div class="citationInfo"><span class="NLM_cas:title">COPD</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-70</span>
        ISSN:<span class="NLM_cas:issn">1541-2555</span>.
    </div><div class="casAbstract">Alveolar macrophages play a critical role in the pathophysiology of COPD and are a major target for future anti-inflammatory therapy.  Macrophage numbers are markedly increased in the lung and alveolar space of patients with COPD and are localized to sites of alveolar destruction.  The increased numbers of macrophages may result from increased recruitment of blood monocytes, prolonged survival in the lung and to a lesser extent to increased proliferation in the lung.  Alveolar macrophages from COPD patients have an increased baseline and stimulated secretion of inflammatory proteins, including certain cytokines, chemokines, reactive oxygen species and elastolytic enzymes, which together could account for all of the pathophysiological features of COPD.  Alveolar macrophages form COPD appear to be resistant to the anti-inflammatory effects of corticosteriods and this is linked to reduced activity and expression of histone deacetylase 2, a nuclear enzyme that switches off inflammatory genes activated through the transcription factor nuclear factor-KB.  Alternative anti-inflammatory therapies that inhibit macrophages are therefore needed in the future to deal with the chronic inflammation of COPD.  These drugs may include resveratrol, theophylline derivatives, MAP kinase inhibitors and phosphodiesterase-4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvAY_iJApUW2HOrQ6qeX-mfW6udTcc2ebZ-fwmkG3Wqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rmslWhsQ%253D%253D&md5=1c47f079210b93257599e964cf0b438c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1081%2FCOPD-120028701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FCOPD-120028701%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DAlveolar%2520macrophages%2520as%2520orchestrators%2520of%2520COPD%26jtitle%3DCOPD%26date%3D2004%26volume%3D1%26spage%3D59%26epage%3D70%26doi%3D10.1081%2FCOPD-120028701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Mediators of Chronic Obstructive Pulmonary Disease</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">548</span><span class="refDoi"> DOI: 10.1124/pr.56.4.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1124%2Fpr.56.4.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=15602009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=515-548&author=P.+J.+Barnes&title=Mediators+of+Chronic+Obstructive+Pulmonary+Disease&doi=10.1124%2Fpr.56.4.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mediators of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">515-548</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem that is now a leading cause of death.  COPD is assocd. with a chronic inflammatory response, predominantly in small airways and lung parenchyma, which is characterized by increased nos. of macrophages, neutrophils, and T lymphocytes.  The inflammatory mediators involved in COPD have not been clearly defined, in contrast to asthma, but it is now apparent that many lipid mediators, inflammatory peptides, reactive oxygen and nitrogen species, chemokines, cytokines, and growth factors are involved in orchestrating the complex inflammatory process that results in small airway fibrosis and alveolar destruction.  Many proteases are also involved in the inflammatory process and are responsible for the destruction of elastin fibers in the lung parenchyma, which is the hallmark of emphysema.  The identification of inflammatory mediators and understanding their interactions is important for the development of anti-inflammatory treatments for this important disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpISgwqcjIYtLVg90H21EOLACvtfcHk0licbmKn6QVxCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWlt7s%253D&md5=937a8351bde4c91872e956746a7d46e2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fpr.56.4.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.56.4.2%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DMediators%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2004%26volume%3D56%26spage%3D515%26epage%3D548%26doi%3D10.1124%2Fpr.56.4.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Hoogsteden, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dongen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hal, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delahaye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilvering, C.</span><span> </span><span class="NLM_article-title">Phenotype of blood monocytes and alveolar macrophages in interstitial lung disease</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">574</span><span class="NLM_x">–</span> <span class="NLM_lpage">577</span><span class="refDoi"> DOI: 10.1378/chest.95.3.574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1378%2Fchest.95.3.574" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1989&pages=574-577&author=H.+C.+Hoogstedenauthor=J.+J.+van+Dongenauthor=P.+T.+van+Halauthor=M.+Delahayeauthor=W.+Hopauthor=C.+Hilvering&title=Phenotype+of+blood+monocytes+and+alveolar+macrophages+in+interstitial+lung+disease&doi=10.1378%2Fchest.95.3.574"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1378%2Fchest.95.3.574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.95.3.574%26sid%3Dliteratum%253Aachs%26aulast%3DHoogsteden%26aufirst%3DH.%2BC.%26aulast%3Dvan%2BDongen%26aufirst%3DJ.%2BJ.%26aulast%3Dvan%2BHal%26aufirst%3DP.%2BT.%26aulast%3DDelahaye%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DW.%26aulast%3DHilvering%26aufirst%3DC.%26atitle%3DPhenotype%2520of%2520blood%2520monocytes%2520and%2520alveolar%2520macrophages%2520in%2520interstitial%2520lung%2520disease%26jtitle%3DChest%26date%3D1989%26volume%3D95%26spage%3D574%26epage%3D577%26doi%3D10.1378%2Fchest.95.3.574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Thorley, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tetley, T. D.</span><span> </span><span class="NLM_article-title">Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Int. J. Chron. Obstruct. Pulmon. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=409-428&author=A.+J.+Thorleyauthor=T.+D.+Tetley&title=Pulmonary+epithelium%2C+cigarette+smoke%2C+and+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThorley%26aufirst%3DA.%2BJ.%26aulast%3DTetley%26aufirst%3DT.%2BD.%26atitle%3DPulmonary%2520epithelium%252C%2520cigarette%2520smoke%252C%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DInt.%2520J.%2520Chron.%2520Obstruct.%2520Pulmon.%2520Dis.%26date%3D2007%26volume%3D4%26spage%3D409%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/j.jaci.2012.12.1564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2Fj.jaci.2012.12.1564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=23360759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2013&pages=636-45&author=P.+J.+Barnes&title=Corticosteroid+resistance+in+patients+with+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.jaci.2012.12.1564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">636-645</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Reduced responsiveness to the anti-inflammatory effects of corticosteroids is a major barrier to effective management of asthma in smokers and patients with severe asthma and in the majority of patients with chronic obstructive pulmonary disease (COPD).  The mol. mechanisms leading to steroid resistance are now better understood, and this has identified new targets for therapy.  In patients with severe asthma, several mol. mechanisms have been identified that might account for reduced steroid responsiveness, including reduced nuclear translocation of glucocorticoid receptor (GR) α after binding corticosteroids.  This might be due to modification of the GR by means of phosphorylation as a result of activation of several kinases (p38 mitogen-activated protein kinase α, p38 mitogen-activated protein kinase γ, and c-Jun N-terminal kinase 1), which in turn might be due to reduced activity and expression of phosphatases, such as mitogen-activated protein kinase phosphatase 1 and protein phosphatase A2.  Other mechanisms proposed include increased expression of GRβ, which competes with and thus inhibits activated GRα; increased secretion of macrophage migration inhibitory factor; competition with the transcription factor activator protein 1; and reduced expression of histone deacetylase (HDAC) 2.  HDAC2 appears to mediate the action of steroids to switch off activated inflammatory genes, but in patients with COPD, patients with severe asthma, and smokers with asthma, HDAC2 activity and expression are reduced by oxidative stress through activation of phosphoinositide 3-kinase δ.  Strategies for managing steroid resistance include alternative anti-inflammatory drugs, but a novel approach is to reverse steroid resistance by increasing HDAC2 expression, which can be achieved with theophylline and phosphoinositide 3-kinase δ inhibitors.  Long-acting β2-agonists can also increase steroid responsiveness by reversing GRα phosphorylation.  Identifying the mol. mechanisms of steroid resistance in asthmatic patients and patients with COPD can thus lead to more effective anti-inflammatory treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7NxvF8RwhRrVg90H21EOLACvtfcHk0ljmcgUCi1I8Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWmtrY%253D&md5=b9f464c23387722c42b85280cc106d07</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2012.12.1564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2012.12.1564%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DCorticosteroid%2520resistance%2520in%2520patients%2520with%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2013%26volume%3D131%26spage%3D636%26epage%3D45%26doi%3D10.1016%2Fj.jaci.2012.12.1564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Saklatvala, J.</span><span> </span><span class="NLM_article-title">The p38 MAP kinase pathway as a therapeutic target in inflammatory disease</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">372</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span><span class="refDoi"> DOI: 10.1016/j.coph.2004.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2Fj.coph.2004.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=15251131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Wgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=372-377&author=J.+Saklatvala&title=The+p38+MAP+kinase+pathway+as+a+therapeutic+target+in+inflammatory+disease&doi=10.1016%2Fj.coph.2004.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The p38 MAP kinase pathway as a therapeutic target in inflammatory disease</span></div><div class="casAuthors">Saklatvala, Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">372-377</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  The p38 MAPK signalling pathway plays an important role in inflammation and other physiol. processes.  Specific inhibitors of p38 α and β MAPK block prodn. of the major inflammatory cytokines (i.e. tumor necrosis factor-α and interleukin-1) and other proteins (e.g. cyclooxygenase-2), and are anti-inflammatory in animal models of disease.  A major function of the pathway is post-transcriptional control of inflammatory gene expression.  Many of the mRNAs are unstable (or untranslatable) because of AU-rich elements in the 3'untranslated region.  Signalling in the p38 pathway counteracts these and stabilizes the mRNAs by preventing their otherwise rapid de-adenylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglO4EVBhJ-LVg90H21EOLACvtfcHk0ljmcgUCi1I8Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Wgu7s%253D&md5=5678936250f1dbc9c27707bd7edf6108</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2004.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2004.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DSaklatvala%26aufirst%3DJ.%26atitle%3DThe%2520p38%2520MAP%2520kinase%2520pathway%2520as%2520a%2520therapeutic%2520target%2520in%2520inflammatory%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2004%26volume%3D4%26spage%3D372%26epage%3D377%26doi%3D10.1016%2Fj.coph.2004.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wang, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diener, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan-Hui, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantlo, N.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">23668</span><span class="NLM_x">–</span> <span class="NLM_lpage">23674</span><span class="refDoi"> DOI: 10.1074/jbc.272.38.23668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1074%2Fjbc.272.38.23668" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=23668-23674&author=X.+S.+Wangauthor=K.+Dienerauthor=C.+L.+Mantheyauthor=S.+Wangauthor=B.+Rosenzweigauthor=J.+Brayauthor=J.+Delaneyauthor=C.+N.+Coleauthor=P.+Chan-Huiauthor=N.+Mantlo&title=Molecular+cloning+and+characterization+of+a+novel+p38+mitogen-activated+protein+kinase&doi=10.1074%2Fjbc.272.38.23668"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.38.23668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.38.23668%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BS.%26aulast%3DDiener%26aufirst%3DK.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DRosenzweig%26aufirst%3DB.%26aulast%3DBray%26aufirst%3DJ.%26aulast%3DDelaney%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DC.%2BN.%26aulast%3DChan-Hui%26aufirst%3DP.%26aulast%3DMantlo%26aufirst%3DN.%26atitle%3DMolecular%2520cloning%2520and%2520characterization%2520of%2520a%2520novel%2520p38%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D23668%26epage%3D23674%26doi%3D10.1074%2Fjbc.272.38.23668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Mercado, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span> </span><span class="NLM_article-title">p38 Mitogen-activated protein kinase−γ inhibition by long-acting β2 adrenergic agonists reversed steroid insensitivity in severe asthma</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">1128</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1124/mol.111.071993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1124%2Fmol.111.071993" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=1128-35&author=N.+Mercadoauthor=Y.+Toauthor=Y.+Kobayashiauthor=I.+M.+Adcockauthor=P.+J.+Barnesauthor=K.+Ito&title=p38+Mitogen-activated+protein+kinase%E2%88%92%CE%B3+inhibition+by+long-acting+%CE%B22+adrenergic+agonists+reversed+steroid+insensitivity+in+severe+asthma&doi=10.1124%2Fmol.111.071993"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.071993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.071993%26sid%3Dliteratum%253Aachs%26aulast%3DMercado%26aufirst%3DN.%26aulast%3DTo%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DAdcock%26aufirst%3DI.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DIto%26aufirst%3DK.%26atitle%3Dp38%2520Mitogen-activated%2520protein%2520kinase%25E2%2588%2592%25CE%25B3%2520inhibition%2520by%2520long-acting%2520%25CE%25B22%2520adrenergic%2520agonists%2520reversed%2520steroid%2520insensitivity%2520in%2520severe%2520asthma%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D1128%26epage%3D35%26doi%3D10.1124%2Fmol.111.071993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabbagh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phippard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suttmann, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leaffer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aud, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Porto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. R.</span><span> </span><span class="NLM_article-title">Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span><span class="refDoi"> DOI: 10.1124/jpet.108.139006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1124%2Fjpet.108.139006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=18776065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=610-619&author=R.+J.+Hillauthor=K.+Dabbaghauthor=D.+Phippardauthor=C.+Liauthor=R.+T.+Suttmannauthor=M.+Welchauthor=E.+Pappauthor=K.+W.+Songauthor=K.-C.+Changauthor=D.+Leafferauthor=Y.-N.+Kimauthor=R.+T.+Robertsauthor=T.+S.+Zabkaauthor=D.+Audauthor=J.+Dal+Portoauthor=A.+M.+Manningauthor=S.+L.+Pengauthor=D.+M.+Goldsteinauthor=B.+R.+Wong&title=Pamapimod%2C+a+novel+p38+mitogen-activated+protein+kinase+inhibitor%3A+preclinical+analysis+of+efficacy+and+selectivity&doi=10.1124%2Fjpet.108.139006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity</span></div><div class="casAuthors">Hill, Ronald J.; Dabbagh, Karim; Phippard, Deborah; Li, Ching; Suttmann, Rebecca T.; Welch, Mary; Papp, Eva; Song, Kyung W.; Chang, Kung-ching; Leaffer, David; Kim, Yong-Nam; Roberts, Richard T.; Zabka, Tanja S.; Aud, Dee; Dal Porto, Joseph; Manning, Anthony M.; Peng, Stanford L.; Goldstein, David M.; Wong, Brian R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">610-619</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P38α is a protein kinase that regulates the expression of inflammatory cytokines, suggesting a role in the pathogenesis of diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus.  Here, we describe the preclin. pharmacol. of pamapimod, a novel p38 mitogen-activated protein kinase inhibitor.  Pamapimod inhibited p38α and p38β enzymic activity, with IC50 values of 0.014±0.002 and 0.48±0.04 μM, resp.  There was no activity against p38δ or p38γ isoforms.  When profiled across 350 kinases, pamapimod bound only to four kinases in addn. to p38.  Cellular potency was assessed using phosphorylation of heat shock protein-27 and c-Jun as selective readouts for p38 and c-Jun NH2-terminal kinase (JNK), resp.  Pamapimod inhibited p38 (IC50, 0.06 μM), but inhibition of JNK was not detected.  Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) α prodn. by monocytes, interleukin (IL)-1β prodn. in human whole blood, and spontaneous TNFα prodn. by synovial explants from RA patients.  LPS- and TNFα-stimulated prodn. of TNFα and IL-6 in rodents also was inhibited by pamapimod.  In murine collagen-induced arthritis, pamapimod reduced clin. signs of inflammation and bone loss at 50 mg/kg or greater.  In a rat model of hyperalgesia, pamapimod increased tolerance to pressure in a dose-dependent manner, suggesting an important role of p38 in pain assocd. with inflammation.  Finally, an analog of pamapimod that has equiv. potency and selectivity inhibited renal disease in lupus-prone MRL/lpr mice.  Our study demonstrates that pamapimod is a potent, selective inhibitor of p38α with the ability to inhibit the signs and symptoms of RA and other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoImm011NnzW7Vg90H21EOLACvtfcHk0lge_iKVmqmwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtL3F&md5=9311aa6b1a51544ac755d1cc77cdd92f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.139006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.139006%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DDabbagh%26aufirst%3DK.%26aulast%3DPhippard%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DSuttmann%26aufirst%3DR.%2BT.%26aulast%3DWelch%26aufirst%3DM.%26aulast%3DPapp%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DK.%2BW.%26aulast%3DChang%26aufirst%3DK.-C.%26aulast%3DLeaffer%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.-N.%26aulast%3DRoberts%26aufirst%3DR.%2BT.%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DAud%26aufirst%3DD.%26aulast%3DDal%2BPorto%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DS.%2BL.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DB.%2BR.%26atitle%3DPamapimod%252C%2520a%2520novel%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%253A%2520preclinical%2520analysis%2520of%2520efficacy%2520and%2520selectivity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D610%26epage%3D619%26doi%3D10.1124%2Fjpet.108.139006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Cohen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chindalore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimany, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, J. P.</span><span> </span><span class="NLM_article-title">Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1002/art.24266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1002%2Fart.24266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=19180516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1CgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=335-44&author=S.+B.+Cohenauthor=T.+T.+Chengauthor=V.+Chindaloreauthor=N.+Damjanovauthor=R.+Burgos-Vargasauthor=P.+Deloraauthor=K.+Zimanyauthor=H.+Traversauthor=J.+P.+Caulfield&title=Evaluation+of+the+efficacy+and+safety+of+pamapimod%2C+a+p38+MAP+kinase+inhibitor%2C+in+a+double-blind%2C+methotrexate-controlled+study+of+patients+with+active+rheumatoid+arthritis&doi=10.1002%2Fart.24266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active Rheumatoid arthritis</span></div><div class="casAuthors">Cohen, Stanley B.; Cheng, Tien-Tsai; Chindalore, Vishala; Damjanov, Nemanja; Burgos-Vargas, Ruben; DeLora, Patricia; Zimany, Kathleen; Travers, Helen; Caulfield, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">335-344</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To det. the efficacy and safety of pamapimod (a selective inhibitor of the α-isoform of p38 MAP kinase) as monotherapy in comparison with methotrexate (MTX) treatment in adult patients with active rheumatoid arthritis (RA).  Methods: Patients were randomly assigned to 1 of 4 treatment groups and received 12 wk of double-blind treatment.  One group received MTX (7.5 mg/wk with planned escalation to 20 mg/wk), and 3 groups received pamapimod (50, 150, or 300 mg) once daily.  The primary efficacy end point was the proportion of patients meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at 12 wk.  Secondary end points included ACR50 and ACR70 responses, change from baseline in the Disease Activity Score in 28 joints (DAS28), categorical analyses of DAS28/European League Against Rheumatism response, and change from baseline in each parameter of the ACR core set of measures.  Safety monitoring included recording of adverse events (AEs), lab. testing, immunol. assessments, administration of electrocardiograms, and assessment of vital signs.  Results: Patients assigned to receive MTX and pamapimod had similar demographics and baseline characteristics.  At week 12, fewer patients taking pamapimod had an ACR20 response (23%, 18%, and 31% in the 50-, 150-, and 300-mg groups, resp.) compared with patients taking MTX (45%).  Secondary efficacy end points showed a similar pattern.  AEs were typically characterized as mild and included infections, skin disorders, and dizziness.  Pamapimod was generally well tolerated, but the 300-mg dose appeared to be more toxic than either the 2 lower doses or MTX.  Conclusion: The present results showed that pamapimod was not as effective as MTX in the treatment of active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp98GB6seTS2rVg90H21EOLACvtfcHk0lge_iKVmqmwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1CgtL4%253D&md5=d76a0ea256ab02b1c16d388be13c2f3e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fart.24266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24266%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DCheng%26aufirst%3DT.%2BT.%26aulast%3DChindalore%26aufirst%3DV.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DDelora%26aufirst%3DP.%26aulast%3DZimany%26aufirst%3DK.%26aulast%3DTravers%26aufirst%3DH.%26aulast%3DCaulfield%26aufirst%3DJ.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520pamapimod%252C%2520a%2520p38%2520MAP%2520kinase%2520inhibitor%252C%2520in%2520a%2520double-blind%252C%2520methotrexate-controlled%2520study%2520of%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D335%26epage%3D44%26doi%3D10.1002%2Fart.24266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wofsy, D.</span><span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled phase 2 study of an oral p38αMAPK inhibitor, SCIO-469, in patients with active rheumatoid arthritis. [abstract 715]</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">S431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=S431&issue=Suppl&author=M.+C.+Genoveseauthor=S.+B.+Cohenauthor=D.+Wofsy&title=A+randomized%2C+double-blind%2C+placebo-controlled+phase+2+study+of+an+oral+p38%CE%B1MAPK+inhibitor%2C+SCIO-469%2C+in+patients+with+active+rheumatoid+arthritis.+%5Babstract+715%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DWofsy%26aufirst%3DD.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25202%2520study%2520of%2520an%2520oral%2520p38%25CE%25B1MAPK%2520inhibitor%252C%2520SCIO-469%252C%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis.%2520%255Babstract%2520715%255D%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26issue%3DSuppl%26spage%3DS431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgnrlF0vqWLzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Selness, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devadas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durley, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rucker, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerome, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrufo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Promo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickory, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvira, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blevis-Bal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yalamanchili, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonder Embse, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, J. B.</span><span> </span><span class="NLM_article-title">Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4066</span><span class="NLM_x">–</span> <span class="NLM_lpage">4071</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2Fj.bmcl.2011.04.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=21641211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4066-4071&author=S.+R.+Selnessauthor=R.+V.+Devrajauthor=B.+Devadasauthor=J.+K.+Walkerauthor=T.+L.+Boehmauthor=R.+C.+Durleyauthor=H.+Shiehauthor=L.+Xingauthor=P.+V.+Ruckerauthor=K.+D.+Jeromeauthor=A.+G.+Bensonauthor=L.+D.+Marrufoauthor=H.+M.+Madsenauthor=J.+Hitchcockauthor=T.+J.+Owenauthor=L.+Christieauthor=M.+A.+Promoauthor=B.+S.+Hickoryauthor=E.+Alviraauthor=W.+Naingauthor=R.+Blevis-Balauthor=D.+Messingauthor=J.+Yangauthor=M.+K.+Maoauthor=G.+Yalamanchiliauthor=R.+Vonder+Embseauthor=J.+Hirschauthor=M.+Saabyeauthor=S.+Bonarauthor=E.+Webbauthor=G.+Andersonauthor=J.+B.+Monahan&title=Discovery+of+PH-797804%2C+a+highly+selective+and+potent+inhibitor+of+p38+MAP+kinase&doi=10.1016%2Fj.bmcl.2011.04.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase</span></div><div class="casAuthors">Selness, Shaun R.; Devraj, Rajesh V.; Devadas, Balekudru; Walker, John K.; Boehm, Terri L.; Durley, Richard C.; Shieh, Huey; Xing, Li; Rucker, Paul V.; Jerome, Kevin D.; Benson, Alan G.; Marrufo, Laura D.; Madsen, Heather M.; Hitchcock, Jeff; Owen, Tom J.; Christie, Lance; Promo, Michele A.; Hickory, Brian S.; Alvira, Edgardo; Naing, Win; Blevis-Bal, Radhika; Messing, Dean; Yang, Jerry; Mao, Michael K.; Yalamanchili, Gopi; Vonder Embse, Richard; Hirsch, Jeffrey; Saabye, Matthew; Bonar, Sheri; Webb, Elizabeth; Anderson, Gary; Monahan, Joseph B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4066-4071</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and SAR studies of a novel N-arylpyridinone class of p38 kinase inhibitors are described.  Systematic structural modifications to the HTS lead led to the identification of a clin. candidate (phase II clin. studies) for the treatment of inflammatory diseases.  Addnl., the chiral synthesis and properties of said clin. candidate are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL54FATgVMdbVg90H21EOLACvtfcHk0lgnrlF0vqWLzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLk%253D&md5=eb900d70d0c84f642e3b09ecbeb0cf91</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.121%26sid%3Dliteratum%253Aachs%26aulast%3DSelness%26aufirst%3DS.%2BR.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DDevadas%26aufirst%3DB.%26aulast%3DWalker%26aufirst%3DJ.%2BK.%26aulast%3DBoehm%26aufirst%3DT.%2BL.%26aulast%3DDurley%26aufirst%3DR.%2BC.%26aulast%3DShieh%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DRucker%26aufirst%3DP.%2BV.%26aulast%3DJerome%26aufirst%3DK.%2BD.%26aulast%3DBenson%26aufirst%3DA.%2BG.%26aulast%3DMarrufo%26aufirst%3DL.%2BD.%26aulast%3DMadsen%26aufirst%3DH.%2BM.%26aulast%3DHitchcock%26aufirst%3DJ.%26aulast%3DOwen%26aufirst%3DT.%2BJ.%26aulast%3DChristie%26aufirst%3DL.%26aulast%3DPromo%26aufirst%3DM.%2BA.%26aulast%3DHickory%26aufirst%3DB.%2BS.%26aulast%3DAlvira%26aufirst%3DE.%26aulast%3DNaing%26aufirst%3DW.%26aulast%3DBlevis-Bal%26aufirst%3DR.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DM.%2BK.%26aulast%3DYalamanchili%26aufirst%3DG.%26aulast%3DVonder%2BEmbse%26aufirst%3DR.%26aulast%3DHirsch%26aufirst%3DJ.%26aulast%3DSaabye%26aufirst%3DM.%26aulast%3DBonar%26aufirst%3DS.%26aulast%3DWebb%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DG.%26aulast%3DMonahan%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520PH-797804%252C%2520a%2520highly%2520selective%2520and%2520potent%2520inhibitor%2520of%2520p38%2520MAP%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4066%26epage%3D4071%26doi%3D10.1016%2Fj.bmcl.2011.04.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">MacNee, W.; Allan, R.; Jones, I.; De Salvo, M. C.; Tan, L.</span><span> </span><span class="NLM_article-title">A Randomised, Placebo Controlled Trial of 6 Weeks’ Treatment with a Novel Oral p38 Inhibitor in Patients with COPD</span>, <span class="NLM_conf-name">European Respiratory Society Meeting</span>, <span class="NLM_conf-loc">Barcelona, Spain</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&conference=European+Respiratory+Society+Meeting&author=W.+MacNee&author=R.+Allan&author=I.+Jones&author=M.+C.+De+Salvo&author=L.+Tan&title=A+Randomised%2C+Placebo+Controlled+Trial+of+6+Weeks%E2%80%99+Treatment+with+a+Novel+Oral+p38+Inhibitor+in+Patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMacNee%26aufirst%3DW.%26atitle%3DA%2520Randomised%252C%2520Placebo%2520Controlled%2520Trial%2520of%25206%2520Weeks%25E2%2580%2599%2520Treatment%2520with%2520a%2520Novel%2520Oral%2520p38%2520Inhibitor%2520in%2520Patients%2520with%2520COPD%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willits, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keene, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnacle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tal-Singer, R.</span><span> </span><span class="NLM_article-title">An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1177/0091270010397050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1177%2F0091270010397050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=22090363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvV2htro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=416-424&author=D.+A.+Lomasauthor=D.+A.+Lipsonauthor=B.+E.+Millerauthor=L.+Willitsauthor=O.+Keeneauthor=H.+Barnacleauthor=N.+C.+Barnesauthor=R.+Tal-Singer&title=An+oral+inhibitor+of+p38+MAP+kinase+reduces+plasma+fibrinogen+in+patients+with+chronic+obstructive+pulmonary+disease&doi=10.1177%2F0091270010397050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Lomas, David A.; Lipson, David A.; Miller, Bruce E.; Willits, Lisa; Keene, Oliver; Barnacle, Helen; Barnes, Neil C.; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">416-424</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aims were to det. the effect of an oral inhibitor of the signaling mediator p38 mitogen-activated protein kinase (GW856553, losmapimod) on sputum neutrophils, pulmonary function, and blood biomarkers of inflammation in chronic obstructive pulmonary disease (COPD).  Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 μg/500 μg combination (SFC), or placebo in a 12-wk, randomized, double-blind, double-dummy study (MKI102428/NCT00642148).  Neither losmapimod nor SFC had an effect on the primary end point of sputum neutrophils.  Losmapimod was well tolerated and reduced plasma fibrinogen by 11% (-0.4 g/L, ratio of effect of losmapimod/placebo 0.89; 95% confidence interval, 0.83-0.96; P = .002) with nonsignificant redns. in interleukin-6, interleukin-8, and C-reactive protein.  There was evidence of improvement in hyperinflation with losmapimod compared with placebo (overall P = .02).  Inhaled SFC significantly improved lung function and reduced serum CC-16 (ratio of effect of SFC/placebo 0.87; 95% confidence interval, 0.82-0.93; P < .001).  It was concluded that oral losmapimod significantly reduced plasma fibrinogen in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDLEldspAO5LVg90H21EOLACvtfcHk0ljJs6P6pDEkcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvV2htro%253D&md5=31913fca689b64e4f958eee382cd55f9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1177%2F0091270010397050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270010397050%26sid%3Dliteratum%253Aachs%26aulast%3DLomas%26aufirst%3DD.%2BA.%26aulast%3DLipson%26aufirst%3DD.%2BA.%26aulast%3DMiller%26aufirst%3DB.%2BE.%26aulast%3DWillits%26aufirst%3DL.%26aulast%3DKeene%26aufirst%3DO.%26aulast%3DBarnacle%26aufirst%3DH.%26aulast%3DBarnes%26aufirst%3DN.%2BC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DAn%2520oral%2520inhibitor%2520of%2520p38%2520MAP%2520kinase%2520reduces%2520plasma%2520fibrinogen%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D52%26spage%3D416%26epage%3D424%26doi%3D10.1177%2F0091270010397050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Watz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnacle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, R.</span><span> </span><span class="NLM_article-title">Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/S2213-2600(13)70200-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2FS2213-2600%2813%2970200-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=24461903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFagsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=63-72&author=H.+Watzauthor=H.+Barnacleauthor=B.+F.+Hartleyauthor=R.+Chan&title=Efficacy+and+safety+of+the+p38+MAPK+inhibitor+losmapimod+for+patients+with+chronic+obstructive+pulmonary+disease%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS2213-2600%2813%2970200-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Watz, Henrik; Barnacle, Helen; Hartley, Benjamin F.; Chan, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The p38 MAPK pathway seems to be involved in pathogenesis of chronic obstructive pulmonary disease (COPD).  Losmapimod is a potent and selective inhibitor of p38 MAPK.  We assessed the effect of losmapimod on exercise tolerance in patients with COPD.  We did this randomised, parallel-group, placebo-controlled trial at 46 secondary care centers in Argentina, Czech Republic, Estonia, Germany, Norway, South Korea, Ukraine, and USA between Nov 4, 2010, and Dec 22, 2011.  We enrolled patients aged 40 years or older with moderate-to-severe COPD (6 min walking distance <350 m) who were current or previous smokers.  Patients were randomly assigned (1:1:1:1) by a computer generated sequence to one of losmapimod 2·5 mg, 7·5 mg, or 15 mg, or placebo, twice daily for 24 wk.  Randomisation was stratified by country and exacerbation history (block size eight).  Patients and investigators were masked to treatment assignment.  The primary outcome was change in 6 min walking distance between baseline and week 24, assessed in the intention-to-treat population.  This study is registered with ClinicalTrial.gov, no. NCT01218126.  We screened 886 patients, of whom 602 were enrolled and received treatment.  The difference between the placebo group and the losmapimod groups for mean change of 6 min walk distance was not significant: -6·7 m (95% CI -18·2 to 4·9) for losmapimod 2·5 mg, -4·7 m (-16·1 to 6·8) for losmapimod 7·5 mg, and -3·4 m (-15·1 to 8·2) for losmapimod 15 mg.  The safety profile was much the same in each group, although drug-related adverse events were more common with losmapimod 7·5 mg (n=19, 13%) and losmapimod 15 mg (n=20, 13%) than with placebo (n=11, 7%) and losmapimod 2·5 mg (n=13, 9%).  The most common serious adverse events were COPD exacerbation resulting in admission to hospital (eight patients [5%] taking placebo, six [4%] taking losmapimod 2·5 mg, two [1%] taking losmapimod 7·5 mg, and three [2%] taking losmapimod 15 mg) and pneumonia (four [3%] vs 0 [0%] vs 1 [1%] vs 4 [3%]).  Losmapimod did not cause an improvement in exercise tolerance or lung function, despite being well-tolerated in this COPD population.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfxc1a62NhF7Vg90H21EOLACvtfcHk0ljJs6P6pDEkcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFagsA%253D%253D&md5=b737200c2467329d4da544ca7b009e14</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2813%2970200-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252813%252970200-5%26sid%3Dliteratum%253Aachs%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DBarnacle%26aufirst%3DH.%26aulast%3DHartley%26aufirst%3DB.%2BF.%26aulast%3DChan%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520p38%2520MAPK%2520inhibitor%2520losmapimod%2520for%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2014%26volume%3D2%26spage%3D63%26epage%3D72%26doi%3D10.1016%2FS2213-2600%2813%2970200-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Regan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capolino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroe, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pargellis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torcellini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span> </span><span class="NLM_article-title">Structure-Activity Relationships of the p38 MAP Kinase Inhibitor 1-(5-<i>tert</i>-Butyl-2-<i>p</i>-tolyl-2<i>H</i>-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph-thalen-1-yl]urea (BIRB-796)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4676</span><span class="NLM_x">–</span> <span class="NLM_lpage">4686</span><span class="refDoi"> DOI: 10.1021/jm030121k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030121k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4676-4686&author=J.+Reganauthor=A.+Capolinoauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=E.+Hickeyauthor=R.+R.+Kroeauthor=J.+Madwedauthor=M.+Moriakauthor=R.+Nelsonauthor=C.+A.+Pargellisauthor=A.+Swinamerauthor=C.+Torcelliniauthor=M.+Tsangauthor=N.+Moss&title=Structure-Activity+Relationships+of+the+p38+MAP+Kinase+Inhibitor+1-%285-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl%29-3-%5B4-%282-morpholin-4-yl-ethoxy%29naph-thalen-1-yl%5Durea+%28BIRB-796%29&doi=10.1021%2Fjm030121k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm030121k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030121k%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DCapolino%26aufirst%3DA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DKroe%26aufirst%3DR.%2BR.%26aulast%3DMadwed%26aufirst%3DJ.%26aulast%3DMoriak%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DR.%26aulast%3DPargellis%26aufirst%3DC.%2BA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DTorcellini%26aufirst%3DC.%26aulast%3DTsang%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520the%2520p38%2520MAP%2520Kinase%2520Inhibitor%25201-%25285-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl%2529-3-%255B4-%25282-morpholin-4-yl-ethoxy%2529naph-thalen-1-yl%255Durea%2520%2528BIRB-796%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4676%26epage%3D4686%26doi%3D10.1021%2Fjm030121k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Branger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Blink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weijer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polmar, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olszyna, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deventer, S. J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peppelenbosch, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Poll, T.</span><span> </span><span class="NLM_article-title">Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">168</span><span class="NLM_x">, </span> <span class="NLM_fpage">4070</span><span class="NLM_x">–</span> <span class="NLM_lpage">4077</span><span class="refDoi"> DOI: 10.4049/jimmunol.168.8.4070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.4049%2Fjimmunol.168.8.4070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2002&pages=4070-4077&author=J.+Brangerauthor=B.+van+den+Blinkauthor=S.+Weijerauthor=J.+Madwedauthor=C.+L.+Bosauthor=A.+Guptaauthor=C.-L.+Yongauthor=S.+H.+Polmarauthor=D.+P.+Olszynaauthor=E.+Hackauthor=S.+J.+H.+van+Deventerauthor=M.+P.+Peppelenboschauthor=T.+van+der+Poll&title=Anti-inflammatory+effects+of+a+p38+mitogen-activated+protein+kinase+inhibitor+during+human+endotoxemia&doi=10.4049%2Fjimmunol.168.8.4070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.168.8.4070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.168.8.4070%26sid%3Dliteratum%253Aachs%26aulast%3DBranger%26aufirst%3DJ.%26aulast%3Dvan%2Bden%2BBlink%26aufirst%3DB.%26aulast%3DWeijer%26aufirst%3DS.%26aulast%3DMadwed%26aufirst%3DJ.%26aulast%3DBos%26aufirst%3DC.%2BL.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DYong%26aufirst%3DC.-L.%26aulast%3DPolmar%26aufirst%3DS.%2BH.%26aulast%3DOlszyna%26aufirst%3DD.%2BP.%26aulast%3DHack%26aufirst%3DE.%26aulast%3Dvan%2BDeventer%26aufirst%3DS.%2BJ.%2BH.%26aulast%3DPeppelenbosch%26aufirst%3DM.%2BP.%26aulast%3Dvan%2Bder%2BPoll%26aufirst%3DT.%26atitle%3DAnti-inflammatory%2520effects%2520of%2520a%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%2520during%2520human%2520endotoxemia%26jtitle%3DJ.%2520Immunol.%26date%3D2002%26volume%3D168%26spage%3D4070%26epage%3D4077%26doi%3D10.4049%2Fjimmunol.168.8.4070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feagan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Haens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geboes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurcov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golovenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffgen, J.</span><span> </span><span class="NLM_article-title">Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Clin. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.cgh.2005.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2Fj.cgh.2005.11.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16527696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFOqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=325-234&author=S.+Schreiberauthor=B.+Feaganauthor=G.+D%E2%80%99Haensauthor=J.+F.+Colombelauthor=K.+Geboesauthor=M.+Yurcovauthor=V.+Isakovauthor=O.+Golovenkoauthor=C.+N.+Bernsteinauthor=D.+Ludwigauthor=T.+Winterauthor=U.+Meierauthor=C.+Yongauthor=J.+Steffgen&title=Oral+p38+mitogen-activated+protein+kinase+inhibition+with+BIRB+796+for+active+Crohn%E2%80%99s+disease%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2Fj.cgh.2005.11.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double- blind, placebo- controlled trial</span></div><div class="casAuthors">Schreiber, Stefan; Feagan, Brian; D'Haens, Geert; Colombel, Jean-Frederic; Geboes, Karel; Yurcov, Mikhail; Isakov, Vasily; Golovenko, Oleg; Bernstein, Charles N.; Ludwig, Diether; Winter, Trevor; Meier, Ulrich; Yong, Chan; Steffgen, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Gastroenterology and Hepatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-334</span>CODEN:
                <span class="NLM_cas:coden">CGHLAW</span>;
        ISSN:<span class="NLM_cas:issn">1542-3565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein kinase (MAPK) regulates the expression of proinflammatory cytokines, which play a crit. role in the pathophysiol. of Crohn's disease (CD).  This study investigated the efficacy and safety of BIRB 796, a highly potent inhibitor of p38 MAPK, in chronic active CD.  In a multicenter, multinational trial, 284 patients with moderate to severe CD were randomized to receive placebo, or 10, 20, 30, or 60 mg of BIRB 796 twice daily for 8 wk.  Clin. endpoints were based on std. safety assessments, CD Activity Index, C-reactive protein levels, and quality of life (Inflammatory Bowel Disease Questionnaire).  In a substudy, the Crohn's Disease Endoscopic Index of Severity and histol. results of biopsy specimens were assessed.  No clin. efficacy (primary end point, clin. remission; secondary end point, clin. response; Inflammatory Bowel Disease Questionnaire; Crohn's Disease Endoscopic Index of Severity) was seen for BIRB 796 in comparison with placebo.  A significant, dose-dependent decrease of C-reactive protein level was obsd. transiently after BIRB 796 after 1 wk with a return to baseline level over time.  The incidence of adverse events was comparable between all treatment groups, with the exception of a mild increase of transaminase levels that was seen more frequently in the BIRB 796 groups.  Geog. center effects were obsd. with Russian centers producing distinctly higher remission and response rates and lower adverse event rates than in other countries in both placebo and active treatment groups.  There was no evidence for clin. efficacy of BIRB 796 in CD.  A remarkable difference in the course of CD exists between Russia and non-Russian centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPlk4HFJbHhrVg90H21EOLACvtfcHk0lj5aOTqdBNyzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFOqsrs%253D&md5=f99fbaeea2b16c7e5fa11069b99518f1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2005.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2005.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DFeagan%26aufirst%3DB.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DGeboes%26aufirst%3DK.%26aulast%3DYurcov%26aufirst%3DM.%26aulast%3DIsakov%26aufirst%3DV.%26aulast%3DGolovenko%26aufirst%3DO.%26aulast%3DBernstein%26aufirst%3DC.%2BN.%26aulast%3DLudwig%26aufirst%3DD.%26aulast%3DWinter%26aufirst%3DT.%26aulast%3DMeier%26aufirst%3DU.%26aulast%3DYong%26aufirst%3DC.%26aulast%3DSteffgen%26aufirst%3DJ.%26atitle%3DOral%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibition%2520with%2520BIRB%2520796%2520for%2520active%2520Crohn%25E2%2580%2599s%2520disease%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2006%26volume%3D4%26spage%3D325%26epage%3D234%26doi%3D10.1016%2Fj.cgh.2005.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer-Green, G. T.</span><span> </span><span class="NLM_article-title">Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1232</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1002/art.24485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1002%2Fart.24485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=19404957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BD1MzkvFarsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1232-41&author=N.+Damjanovauthor=R.+S.+Kauffmanauthor=G.+T.+Spencer-Green&title=Efficacy%2C+pharmacodynamics%2C+and+safety+of+VX-702%2C+a+novel+p38+MAPK+inhibitor%2C+in+rheumatoid+arthritis%3A+results+of+two+randomized%2C+double-blind%2C+placebo-controlled+clinical+studies&doi=10.1002%2Fart.24485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies</span></div><div class="casAuthors">Damjanov Nemanja; Kauffman Robert S; Spencer-Green George T</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1232-41</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To assess the efficacy and safety of VX-702, a p38 MAPK inhibitor, in patients with active, moderate-to-severe rheumatoid arthritis (RA).  METHODS:  Two 12-week, double-blind, placebo-controlled studies of VX-702 were conducted in patients with active, moderate-to-severe RA.  In the VeRA study, 313 patients received placebo or 2 daily doses of VX-702.  In Study 304, 117 patients received placebo, daily VX-702, or twice weekly VX-702 in addition to concomitant methotrexate (MTX).  Study end points included the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (an ACR20 response), ACR50 and ACR70 responses, changes in the serum levels of biomarkers of inflammation, and safety assessments.  RESULTS:  The numerically superior ACR20 response rates among patients receiving VX-702 compared with those receiving placebo in both studies did not reach pairwise statistical significance at the highest doses in either study.  At week 12 in the VeRA study, ACR20 response rates were 40%, 36%, and 28% among patients receiving 10 mg of VX-702, 5 mg of VX-702, and placebo, respectively.  In Study 304, the response rates were 40%, 44%, and 22% for patients receiving 10 mg VX-702 daily plus MTX, 10 mg VX-702 twice weekly plus MTX, and placebo, respectively.  Reductions in the levels of C-reactive protein, soluble tumor necrosis factor receptor p55, and serum amyloid A were observed as early as week 1 in both studies, but these levels rapidly returned to baseline values by week 4.  The overall frequency of adverse events was similar between the VX-702 and placebo groups.  In the VeRA study, serious infections were more frequent in the VX-702 groups compared with the placebo group (2.4% versus 0%) but not in Study 304 (2.6% versus 4.9%).  CONCLUSION:  The modest clinical efficacy plus the transient suppression of biomarkers of inflammation observed in this study suggest that p38 MAPK inhibition may not provide meaningful, sustained suppression of the chronic inflammation seen in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuFLVCXOhEpYkFb3mqPUYDfW6udTcc2eYMRSa_4eQTy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzkvFarsQ%253D%253D&md5=f23f3b448939ed3cafd7d20410ff81f7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fart.24485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24485%26sid%3Dliteratum%253Aachs%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DSpencer-Green%26aufirst%3DG.%2BT.%26atitle%3DEfficacy%252C%2520pharmacodynamics%252C%2520and%2520safety%2520of%2520VX-702%252C%2520a%2520novel%2520p38%2520MAPK%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%253A%2520results%2520of%2520two%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520clinical%2520studies%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1232%26epage%3D41%26doi%3D10.1002%2Fart.24485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Barouch-Bentov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, K.</span><span> </span><span class="NLM_article-title">Mechanisms of Drug-Resistance in Kinase</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span><span class="refDoi"> DOI: 10.1517/13543784.2011.546344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1517%2F13543784.2011.546344" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=153-208&author=R.+Barouch-Bentovauthor=K.+Sauer&title=Mechanisms+of+Drug-Resistance+in+Kinase&doi=10.1517%2F13543784.2011.546344"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.546344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.546344%26sid%3Dliteratum%253Aachs%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DSauer%26aufirst%3DK.%26atitle%3DMechanisms%2520of%2520Drug-Resistance%2520in%2520Kinase%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D153%26epage%3D208%26doi%3D10.1517%2F13543784.2011.546344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Millan, D. S.</span><span> </span><span class="NLM_article-title">What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1635</span><span class="NLM_x">–</span> <span class="NLM_lpage">1645</span><span class="refDoi"> DOI: 10.4155/fmc.11.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.4155%2Ffmc.11.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=21942253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1635-1645&author=D.+S.+Millan&title=What+is+the+potential+for+inhaled+p38+inhibitors+in+the+treatment+of+chronic+obstructive+pulmonary+disease%3F&doi=10.4155%2Ffmc.11.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?</span></div><div class="casAuthors">Millan, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1635-1645</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  P38 has been an intensely studied therapeutic target in the pharmaceutical industry.  With more than 20 compds. entering human trials, none have progressed beyond Phase II to the best of our knowledge.  The transient efficacy seen in many of the Phase II trials has raised some concerns for the future potential of this target, particularly in rheumatoid arthritis.  With this caveat, there is good evidence for p38 inhibition to be efficacious in chronic obstructive pulmonary disease and there are now several oral compds. currently in development for this disease, with encouraging data beginning to emerge.  With an inhaled agent likely to improve the therapeutic window between efficacy and some of the common adverse events obsd. with oral p38 inhibitors it would seem a sensible approach to take for a disease of the lung.  This review will highlight the potential for an inhaled p38 inhibitor in chronic obstructive pulmonary disease, as well as some of the design principles that are important to consider when developing an inhaled kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4waRvOu6S_LVg90H21EOLACvtfcHk0ljGj0EBd-H47A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvK&md5=81104fda424ad56be567693b9207b4f3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.96%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26atitle%3DWhat%2520is%2520the%2520potential%2520for%2520inhaled%2520p38%2520inhibitors%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1635%26epage%3D1645%26doi%3D10.4155%2Ffmc.11.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Millan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilty, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaitre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahnke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathias, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefaniak, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, C.</span><span> </span><span class="NLM_article-title">Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7797</span><span class="NLM_x">–</span> <span class="NLM_lpage">7814</span><span class="refDoi"> DOI: 10.1021/jm200677b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200677b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7797-7814&author=D.+S.+Millanauthor=M.+E.+Bunnageauthor=J.+L.+Burrowsauthor=K.+J.+Butcherauthor=P.+G.+Doddauthor=T.+J.+Evansauthor=D.+A.+Fairmanauthor=S.+J.+Hughesauthor=I.+C.+Kiltyauthor=A.+Lemaitreauthor=R.+A.+Lewthwaiteauthor=A.+Mahnkeauthor=J.+P.+Mathiasauthor=J.+Philipauthor=R.+T.+Smithauthor=M.+H.+Stefaniakauthor=M.+Yeadonauthor=C.+Phillips&title=Design+and+synthesis+of+inhaled+p38+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm200677b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Millan, David S.; Bunnage, Mark E.; Burrows, Jane L.; Butcher, Kenneth J.; Dodd, Peter G.; Evans, Timothy J.; Fairman, David A.; Hughes, Samantha J.; Kilty, Iain C.; Lemaitre, Arnaud; Lewthwaite, Russell A.; Mahnke, Axel; Mathias, John P.; Philip, James; Smith, Robert T.; Stefaniak, Mark H.; Yeadon, Michael; Phillips, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7797-7814</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes the identification and optimization of a novel series of DFG-out binding p38 inhibitors as inhaled agents for the treatment of chronic obstructive pulmonary disease.  Structure based drug design and "inhalation by design" principles have been applied to the optimization of the lead series exemplified by compd. I.  Analogs have been designed to be potent and selective for p38, with an emphasis on slow enzyme dissocn. kinetics to deliver prolonged lung p38 inhibition.  Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimize systemic exposure and reduce systemically driven adverse events.  High CYP mediated clearance and glucuronidation were targeted to achieve high intrinsic clearance coupled with multiple routes of clearance to minimize drug-drug interactions.  Furthermore, pharmaceutical properties such as stability, crystallinity, and soly. were considered to ensure compatibility with a dry powder inhaler.  P38 Inhibitor II (PF-03715455) was subsequently identified as a clin. candidate from this series with efficacy and safety profiles confirming its potential as an inhaled agent for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzy5ivwDBL6rVg90H21EOLACvtfcHk0ljGj0EBd-H47A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu73E&md5=9bc6cccf04a78831f50fb402bf7cb4b1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm200677b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200677b%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DButcher%26aufirst%3DK.%2BJ.%26aulast%3DDodd%26aufirst%3DP.%2BG.%26aulast%3DEvans%26aufirst%3DT.%2BJ.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLemaitre%26aufirst%3DA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMahnke%26aufirst%3DA.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BT.%26aulast%3DStefaniak%26aufirst%3DM.%2BH.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DC.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520inhaled%2520p38%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7797%26epage%3D7814%26doi%3D10.1021%2Fjm200677b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Smith, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenwick, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschenbaum, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finney-Hayward, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giembycz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, L. E.</span><span> </span><span class="NLM_article-title">Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. B</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0706885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1038%2Fsj.bjp.0706885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16953188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOmu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2006&pages=393-404&author=S.+J.+Smithauthor=P.+S.+Fenwickauthor=A.+G.+Nicholsonauthor=F.+Kirschenbaumauthor=T.+K.+Finney-Haywardauthor=L.+S.+Higginsauthor=M.+A.+Giembyczauthor=P.+J.+Barnesauthor=L.+E.+Donnelly&title=Inhibitory+effect+of+p38+mitogen-activated+protein+kinase+inhibitors+on+cytokine+release+from+human+macrophages.+B&doi=10.1038%2Fsj.bjp.0706885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages</span></div><div class="casAuthors">Smith, S. J.; Fenwick, P. S.; Nicholson, A. G.; Kirschenbaum, F.; Finney-Hayward, T. K.; Higgins, L. S.; Giembycz, M. A.; Barnes, P. J.; Donnelly, L. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-404</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Macrophages release cytokines that may contribute to pulmonary inflammation in conditions such as chronic obstructive pulmonary disease.  Thus, inhibition of macrophage cytokine prodn. may have therapeutic benefit.  P38 MAPK may regulate cytokine prodn., therefore, the effect of two p38 MAPK inhibitors, SB239063 and SD-282, on the release of TNF-α, GM-CSF and IL-8 from human macrophages was investigated.  Cytokine release was measured by ELISA.  Immunoblots and mRNA expression studies were performed to confirm p38 MAPK isoform expression and activity.  Macrophages were isolated from lung tissue of current smokers, ex-smokers and emphysema patients and exposed to lipopolysaccharide.  These cells then released cytokines in a concn.-dependent manner.  SB239063 only inhibited TNF-α release (EC50 0.3±0.1 μM).  Disease status had no effect on the efficacy of SB239063.  SD-282 inhibited both TNF-α and GM-CSF release from macrophages (EC50 6.1±1.4 nM and 1.8±0.6 μM resp.) but had no effect on IL-8 release.  In contrast, both inhibitors suppressed cytokine prodn. in monocytes.  The differential effects of p38 MAPK inhibitors between macrophages and monocytes could not be explained by differences in p38 MAPK isoform expression or activity.  However, the stability of TNF-α mRNA was significantly increased in macrophages compared to monocytes.  These data suggest a differential involvement for p38 MAPK in macrophage cytokine prodn. compared with monocytes.  These effects are not due to lack of p38 activation or p38α expression in macrophages but may reflect differential effects on the stability of cytokine mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBx3hSnKxEsrVg90H21EOLACvtfcHk0lht48E4k0zC_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOmu7fK&md5=24084ac9798291eb4ee62133b779b7c4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706885%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%2BJ.%26aulast%3DFenwick%26aufirst%3DP.%2BS.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DKirschenbaum%26aufirst%3DF.%26aulast%3DFinney-Hayward%26aufirst%3DT.%2BK.%26aulast%3DHiggins%26aufirst%3DL.%2BS.%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DInhibitory%2520effect%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitors%2520on%2520cytokine%2520release%2520from%2520human%2520macrophages.%2520B%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D149%26spage%3D393%26epage%3D404%26doi%3D10.1038%2Fsj.bjp.0706885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Yanagisawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamagata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akamatsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koarai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minakata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, M.</span><span> </span><span class="NLM_article-title">The possible role of hematopoietic cell kinase in the pathophysiology of COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1378/chest.07-3020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1378%2Fchest.07-3020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2009&pages=94-101&author=S.+Yanagisawaauthor=H.+Sugiuraauthor=T.+Yokoyamaauthor=T.+Yamagataauthor=T.+Ichikawaauthor=K.+Akamatsuauthor=A.+Koaraiauthor=T.+Hiranoauthor=M.+Nakanishiauthor=K.+Matsunagaauthor=Y.+Minakataauthor=M.+Ichinose&title=The+possible+role+of+hematopoietic+cell+kinase+in+the+pathophysiology+of+COPD&doi=10.1378%2Fchest.07-3020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1378%2Fchest.07-3020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.07-3020%26sid%3Dliteratum%253Aachs%26aulast%3DYanagisawa%26aufirst%3DS.%26aulast%3DSugiura%26aufirst%3DH.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DYamagata%26aufirst%3DT.%26aulast%3DIchikawa%26aufirst%3DT.%26aulast%3DAkamatsu%26aufirst%3DK.%26aulast%3DKoarai%26aufirst%3DA.%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DM.%26aulast%3DMatsunaga%26aufirst%3DK.%26aulast%3DMinakata%26aufirst%3DY.%26aulast%3DIchinose%26aufirst%3DM.%26atitle%3DThe%2520possible%2520role%2520of%2520hematopoietic%2520cell%2520kinase%2520in%2520the%2520pathophysiology%2520of%2520COPD%26jtitle%3DChest%26date%3D2009%26volume%3D135%26spage%3D94%26epage%3D101%26doi%3D10.1378%2Fchest.07-3020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Smolinska, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbaniak, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutch, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horwood, N. J.</span><span> </span><span class="NLM_article-title">Hck Tyrosine Kinase Regulates TLR4-Induced TNF and IL-6 Production via AP-1</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">187</span><span class="NLM_x">, </span> <span class="NLM_fpage">6043</span><span class="NLM_x">–</span> <span class="NLM_lpage">6051</span><span class="refDoi"> DOI: 10.4049/jimmunol.1100967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.4049%2Fjimmunol.1100967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=6043-6051&author=M.+J.+Smolinskaauthor=T.+H.+Pageauthor=A.+M.+Urbaniakauthor=B.+E.+Mutchauthor=N.+J.+Horwood&title=Hck+Tyrosine+Kinase+Regulates+TLR4-Induced+TNF+and+IL-6+Production+via+AP-1&doi=10.4049%2Fjimmunol.1100967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1100967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1100967%26sid%3Dliteratum%253Aachs%26aulast%3DSmolinska%26aufirst%3DM.%2BJ.%26aulast%3DPage%26aufirst%3DT.%2BH.%26aulast%3DUrbaniak%26aufirst%3DA.%2BM.%26aulast%3DMutch%26aufirst%3DB.%2BE.%26aulast%3DHorwood%26aufirst%3DN.%2BJ.%26atitle%3DHck%2520Tyrosine%2520Kinase%2520Regulates%2520TLR4-Induced%2520TNF%2520and%2520IL-6%2520Production%2520via%2520AP-1%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D6043%26epage%3D6051%26doi%3D10.4049%2Fjimmunol.1100967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Ziegler, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlmutter, R. M.</span><span> </span><span class="NLM_article-title">Novel Protein-Tyrosine Kinase Gene (hck) Preferentially Expressed in Cells of Hematopoietic Origin</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2276</span><span class="NLM_x">–</span> <span class="NLM_lpage">2285</span><span class="refDoi"> DOI: 10.1128/MCB.7.6.2276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1128%2FMCB.7.6.2276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=3453117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADyaL2sXlvFajsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1987&pages=2276-2285&author=S.+F.+Zieglerauthor=J.+D.+Marthauthor=D.+B.+Lewisauthor=R.+M.+Perlmutter&title=Novel+Protein-Tyrosine+Kinase+Gene+%28hck%29+Preferentially+Expressed+in+Cells+of+Hematopoietic+Origin&doi=10.1128%2FMCB.7.6.2276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin</span></div><div class="casAuthors">Ziegler, Steven F.; Marth, Jamey D.; Lewis, David B.; Perlmutter, Roger M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2276-85</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">Protein-tyrosine kinases are implicated in the control of cell growth by virtue of their frequent appearance as products of retroviral oncogenes and as components of growth factor receptors.  A novel human protein-tyrosine kinase gene (hck) was studied that is primarily expressed in hematopoietic cells, particularly granulocytes.  The hck gene encodes a 505-residue polypeptide that is closely related to pp56lck, as lymphocyte-specific protein-tyrosine kinase.  The exon breakpoints of the hck gene, partially defined by using murine genomic clones, demonstrate that hck is a member of the src gene family and has been subjected to strong selection pressure during mammalian evolution.  High-level expression of hck transcripts in granulocytes is esp. provocative since these cells are terminally differentiated and typically survive in vivo for only a few hours.  Thus, the hck gene, like other members of the src gene family, appears to function primarily in cells with little growth potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzU8u9VR4CC7Vg90H21EOLACvtfcHk0lht48E4k0zC_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXlvFajsL8%253D&md5=c39c6db9d7302f3c3a81f811840cb396</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FMCB.7.6.2276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.7.6.2276%26sid%3Dliteratum%253Aachs%26aulast%3DZiegler%26aufirst%3DS.%2BF.%26aulast%3DMarth%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DD.%2BB.%26aulast%3DPerlmutter%26aufirst%3DR.%2BM.%26atitle%3DNovel%2520Protein-Tyrosine%2520Kinase%2520Gene%2520%2528hck%2529%2520Preferentially%2520Expressed%2520in%2520Cells%2520of%2520Hematopoietic%2520Origin%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1987%26volume%3D7%26spage%3D2276%26epage%3D2285%26doi%3D10.1128%2FMCB.7.6.2276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Morphy, R.</span><span> </span><span class="NLM_article-title">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1413</span><span class="NLM_x">–</span> <span class="NLM_lpage">1437</span><span class="refDoi"> DOI: 10.1021/jm901132v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901132v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1413-1437&author=R.+Morphy&title=Selectively+Nonselective+Kinase+Inhibition%3A+Striking+the+Right+Balance&doi=10.1021%2Fjm901132v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span></div><div class="casAuthors">Morphy, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1413-1437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Marketed kinase inhibitors (MKIs) can deliver superior efficacy compared to inhibitors with high specificity for a single kinase, and the recent introduction of several MKIs to the market opens the door to a new era of safer and effective anticancer therapy.  The key to combining high efficacy with acceptable safety is to inhibit multiple targets in a selectively nonselective fashion.  Strategies for intentionally designing MKIs are emerging, but the field is still in its infancy and we are as medicinal chemists currently on the steepest part of the learning curve.  MTDD can be time-consuming and expensive, and we need to become more proficient first at identifying disease-relevant target combinations and second at discovering MKIs that combine optimal physicochem. and biol. properties.  Bold and innovative medicinal chem. strategies are required to tackle "difficult combinations" where the disease rationale is compelling but where it is a struggle to combine all the desired attributes of an oral MKI drug into a single mol.  At present it is unclear to what extent MKIs with highly tuned selectivity profiles can be rationally designed, particularly for targets that are unrelated by sequence.  In addn. to the well-known selectivity challenge, the physicochem. property profiles of AT P-competitive MKIs can be inherently challenging and limited scope for patentability can also be a serious hindrance.  On the plus side, the amt. of kinase-specific structural information is growing very rapidly, and ultimately this may reveal distinct features and design rules that enable a medicinal chemist to rationally modify and refine the profile of MKIs.  In addn., increasing SAR knowledge is emerging from large scale panel screening with the binding profiles starting to reveal to medicinal chemists how chem. structure affects cross-reactivity across large parts of the kinome.  The merit of MKIs compared with single kinase inhibitors is a subject of controversy in drug discovery that is unlikely to be resolved in the near future.  At the start of a new MTDD project, a rigorous debate needs to take place as to whether it makes more sense to seek a combination of highly selective agents or a DML.  Many factors need to be taken into account in this decision such as the no., similarity, and promiscuity of the targets in the profile and the disease area.  Conformational plasticity and the occurrence of multiple binding modes complicate the in silico prediction of kinase polypharmacol. based solely upon protein structure.  The use of ligand-based similarity to assess the feasibility of a given combination can add real value.  Currently, serendipity plays a significant role in MKI discovery and many, if not most, MKIs have been discovered by chance during the search for selective inhibitors.  Medicinal chemists need to be alert to the possibilities when a surprising combination is found by chance.  To exploit such serendipity, you need a good appreciation of when you have a sufficiently high quality starting compd. and then you need to be able to make and test sufficient analogs to explore your new disease-based hypothesis.  MKIs are costly to develop and are consequently priced at a premium level, so they will need to show clear improvements in order to get reimbursement.  There have already been problems with reimbursement for some MKIs in some markets due to concerns from funding bodies over insufficient efficacy.  The true value of MKIs relative to other anticancer drugs still has to be established, and the results from recent clin. trials have been mixed.  Despite the broad activity profile of many MKIs, the patient response can be inconsistent and unpredictable.  The identification of predictive biomarkers of response or resistance is a crit. step to ascertain which specific combination of targets produces a significant clin. benefit with respect to specific tumor types.  More clin. feedback is needed to facilitate the design of the next generation of inhibitors with more precisely defined profiles.  Although it might seem immeasurably distant at the present time, the ultimate goal should be to derive the prerequisite knowledge and tools so that MTDD becomes a rational endeavor rather than a black box approach that relies upon serendipity.  This will help banish claims that MKIs are merely dirty, nonspecific drugs with insufficient specificity for treating a wider range of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-L-NWmtdikbVg90H21EOLACvtfcHk0ljG7gMweilSWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmtbfF&md5=3c915b5debf9d005993c8ad31c68bc2e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm901132v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901132v%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DSelectively%2520Nonselective%2520Kinase%2520Inhibition%253A%2520Striking%2520the%2520Right%2520Balance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1413%26epage%3D1437%26doi%3D10.1021%2Fjm901132v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lorusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eder, J. P.</span><span> </span><span class="NLM_article-title">Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1517/13543784.17.7.1013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1517%2F13543784.17.7.1013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1013-28&author=P.+M.+Lorussoauthor=J.+P.+Eder&title=Therapeutic+potential+of+novel+selective-spectrum+kinase+inhibitors+in+oncology&doi=10.1517%2F13543784.17.7.1013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.7.1013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.7.1013%26sid%3Dliteratum%253Aachs%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520potential%2520of%2520novel%2520selective-spectrum%2520kinase%2520inhibitors%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D1013%26epage%3D28%26doi%3D10.1517%2F13543784.17.7.1013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span>Protein Data Bank. <a href="http://www.pdb.org" class="extLink">www.pdb.org</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Protein+Data+Bank.+www.pdb.org."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Data%2520Bank" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Cirillo, P. F.; Gilmore, T. A.; Hickey, E. R.; Regan, J. R.; Zhang, L.-H.</span><span> </span><span class="NLM_article-title">Preparation of aromatic heterocyclic ureas as anti-inflammatory agents</span>. Patent WO2000043384,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=P.+F.+Cirillo&author=T.+A.+Gilmore&author=E.+R.+Hickey&author=J.+R.+Regan&author=L.-H.+Zhang&title=Preparation+of+aromatic+heterocyclic+ureas+as+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26atitle%3DPreparation%2520of%2520aromatic%2520heterocyclic%2520ureas%2520as%2520anti-inflammatory%2520agents%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Aicher, T. D.; Boyd, S. A.; Chicarelli, M. J.; Condroski, K. R.; Hinklin, R. J.; Singh, A.; Turner, T. M.; Rustam, F. G.</span><span> </span><span class="NLM_article-title">Preparation of heterocyclic compounds as glucokinase activators</span>. Patent WO2007089512,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+D.+Aicher&author=S.+A.+Boyd&author=M.+J.+Chicarelli&author=K.+R.+Condroski&author=R.+J.+Hinklin&author=A.+Singh&author=T.+M.+Turner&author=F.+G.+Rustam&title=Preparation+of+heterocyclic+compounds+as+glucokinase+activators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAicher%26aufirst%3DT.%2BD.%26atitle%3DPreparation%2520of%2520heterocyclic%2520compounds%2520as%2520glucokinase%2520activators%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Simeone, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bugianesi, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponpipom, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yudkovitz, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mount, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, M. T.</span><span> </span><span class="NLM_article-title">Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3329</span><span class="NLM_x">–</span> <span class="NLM_lpage">3332</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00751-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2FS0960-894X%2802%2900751-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=3329-3332&author=J.+P.+Simeoneauthor=R.+L.+Bugianesiauthor=M.+M.+Ponpipomauthor=Y.+T.+Yangauthor=J.+L.+Loauthor=J.+B.+Yudkovitzauthor=J.+Cuiauthor=G.+R.+Mountauthor=R.+N.+Renauthor=M.+Creightonauthor=A.+Maoauthor=S.+H.+Vincentauthor=K.+Chengauthor=M.+T.+Goulet&title=Modification+of+the+pyridine+moiety+of+non-peptidyl+indole+GnRH+receptor+antagonists&doi=10.1016%2FS0960-894X%2802%2900751-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900751-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900751-5%26sid%3Dliteratum%253Aachs%26aulast%3DSimeone%26aufirst%3DJ.%2BP.%26aulast%3DBugianesi%26aufirst%3DR.%2BL.%26aulast%3DPonpipom%26aufirst%3DM.%2BM.%26aulast%3DYang%26aufirst%3DY.%2BT.%26aulast%3DLo%26aufirst%3DJ.%2BL.%26aulast%3DYudkovitz%26aufirst%3DJ.%2BB.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DMount%26aufirst%3DG.%2BR.%26aulast%3DRen%26aufirst%3DR.%2BN.%26aulast%3DCreighton%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DS.%2BH.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DGoulet%26aufirst%3DM.%2BT.%26atitle%3DModification%2520of%2520the%2520pyridine%2520moiety%2520of%2520non-peptidyl%2520indole%2520GnRH%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D3329%26epage%3D3332%26doi%3D10.1016%2FS0960-894X%2802%2900751-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Bonfanti, J. F.; Muller, P.; Fortin, J. M. C.; Doublet, F. M. M.</span><span> </span><span class="NLM_article-title">Preparation of heterocyclylaminoalkyl substituted benzimidazoles as respiratory syncytial virus (RSV) replication inhibitors</span>. Patent WO2006136562,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=J.+F.+Bonfanti&author=P.+Muller&author=J.+M.+C.+Fortin&author=F.+M.+M.+Doublet&title=Preparation+of+heterocyclylaminoalkyl+substituted+benzimidazoles+as+respiratory+syncytial+virus+%28RSV%29+replication+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBonfanti%26aufirst%3DJ.%2BF.%26atitle%3DPreparation%2520of%2520heterocyclylaminoalkyl%2520substituted%2520benzimidazoles%2520as%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520replication%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L. H.</span><span> </span><span class="NLM_article-title">Preparation of aromatic heterocyclic ureas as antiinflammatory agents</span>. Patent WO 2000043384,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=P.+F.+Cirilloauthor=T.+A.+Gilmoreauthor=E.+R.+Hickeyauthor=J.+R.+Reganauthor=L.+H.+Zhang&title=Preparation+of+aromatic+heterocyclic+ureas+as+antiinflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%2BA.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DRegan%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%2BH.%26atitle%3DPreparation%2520of%2520aromatic%2520heterocyclic%2520ureas%2520as%2520antiinflammatory%2520agents%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Montuschi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciabattoni, G.</span><span> </span><span class="NLM_article-title">Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4131</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1021/jm5013227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5013227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4131-64&author=P.+Montuschiauthor=G.+Ciabattoni&title=Bronchodilating+drugs+for+chronic+obstructive+pulmonary+disease%3A+current+status+and+future+trends&doi=10.1021%2Fjm5013227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends</span></div><div class="casAuthors">Montuschi, Paolo; Ciabattoni, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4131-4164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacol. treatment of stable chronic obstructive pulmonary disease (COPD).  Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h.  New LAMA are under development for COPD.  Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration.  New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development.  LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler.  Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a std. pharmacol. strategy for COPD.  Inhaled dual-pharmacol. compds., combining muscarinic antagonism and β2-agonism (MABA) in a single mol., potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β2-agonist monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLB6Vc0-8tzbVg90H21EOLACvtfcHk0li83lfwlmmxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVygtA%253D%253D&md5=816e44be469a0396d859cd3576514085</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm5013227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5013227%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DCiabattoni%26aufirst%3DG.%26atitle%3DBronchodilating%2520drugs%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520current%2520status%2520and%2520future%2520trends%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4131%26epage%3D64%26doi%3D10.1021%2Fjm5013227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting β2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6652</span><span class="refDoi"> DOI: 10.1021/jm1005989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2ktLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+L.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+J.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B22-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup&doi=10.1021%2Fjm1005989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by Design: Novel Ultra-Long-Acting β2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup</span></div><div class="casAuthors">Glossop, Paul A.; Lane, Charlotte A. L.; Price, David A.; Bunnage, Mark E.; Lewthwaite, Russell A.; James, Kim; Brown, Alan D.; Yeadon, Michael; Perros-Huguet, Christelle; Trevethick, Michael A.; Clarke, Nicholas P.; Webster, Robert; Jones, Rhys M.; Burrows, Jane L.; Feeder, Neil; Taylor, Stefan C. J.; Spence, Fiona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6640-6652</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of potent and selective sulfonamide derived β2-adrenoreceptor agonists are described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease.  Analogs from this series mediate very long-lasting smooth muscle relaxation in guinea pig tracheal strips.  The sulfonamide agonist headgroup confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state.  Optimization of pharmacokinetic properties was achieved through targeted introduction of a phenolic moiety to support rapid phase II clearance, thereby minimizing systemic exposure following inhalation and reducing systemically mediated adverse events.  Compd. 38 (PF-610355) is identified as a clin. candidate from this series, with in vivo duration of action studies confirming its potential for once-daily use in humans.  Compd. 38 is currently in advanced phase II clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGaBcfoYeu7Vg90H21EOLACvtfcHk0li83lfwlmmxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2ktLjJ&md5=34cf266aa0f796ee5ec370369c726f6e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%2BL.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%2BJ.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B22-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652%26doi%3D10.1021%2Fjm1005989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0li83lfwlmmxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Ito, K.; Charron, C. E.; Murray, P. J.; Onions, S. T.; Rapeport, G.; Strong, P.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ito%2C+K.%3B+Charron%2C+C.+E.%3B+Murray%2C+P.+J.%3B+Onions%2C+S.+T.%3B+Rapeport%2C+G.%3B+Strong%2C+P.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DK." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">To, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Failla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">905</span><span class="refDoi"> DOI: 10.1164/rccm.200906-0937OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1164%2Frccm.200906-0937OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=20224070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlymsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=897-905&author=Y.+Toauthor=K.+Itoauthor=Y.+Kizawaauthor=M.+Faillaauthor=M.+Itoauthor=T.+Kusamaauthor=W.+M.+Elliottauthor=J.+C.+Hoggauthor=I.+M.+Adcockauthor=P.+J.+Barnes&title=Targeting+Phosphoinositide-3-Kinase-%CE%B4+with+Theophylline+Reverses+Corticosteroid+Insensitivity+in+Chronic+Obstructive+Pulmonary+Disease&doi=10.1164%2Frccm.200906-0937OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease</span></div><div class="casAuthors">To, Yasuo; Ito, Kazuhiro; Kizawa, Yasuo; Failla, Marco; Ito, Misako; Kusama, Tadashi; Elliott, W. Mark; Hogg, James C.; Adcock, Ian M.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">897-904</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Patients with chronic obstructive pulmonary disease (COPD) show a poor response to corticosteroids.  This has been linked to a redn. of histone deacetylase-2 as a result of oxidative stress and is reversed by theophylline.  Objectives: To det. the role of phosphoinositide-3-kinase-delta (PI3K-δ) on the development of corticosteroid insensitivity in COPD and under oxidative stress, and as a target for theophylline.  Methods: Corticosteroid sensitivity was detd. as the 50% inhibitory concn. of dexamethasone on tumor necrosis factor-α-induced interleukin-8 release in peripheral blood mononuclear cells from patients with COPD (n = 17) and compared with that of nonsmoking (n = 8) and smoking (n = 7) control subjects.  The effect of theophylline and a selective PI3K-δ inhibitor (IC87114) on restoration of corticosteroid sensitivity was confirmed in cigarette smoke-exposed mice.  Measurements and Main Results: Peripheral blood mononuclear cells of COPD (50% inhibitory concn. of dexamethasone: 156.8 ± 32.6 nM) were less corticosteroid sensitive than those of nonsmoking (41.2 ± 10.5 nM; P = 0.018) and smoking control subjects (47.5 ± 19.6 nM; P = 0.031).  Corticosteroid insensitivity and reduced histone deacetylase-2 activity after oxidative stress were reversed by a non-selective PI3K inhibitor (LY294002) and low concns. of theophylline.  Theophylline was a potent selective inhibitor of oxidant-activated PI3K-δ, which was up-regulated in peripheral lung tissue of patients with COPD.  Furthermore, cells with knock-down of PI3K-δ failed to develop corticosteroid insensitivity with oxidative stress.  Both theophylline and IC87114, combined with dexamethasone, inhibited corticosteroid-insensitive lung inflammation in cigarette-smoke-exposed mice in vivo.  Conclusions: Inhibition of oxidative stress dependent PI3K-δ activation by a selective inhibitor or theophylline provides a novel approach to reversing corticosteroid insensitivity in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrntINJnOqMbrVg90H21EOLACvtfcHk0lgpSr9UW-zUTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlymsbzO&md5=5338bbb7050e1700b0e4eda068cdb05c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1164%2Frccm.200906-0937OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200906-0937OC%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DKizawa%26aufirst%3DY.%26aulast%3DFailla%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DKusama%26aufirst%3DT.%26aulast%3DElliott%26aufirst%3DW.%2BM.%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26aulast%3DAdcock%26aufirst%3DI.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DTargeting%2520Phosphoinositide-3-Kinase-%25CE%25B4%2520with%2520Theophylline%2520Reverses%2520Corticosteroid%2520Insensitivity%2520in%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D897%26epage%3D905%26doi%3D10.1164%2Frccm.200906-0937OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Tadashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuniaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasunori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanae, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taeko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuzo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sataro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazuhisa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshinosuke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akihito, I.</span><span> </span><span class="NLM_article-title">Senescence marker protein-30 protects mice lungs from oxidative stress, aging, and smoking</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span><span class="refDoi"> DOI: 10.1164/rccm.200511-1816OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1164%2Frccm.200511-1816OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16728709" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2006&pages=530-537&author=S.+Tadashiauthor=S.+Kuniakiauthor=S.+Yasunoriauthor=M.+Hiroakiauthor=S.+Sanaeauthor=A.+Taekoauthor=K.+Yuzoauthor=M.+Takanoriauthor=G.+Sataroauthor=T.+Kazuhisaauthor=F.+Yoshinosukeauthor=M.+Naokiauthor=I.+Akihito&title=Senescence+marker+protein-30+protects+mice+lungs+from+oxidative+stress%2C+aging%2C+and+smoking&doi=10.1164%2Frccm.200511-1816OC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1164%2Frccm.200511-1816OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200511-1816OC%26sid%3Dliteratum%253Aachs%26aulast%3DTadashi%26aufirst%3DS.%26aulast%3DKuniaki%26aufirst%3DS.%26aulast%3DYasunori%26aufirst%3DS.%26aulast%3DHiroaki%26aufirst%3DM.%26aulast%3DSanae%26aufirst%3DS.%26aulast%3DTaeko%26aufirst%3DA.%26aulast%3DYuzo%26aufirst%3DK.%26aulast%3DTakanori%26aufirst%3DM.%26aulast%3DSataro%26aufirst%3DG.%26aulast%3DKazuhisa%26aufirst%3DT.%26aulast%3DYoshinosuke%26aufirst%3DF.%26aulast%3DNaoki%26aufirst%3DM.%26aulast%3DAkihito%26aufirst%3DI.%26atitle%3DSenescence%2520marker%2520protein-30%2520protects%2520mice%2520lungs%2520from%2520oxidative%2520stress%252C%2520aging%252C%2520and%2520smoking%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2006%26volume%3D174%26spage%3D530%26epage%3D537%26doi%3D10.1164%2Frccm.200511-1816OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Huihui Ti, Yang Zhou, Xue Liang, Runfeng Li, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xin Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 5944-5978. <a href="https://doi.org/10.1021/acs.jmedchem.8b01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01520%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BTreatments%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%252B%252528COPD%252529%252BUsing%252BLow-Molecular-Weight%252BDrugs%252B%252528LMWDs%252529%26aulast%3DTi%26aufirst%3DHuihui%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D30092018%26date%3D12022019%26date%3D25012019%26volume%3D62%26issue%3D13%26spage%3D5944%26epage%3D5978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Pratul K. Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">A Biophysical Perspective on Enzyme Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (6)
                                     , 438-449. <a href="https://doi.org/10.1021/acs.biochem.8b01004" title="DOI URL">https://doi.org/10.1021/acs.biochem.8b01004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.8b01004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.8b01004%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DA%252BBiophysical%252BPerspective%252Bon%252BEnzyme%252BCatalysis%26aulast%3DAgarwal%26aufirst%3DPratul%2BK.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D20092018%26date%3D25112018%26date%3D18122018%26date%3D03122018%26volume%3D58%26issue%3D6%26spage%3D438%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meijun  Xiong</span>, <span class="hlFld-ContribAuthor ">Xin  Xie</span>, and <span class="hlFld-ContribAuthor ">Yuanhong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Copper-Catalyzed Borylative Cyclization of in Situ Generated o-Allenylaryl Nitriles with Bis(pinacolato)diboron. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (13)
                                     , 3398-3401. <a href="https://doi.org/10.1021/acs.orglett.7b01355" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b01355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b01355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b01355%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCopper-Catalyzed%252BBorylative%252BCyclization%252Bof%252Bin%252BSitu%252BGenerated%252Bo-Allenylaryl%252BNitriles%252Bwith%252BBis%252528pinacolato%252529diboron%26aulast%3DXiong%26aufirst%3DMeijun%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D05052017%26date%3D27062017%26date%3D07072017%26volume%3D19%26issue%3D13%26spage%3D3398%26epage%3D3401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoru  Noji</span>, <span class="hlFld-ContribAuthor ">Noriyoshi  Seki</span>, <span class="hlFld-ContribAuthor ">Takaki  Maeba</span>, <span class="hlFld-ContribAuthor ">Takayuki  Sakai</span>, <span class="hlFld-ContribAuthor ">Eiichi  Watanabe</span>, <span class="hlFld-ContribAuthor ">Katsuya  Maeda</span>, <span class="hlFld-ContribAuthor ">Kyoko  Fukushima</span>, <span class="hlFld-ContribAuthor ">Toru  Noguchi</span>, <span class="hlFld-ContribAuthor ">Kazuya  Ogawa</span>, <span class="hlFld-ContribAuthor ">Yukiyo  Toyonaga</span>, <span class="hlFld-ContribAuthor ">Tamotsu  Negoro</span>, <span class="hlFld-ContribAuthor ">Hisashi  Kawasaki</span>, and <span class="hlFld-ContribAuthor ">Makoto  Shiozaki</span>  . </span><span class="cited-content_cbyCitation_article-title">Concise SAR Exploration Based on the “Head-to-Tail” Approach: Discovery of PI4KIIIα Inhibitors Bearing Diverse Scaffolds. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (10)
                                     , 919-923. <a href="https://doi.org/10.1021/acsmedchemlett.6b00232" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00232%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DConcise%252BSAR%252BExploration%252BBased%252Bon%252Bthe%252B%2525E2%252580%25259CHead-to-Tail%2525E2%252580%25259D%252BApproach%25253A%252BDiscovery%252Bof%252BPI4KIII%2525CE%2525B1%252BInhibitors%252BBearing%252BDiverse%252BScaffolds%26aulast%3DNoji%26aufirst%3DSatoru%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D07062016%26date%3D03082016%26date%3D16082016%26date%3D13102016%26date%3D03082016%26volume%3D7%26issue%3D10%26spage%3D919%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Svetlana O.  Kasatkina</span>, <span class="hlFld-ContribAuthor ">Kirill K.  Geyl</span>, <span class="hlFld-ContribAuthor ">Sergey V.  Baykov</span>, <span class="hlFld-ContribAuthor ">Irina A.  Boyarskaya</span>, <span class="hlFld-ContribAuthor ">Vadim P.  Boyarskiy</span>. </span><span class="cited-content_cbyCitation_article-title">Catalyst-free synthesis of substituted pyridin-2-yl, quinolin-2-yl, and isoquinolin-1-yl carbamates from the corresponding hetaryl ureas and alcohols. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (27)
                                     , 6059-6065. <a href="https://doi.org/10.1039/D1OB00783A" title="DOI URL">https://doi.org/10.1039/D1OB00783A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00783A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00783A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DCatalyst-free%252Bsynthesis%252Bof%252Bsubstituted%252Bpyridin-2-yl%25252C%252Bquinolin-2-yl%25252C%252Band%252Bisoquinolin-1-yl%252Bcarbamates%252Bfrom%252Bthe%252Bcorresponding%252Bhetaryl%252Bureas%252Band%252Balcohols%26aulast%3DKasatkina%26aufirst%3DSvetlana%2BO.%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D27%26spage%3D6059%26epage%3D6065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew S.  Coates</span>, <span class="hlFld-ContribAuthor ">Eric W. F. W.  Alton</span>, <span class="hlFld-ContribAuthor ">Garth W.  Rapeport</span>, <span class="hlFld-ContribAuthor ">Jane C.  Davies</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Ito</span>, . </span><span class="cited-content_cbyCitation_article-title">Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2021,</strong> <em>16 </em>
                                    (2)
                                     , e0246050. <a href="https://doi.org/10.1371/journal.pone.0246050" title="DOI URL">https://doi.org/10.1371/journal.pone.0246050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0246050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0246050%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DPseudomonas%252Baeruginosa%252Binduces%252Bp38MAP%252Bkinase-dependent%252BIL-6%252Band%252BCXCL8%252Brelease%252Bfrom%252Bbronchial%252Bepithelial%252Bcells%252Bvia%252Ba%252BSyk%252Bkinase%252Bpathway%26aulast%3DCoates%26aufirst%3DMatthew%2BS.%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D2%26spage%3De0246050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jürgen  Knobloch</span>, <span class="hlFld-ContribAuthor ">David  Jungck</span>, <span class="hlFld-ContribAuthor ">Juliane  Kronsbein</span>, <span class="hlFld-ContribAuthor ">Erich  Stoelben</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Ito</span>, <span class="hlFld-ContribAuthor ">Andrea  Koch</span>. </span><span class="cited-content_cbyCitation_article-title">LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2019,</strong> <em>8 </em>
                                    (12)
                                     , 2058. <a href="https://doi.org/10.3390/jcm8122058" title="DOI URL">https://doi.org/10.3390/jcm8122058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm8122058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm8122058%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DLABAs%252Band%252Bp38MAPK%252BInhibitors%252BReverse%252Bthe%252BCorticosteroid-Insensitivity%252Bof%252BIL-8%252Bin%252BAirway%252BSmooth%252BMuscle%252BCells%252Bof%252BCOPD%26aulast%3DKnobloch%26aufirst%3DJ%25C3%25BCrgen%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D12%26spage%3D2058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Strong</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Ito</span>, <span class="hlFld-ContribAuthor ">John  Murray</span>, <span class="hlFld-ContribAuthor ">Garth  Rapeport</span>. </span><span class="cited-content_cbyCitation_article-title">Current approaches to the discovery of novel inhaled medicines. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2018,</strong> <em>23 </em>
                                    (10)
                                     , 1705-1717. <a href="https://doi.org/10.1016/j.drudis.2018.05.017" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.05.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.05.017%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DCurrent%252Bapproaches%252Bto%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Binhaled%252Bmedicines%26aulast%3DStrong%26aufirst%3DPeter%26date%3D2018%26volume%3D23%26issue%3D10%26spage%3D1705%26epage%3D1717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jürgen  Knobloch</span>, <span class="hlFld-ContribAuthor ">David  Jungck</span>, <span class="hlFld-ContribAuthor ">Catherine  Charron</span>, <span class="hlFld-ContribAuthor ">Erich  Stoelben</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Ito</span>, <span class="hlFld-ContribAuthor ">Andrea  Koch</span>. </span><span class="cited-content_cbyCitation_article-title">Superior anti-inflammatory effects of narrow-spectrum kinase inhibitors in airway smooth muscle cells from subjects with chronic obstructive pulmonary disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Allergy and Clinical Immunology</span><span> <strong>2018,</strong> <em>141 </em>
                                    (3)
                                     , 1122-1124.e11. <a href="https://doi.org/10.1016/j.jaci.2017.09.026" title="DOI URL">https://doi.org/10.1016/j.jaci.2017.09.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaci.2017.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaci.2017.09.026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Allergy%2520and%2520Clinical%2520Immunology%26atitle%3DSuperior%252Banti-inflammatory%252Beffects%252Bof%252Bnarrow-spectrum%252Bkinase%252Binhibitors%252Bin%252Bairway%252Bsmooth%252Bmuscle%252Bcells%252Bfrom%252Bsubjects%252Bwith%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%26aulast%3DKnobloch%26aufirst%3DJ%25C3%25BCrgen%26date%3D2018%26volume%3D141%26issue%3D3%26spage%3D1122%26epage%3D1124.e11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Catherine E.  Charron</span>, <span class="hlFld-ContribAuthor ">Paul  Russell</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Ito</span>, <span class="hlFld-ContribAuthor ">Simon  Lea</span>, <span class="hlFld-ContribAuthor ">Yasuo  Kizawa</span>, <span class="hlFld-ContribAuthor ">Charlie  Brindley</span>, <span class="hlFld-ContribAuthor ">Dave  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. </span><span class="cited-content_cbyCitation_journal-name">European Respiratory Journal</span><span> <strong>2017,</strong> <em>50 </em>
                                    (4)
                                     , 1700188. <a href="https://doi.org/10.1183/13993003.00188-2017" title="DOI URL">https://doi.org/10.1183/13993003.00188-2017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1183/13993003.00188-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1183%2F13993003.00188-2017%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Respiratory%2520Journal%26atitle%3DRV568%25252C%252Ba%252Bnarrow-spectrum%252Bkinase%252Binhibitor%252Bwith%252Bp38%252BMAPK-%2525CE%2525B1%252Band%252B-%2525CE%2525B3%252Bselectivity%25252C%252Bsuppresses%252BCOPD%252Binflammation%26aulast%3DCharron%26aufirst%3DCatherine%2BE.%26date%3D2017%26date%3D2017%26volume%3D50%26issue%3D4%26spage%3D1700188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Han</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Huaping  Tang</span>, <span class="hlFld-ContribAuthor ">Lixin  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2017,</strong> <em>484 </em>
                                    (2)
                                     , 396-402. <a href="https://doi.org/10.1016/j.bbrc.2017.01.135" title="DOI URL">https://doi.org/10.1016/j.bbrc.2017.01.135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2017.01.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2017.01.135%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DTreatment%252Bof%252Bobese%252Basthma%252Bin%252Ba%252Bmouse%252Bmodel%252Bby%252Bsimvastatin%252Bis%252Bassociated%252Bwith%252Bimproving%252Bdyslipidemia%252Band%252Bdecreasing%252Bleptin%252Blevel%26aulast%3DHan%26aufirst%3DWei%26date%3D2017%26volume%3D484%26issue%3D2%26spage%3D396%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter J.  Barnes</span>, . </span><span class="cited-content_cbyCitation_article-title">Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2016,</strong> <em>68 </em>
                                    (3)
                                     , 788-815. <a href="https://doi.org/10.1124/pr.116.012518" title="DOI URL">https://doi.org/10.1124/pr.116.012518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.116.012518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.116.012518%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DKinases%252Bas%252BNovel%252BTherapeutic%252BTargets%252Bin%252BAsthma%252Band%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DBarnes%26aufirst%3DPeter%2BJ.%26date%3D2016%26date%3D2016%26volume%3D68%26issue%3D3%26spage%3D788%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amir H.  Nasiri</span>, <span class="hlFld-ContribAuthor ">Krishna  Saxena</span>, <span class="hlFld-ContribAuthor ">Jan W.  Bats</span>, <span class="hlFld-ContribAuthor ">Hamid R.  Nasiri</span>, <span class="hlFld-ContribAuthor ">Harald  Schwalbe</span>. </span><span class="cited-content_cbyCitation_article-title">Biophysical investigation and conformational analysis of p38α kinase inhibitor doramapimod and its analogues. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2016,</strong> <em>7 </em>
                                    (7)
                                     , 1421-1428. <a href="https://doi.org/10.1039/C6MD00262E" title="DOI URL">https://doi.org/10.1039/C6MD00262E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MD00262E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MD00262E%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DBiophysical%252Binvestigation%252Band%252Bconformational%252Banalysis%252Bof%252Bp38%2525CE%2525B1%252Bkinase%252Binhibitor%252Bdoramapimod%252Band%252Bits%252Banalogues%26aulast%3DNasiri%26aufirst%3DAmir%2BH.%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D7%26spage%3D1421%26epage%3D1428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. p38 MAPK inhibitors profiled in the clinic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Strategy</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route To Access the Ethylene Linker Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <i>t</i>-BuOCONH<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Xantphos, THF, 65 °C; (b) DIBAL, −78 °C, THF; (c) TBDMSCl, imidazole, DCM, rt; (d) H<sub>2</sub>O<sub>2</sub>, MeReO<sub>3</sub>, DCM, rt; (e) TMS-CN, Me<sub>2</sub>NC(O)Cl, DCM, rt; (f) Na, MeOH, then aq. HCl, rt; (g) Triton B, paraformaldehyde, DMSO, rt; (h) H<sub>2</sub>, Pd/C, MeOH; (j) NaH, 1-fluoro-4-nitronaphthalene, THF, 0 °C; (k) 4-nitronaphthalen-1-ol, DIAD, PPh<sub>3</sub>, THF, −78 °C; (m) Fe, AcOH, 50 °C (<b>46a</b>) or H<sub>2</sub>, Pt/C, rt (<b>46b</b> and <b>46c</b>); (n) CDI, DCM (<b>47a</b> and <b>47b</b>) or diphosgene, aq. NaHCO<sub>3</sub> (<b>47c</b>); (p) TFA, DCM; (q) aq. NaOH; (r) RCOCl, base, THF/DMF, rt; (s) RNH<sub>2</sub>, HATU, DMF, rt.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the Imidazolyl Analogue<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 2-nitro-1<i>H</i>-imidazole, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C; (b) Fe, AcOH, 50 °C; (c) MeCOCl, DIPEA, DCM, rt.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route To Access the Methylene Linker Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) 4-nitronaphthalen-1-ol, DIAD, PPh<sub>3</sub>, −78 °C, THF; (b) MeOCH<sub>2</sub>COCl, DIPEA, THF, rt; (c) Fe, AcOH, 50 °C or H<sub>2</sub>, Pt/C, rt; (d) NaH, MeI, THF, 0 °C; (e) CDI, <b>34</b>, DCM; or diphosgene, NaHCO<sub>3</sub>, DCM, 0 °C; (f) LiOH, THF/H<sub>2</sub>O, rt; (g) RCOCl, DIPEA, THF/DMF, rt; or ROCOCl, DIPEA, THF/DMF, rt; or RSO<sub>2</sub>Cl, DIPEA, THF/DMF, rt; or RNCO, DCM/DMF, rt; (h) HATU, RNH<sub>2</sub>, DMF, rt.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of N-Acetyl Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) ClCH<sub>2</sub>COCl, DCM, DIPEA, rt; (b) RYH, DIPEA, DCM/DMF, 40 °C (Y = N, S).</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route To Access the Side-Chain-Substituted Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) MeLi, THF, −78 °C; (b) NaBH<sub>4</sub>, MeOH, 0 °C; (c) NaH, 1-fluoro-4-nitronaphthalene, DMF, 0 °C; (d) H<sub>2</sub>, Pt/C, rt; (e) diphosgene, aq. NaHCO<sub>3</sub>, 0 °C to rt; (f) MeOCH<sub>2</sub>COCl, DIPEA, THF/DCM, 0 °C.</p></p></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Comparison of the effects of treatment with BIRB-796 or compound <b>30</b> on LPS-induced airway neutrophilia in mice. it = intratracheal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/medium/jm-2015-01029g_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of treatment with either FP (A), BIRB-796 (A), or <b>30</b> (B) on tobacco smoke-induced airway neutrophilia in mice. in = intranasal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01029/20160310/images/large/jm-2015-01029g_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01029&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35765" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35765" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Corticosteroid Resistance in Airway Disease</span> <span class="citation_source-journal">Proc. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span><span class="refDoi"> DOI: 10.1513/pats.200402-014MS</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1513%2Fpats.200402-014MS" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16113444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFGis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=264-268&author=P.+J.+Barnes&title=Corticosteroid+Resistance+in+Airway+Disease&doi=10.1513%2Fpats.200402-014MS"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Corticosteroid resistance in airway disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-268</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Resistance to the antiinflammatory effects of corticosteroids is very uncommon in asthma but common in chronic obstructive pulmonary disease.  Recent understanding of the mol. mechanisms involved in the antiinflammatory actions of corticosteroids has revealed that there are several possible mechanisms for corticosteroid resistance.  Certain cytokines activate p38 mitogen-activated protein kinase, which may interfere with the nuclear localization of glucocorticoid receptors (GRs).  In other patients, nuclear localization of GR is normal but there is a redn. in acetylation of a lysine residue in histone-4, thus leading to impaired activation of certain antiinflammatory genes.  In chronic obstructive pulmonary disease and severe asthma, oxidative stress may reduce the activity and expression of certain histone deacetylases and therefore interfere with the antiinflammatory action of corticosteroids.  These mechanisms suggest that there may be several therapeutic approaches to treating corticosteroid resistance in the future, including antioxidants, p38 mitogen-activated protein kinase inhibitors, and theophylline, which activates histone deacetylases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6nBRWXvawEbVg90H21EOLACvtfcHk0lg3Hee-_MX1ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFGis74%253D&md5=594dd4af104bf0d61a0b992093e9a3d6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1513%2Fpats.200402-014MS&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.200402-014MS%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DCorticosteroid%2520Resistance%2520in%2520Airway%2520Disease%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2004%26volume%3D1%26spage%3D264%26epage%3D268%26doi%3D10.1513%2Fpats.200402-014MS" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Creed, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probert, C. S. J.</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1111/j.1365-2036.2006.03156.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1111%2Fj.1365-2036.2006.03156.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=17229236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVCqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Creed%2C+T.+J.%3B+Probert%2C+C.+S.+J.Aliment.+Pharmacol.+Ther.+2007%2C+25%2C+111%E2%80%93122+10.1111%2Fj.1365-2036.2006.03156.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies</span></div><div class="casAuthors">Creed, T. J.; Probert, C. S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Steroid resistance in inflammatory bowel disease presents a difficult clin. challenge.  The advent of biol. therapies coupled with an increasing understanding of the pathogenesis of inflammatory bowel disease has provided new therapeutic options.  Methods: We review the available literature of the mechanisms behind steroid resistance.  In addn., we outline some of the options available for treating those patients who fail to respond adequately to glucocorticoids.  Results: Approx. 30% of patients prescribed glucocorticoids will not achieve clin. remission.  Many such patients are offered immunosuppressive or, recently, biol. agents.  However, these agents are ineffective in a large proportion of patients.  Immunosuppressive agents only bring 40-60% of patients into remission, and biol. agents typically induce remission in just 40% of patients.  In this review, the possible explanations for glucocorticoid resistance are discussed.  Recent evidence suggests that in many patients it is mediated by interleukin-2.  Basiliximab, a biol. agent that interrupts interleukin-2 signalling, has shown significant benefit in early clin. studies.  Conclusions: Patients who fail to respond to steroid therapy should have alternative agents introduced in a timely fashion.  Steroid refractory inflammatory bowel disease remains a difficult condition to treat, but new therapies and managements are emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraCvpI3aTsX7Vg90H21EOLACvtfcHk0lg3Hee-_MX1ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVCqt7o%253D&md5=48640f3485441178c8efa129a56923ed</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2006.03156.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2006.03156.x%26sid%3Dliteratum%253Aachs%26aulast%3DCreed%26aufirst%3DT.%2BJ.%26aulast%3DProbert%26aufirst%3DC.%2BS.%2BJ.%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2007%26volume%3D25%26spage%3D111%26epage%3D122%26doi%3D10.1111%2Fj.1365-2036.2006.03156.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Hogg, J.</span><span> </span><span class="NLM_article-title">Role of Latent Viral Infections in Chronic Obstructive Pulmonary Disease and Asthma</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span><span class="refDoi"> DOI: 10.1164/ajrccm.164.supplement_2.2106063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1164%2Fajrccm.164.supplement_2.2106063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=11734471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BD3MnovVSjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2001&pages=71-75&author=J.+Hogg&title=Role+of+Latent+Viral+Infections+in+Chronic+Obstructive+Pulmonary+Disease+and+Asthma&doi=10.1164%2Fajrccm.164.supplement_2.2106063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Role of latent viral infections in chronic obstructive pulmonary disease and asthma</span></div><div class="casAuthors">Hogg J C</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">10 Pt 2</span>),
    <span class="NLM_cas:pages">S71-5</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Acute viral respiratory tract infections are well known to precipitate asthma attacks and acute exacerbations of chronic obstructive pulmonary disease, but their role in the pathogenesis of chronic disease is poorly defined.  Double-stranded DNA viruses have the ability to persist in airway epithelial cells long after the acute infection has cleared.  During these latent infections, viral genes are expressed at the protein level without replication of a complete virus.  The expression of the adenoviral trans-activating protein has been demonstrated in the airway epithelium of both human and animal lungs and is associated with an amplification of the cigarette smoke-induced inflammatory response.  Studies of cultured human airway epithelial cells have also shown that transfection with this viral gene upregulates the expression of intercellular adhesion molecule 1 and interleukin 8 by these cells when they are challenged with endotoxin.  In guinea pigs, cigarette smoke-induced emphysema is amplified by latent adenoviral infection.  Furthermore, this infection independently increased the number of CD-8 cells, whereas the cigarette smoke independently increased the number of CD-4 cells in the inflammatory infiltrate.  On the other hand, allergen-induced lung inflammation was uninfluenced by latent adenoviral infection in the guinea pig, but the latent infection caused the eosinophilic component of this response to become steroid resistant.  These studies suggest that latent adenoviral infections may have a role in the pathogenesis of obstructive airway disease by amplifying the response to cigarette smoke and inducing steroid resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPhJKChJg9hZdYoSR9eyvsfW6udTcc2eaCNtGD67gQa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnovVSjsw%253D%253D&md5=93b2a54c601fed2e4bfaf20e512cebea</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.164.supplement_2.2106063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.164.supplement_2.2106063%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%26atitle%3DRole%2520of%2520Latent%2520Viral%2520Infections%2520in%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%2520and%2520Asthma%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2001%26volume%3D164%26spage%3D71%26epage%3D75%26doi%3D10.1164%2Fajrccm.164.supplement_2.2106063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Pauwels, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurd, S. S.</span><span> </span><span class="NLM_article-title">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">1256</span><span class="refDoi"> DOI: 10.1164/ajrccm.163.5.2101039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1164%2Fajrccm.163.5.2101039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=11316667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BD3MzisFGqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2001&pages=1256&author=R.+A.+Pauwelsauthor=A.+S.+Buistauthor=P.+M.+A.+Calverleyauthor=C.+R.+Jenkinsauthor=S.+S.+Hurd&title=Global+strategy+for+the+diagnosis%2C+management%2C+and+prevention+of+chronic+obstructive+pulmonary+disease.+NHLBI%2FWHO+Global+Initiative+for+Chronic+Obstructive+Lung+Disease+%28GOLD%29+workshop+summary&doi=10.1164%2Fajrccm.163.5.2101039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary</span></div><div class="casAuthors">Pauwels R A; Buist A S; Calverley P M; Jenkins C R; Hurd S S</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1256-76</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS64ADS-aOebBwLZxei1HN8fW6udTcc2eaCNtGD67gQa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MzisFGqtw%253D%253D&md5=880de2434feae4d24c905f9ea6d4c504</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.163.5.2101039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.163.5.2101039%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DR.%2BA.%26aulast%3DBuist%26aufirst%3DA.%2BS.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3DJenkins%26aufirst%3DC.%2BR.%26aulast%3DHurd%26aufirst%3DS.%2BS.%26atitle%3DGlobal%2520strategy%2520for%2520the%2520diagnosis%252C%2520management%252C%2520and%2520prevention%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease.%2520NHLBI%252FWHO%2520Global%2520Initiative%2520for%2520Chronic%2520Obstructive%2520Lung%2520Disease%2520%2528GOLD%2529%2520workshop%2520summary%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2001%26volume%3D163%26spage%3D1256%26doi%3D10.1164%2Fajrccm.163.5.2101039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Yang, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, K. M.</span><span> </span><span class="NLM_article-title">Inhaled corticosteroids for stable chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD002991</span><span class="refDoi"> DOI: 10.1002/14651858.CD002991.pub3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1002%2F14651858.CD002991.pub3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=CD002991&author=I.+A.+Yangauthor=M.+S.+Clarkeauthor=E.+H.+Simauthor=K.+M.+Fong&title=Inhaled+corticosteroids+for+stable+chronic+obstructive+pulmonary+disease&doi=10.1002%2F14651858.CD002991.pub3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD002991.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD002991.pub3%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DI.%2BA.%26aulast%3DClarke%26aufirst%3DM.%2BS.%26aulast%3DSim%26aufirst%3DE.%2BH.%26aulast%3DFong%26aufirst%3DK.%2BM.%26atitle%3DInhaled%2520corticosteroids%2520for%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2012%26volume%3D7%26spage%3DCD002991%26doi%3D10.1002%2F14651858.CD002991.pub3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Fuso, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mores, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malerba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montuschi, P.</span><span> </span><span class="NLM_article-title">Long-acting beta-agonists and their association with inhaled corticosteroids in COPD</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.2174/0929867311320120003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.2174%2F0929867311320120003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=23409722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1477-95&author=L.+Fusoauthor=N.+Moresauthor=S.+Valenteauthor=M.+Malerbaauthor=P.+Montuschi&title=Long-acting+beta-agonists+and+their+association+with+inhaled+corticosteroids+in+COPD&doi=10.2174%2F0929867311320120003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting beta-agonists and their association with inhaled corticosteroids in COPD</span></div><div class="casAuthors">Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1495</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD).  The short-acting beta2-agonists, including salbutamol, and fenoterol, have a rapid onset of action, a bronchodilating effect for 3-6 h and are used on demand.  The long-acting beta2-agonists (LABAs), including salmeterol and formoterol, have 12-h duration of action and are used with a twice-daily dosing regimen for long-term COPD treatment.  Unlike salmeterol, formoterol has a rapid onset of action.  Pharmacol. characteristics required by novel inhaled LABAs include 24 h bronchodilator effect in vivo which would make them suitable for once daily administration (ultra-LABA), high potency and selectivity for beta2-adrenoceptors, rapid onset of action, low oral bioavailability (< 5%) after inhalation, and high systemic clearance.  Indacaterol, which has been approved for long-term treatment of COPD in Europe and in the USA, has a 24-h duration of action and a once-daily dosing regimen.  Newer ultra-LABAs, including olodaterol, vilanterol, milveterol, carmoterol, and abediterol, are in development.  Combination with ICS (fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formoterol) appears to provide an addnl. benefit over the monocomponent therapy, although the extent of this benefit is variable and often not clin. significant in all the endpoints assessed.  In patients with COPD, treatment with ICS is assocd. with increased risk of pneumonia which should be carefully considered when assessing the risk/benefit ratio of ICS/LABA combinations.  Subphenotyping of patients with COPD (e.g., frequent exacerbations, sputum eosinophilia, mixed asthma/COPD phenotype) might help identify those patients who are most likely to benefit from addn. of ICS to bronchodilating treatment.  Ultra-LABA/ long-acting muscarinic receptor antagonist (LAMA) combination treatment is under development and is likely to become a std. pharmacol. strategy for COPD.  Dual-pharmacol. inhaled muscarinic antagonist-beta2 agonist (MABA) mols. provide a new approach to the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqtajjRd8d0LVg90H21EOLACvtfcHk0lge9nPmewlAtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLk%253D&md5=32add113b9bc1d3a8e68df8d1acb7fe8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120003%26sid%3Dliteratum%253Aachs%26aulast%3DFuso%26aufirst%3DL.%26aulast%3DMores%26aufirst%3DN.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DMalerba%26aufirst%3DM.%26aulast%3DMontuschi%26aufirst%3DP.%26atitle%3DLong-acting%2520beta-agonists%2520and%2520their%2520association%2520with%2520inhaled%2520corticosteroids%2520in%2520COPD%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1477%26epage%3D95%26doi%3D10.2174%2F0929867311320120003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Teo, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abisheganaden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lew, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, B. H.</span><span> </span><span class="NLM_article-title">Economic burden of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respirology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1111/j.1440-1843.2011.02073.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1111%2Fj.1440-1843.2011.02073.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=21954985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FptVOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=120-126&author=W.+S.+Teoauthor=W.+S.+Tanauthor=W.+F.+Chongauthor=J.+Abisheganadenauthor=Y.+J.+Lewauthor=T.+K.+Limauthor=B.+H.+Heng&title=Economic+burden+of+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1440-1843.2011.02073.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Economic burden of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Teo W-S Kelvin; Tan Woan-Shin; Chong Wai-Fung; Abisheganaden John; Lew Yii-Jen; Lim Tow-Keang; Heng Bee-Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND OBJECTIVE:  The aim of this study was to estimate the direct medical costs of COPD in two public health clusters in Singapore from 2005 to 2009.  METHODS:  Patients aged 40 years and over, who had been diagnosed with COPD, were identified in a Chronic Disease Management Data-mart.  Annual utilization of health services in inpatient, specialist outpatient, emergency department and primary care settings was extracted from the Chronic Disease Management Data-mart.  Trends in attributable costs, proportions of costs and health-care utilization were analyzed across each level of care.  A weighted attribution approach was used to allocate costs to each health-care utilization episode, depending on the relevance of co-morbidities.  RESULTS:  The mean total cost was approximately $9.9 million per year.  Inpatient admissions were the major cost driver, contributing an average of $7.2 million per year.  The proportion of hospitalization costs declined from 75% in 2005 to 68% in 2009.  Based on the 5-year average, attendances at primary care clinics, emergency department and specialist clinics contributed 3%, 5% and 17%, respectively, of overall COPD costs.  On average, 42% of the total cost burden was incurred for the medical management of COPD.  The share of cost incurred for the treatment of conditions related and unrelated to COPD were 29% and 26%, respectively, of the total average costs.  CONCLUSIONS:  COPD is likely to represent a significant burden to the public health system in most countries.  The findings are particularly relevant to understanding the allocation of health-care resources and informing appropriate cost containment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROsHOCQUWjJSCEBeYuoi7AfW6udTcc2eax2sOlVKF0erntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FptVOqtQ%253D%253D&md5=9366bb24664acaa1af55a3ce9167fe63</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1843.2011.02073.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1843.2011.02073.x%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DW.%2BS.%26aulast%3DTan%26aufirst%3DW.%2BS.%26aulast%3DChong%26aufirst%3DW.%2BF.%26aulast%3DAbisheganaden%26aufirst%3DJ.%26aulast%3DLew%26aufirst%3DY.%2BJ.%26aulast%3DLim%26aufirst%3DT.%2BK.%26aulast%3DHeng%26aufirst%3DB.%2BH.%26atitle%3DEconomic%2520burden%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespirology%26date%3D2012%26volume%3D17%26spage%3D120%26epage%3D126%26doi%3D10.1111%2Fj.1440-1843.2011.02073.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span>Chronic Respiratory Diseases; <span class="NLM_publisher-name">WHO</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>. <a href="http://www.who.int/gard/publications/chronic_respiratory_diseases.pdf" class="extLink">http://www.who.int/gard/publications/chronic_respiratory_diseases.pdf</a> (accessed July, 2013).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chronic+Respiratory+Diseases%3B+WHO%3A+Geneva%2C+Switzerland.+http%3A%2F%2Fwww.who.int%2Fgard%2Fpublications%2Fchronic_respiratory_diseases.pdf+%28accessed+July%2C+2013%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DChronic%2520Respiratory%2520Diseases%26pub%3DWHO" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B. R.</span><span> </span><span class="NLM_article-title">Systemic manifestations and comorbidities of COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1185</span><span class="refDoi"> DOI: 10.1183/09031936.00128008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1183%2F09031936.00128008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=19407051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFahtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=1165-1185&author=P.+J.+Barnesauthor=B.+R.+Celli&title=Systemic+manifestations+and+comorbidities+of+COPD&doi=10.1183%2F09031936.00128008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic manifestations and comorbidities of COPD</span></div><div class="casAuthors">Barnes, P. J.; Celli, B. R.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1165-1185</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Increasing evidence indicates that chronic obstructive pulmonary disease (COPD) is a complex disease involving more than airflow obstruction.  Airflow obstruction has profound effects on cardiac function and gas exchange with systemic consequences.  In addn., as COPD results from inflammation and/or alterations in repair mechanisms, the "spill-over" of inflammatory mediators into the circulation may results in important systemic manifestations of the disease, such as skeletal muscle wasting and cachexia.  Systemic inflammation may also initiate or worsen comorbid diseases, such as ischemic heart disease, heart failure, osteoporosis, normocytic anemia, lung cancer, depression and diabetes.  Comorbid diseases potentiate the morbidity of COPD, leading to increased hospitalizations, mortality and healthcare costs.  Comorbidities complicate the management of COPD and need to be evaluated carefully.  Current therapies for comorbid diseases, such as statins and peroxisome proliferator-activated receptor-agonists, may provide unexpected benefits for COPD patients.  Treatment of COPD inflammation may concomitantly treat systemic inflammation and assocd. comorbidities.  However, new broad-spectrum anti-inflammatory treatments, such as phosphodiesterase 4 inhibitors, have significant side-effects so it may be necessary to develop inhaled drugs in the future.  Another approach is the reversal of corticosteroid resistance, for example with effective antioxidants.  More research is needed on COPD comorbidities and their treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Pa8nodQf1LVg90H21EOLACvtfcHk0ljkw-J_CWfZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFahtbk%253D&md5=645e93d5c627e42dd0e1bbd0f25259cb</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1183%2F09031936.00128008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00128008%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DCelli%26aufirst%3DB.%2BR.%26atitle%3DSystemic%2520manifestations%2520and%2520comorbidities%2520of%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D33%26spage%3D1165%26epage%3D1185%26doi%3D10.1183%2F09031936.00128008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Montuschi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuso, L.</span><span> </span><span class="NLM_article-title">Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1464</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span><span class="refDoi"> DOI: 10.2174/0929867311320120002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.2174%2F0929867311320120002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=22963553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1464-76&author=P.+Montuschiauthor=F.+Macagnoauthor=S.+Valenteauthor=L.+Fuso&title=Inhaled+muscarinic+acetylcholine+receptor+antagonists+for+treatment+of+COPD&doi=10.2174%2F0929867311320120002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD</span></div><div class="casAuthors">Montuschi, P.; Macagno, F.; Valente, S.; Fuso, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1464-1476</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Bronchodilators, generally administered via metered dose or dry powder inhalers, are the mainstays of pharmacol. treatment of stable COPD.  Inhaled long-acting beta-agonists (LABA) and anticholinergics are the broncholidators primarily used in the chronic treatment of COPD.  Anticholinergics act as muscarinic acetylcholine receptor antagonists and are frequently preferred over beta-agonists for their minimal cardiac stimulatory effects and greater efficacy in most studies.  Their therapeutic efficacy is based on the fact that vagally mediated bronchoconstriction is the major reversible component of airflow obstruction in patients with COPD.  However, bronchodilators are effective only on the reversible component of airflow obstruction, which by definition is limited, as COPD is characterized by a fixed or poorly reversible airflow obstruction.  Inhaled anticholinergic antimuscarinic drugs approved for the treatment of COPD include ipratropium bromide, oxitropium bromide and tiotropium bromide.  Ipratropium bromide, the prototype of anticholinergic bronchodilators, is a short-acting agent.  Oxitropium bromide is administered twice a day.  Tiotropium bromide, the only long-acting antimuscarinic agent (LAMA) currently approved, is administered once a day.  Newer LAMAs including aclidinium bromide and glycopyrrolate bromide are currently in phase III development for treatment of COPD.  Some new LAMAs, including glycocpyrrolate, are suitable for once daily administration and, unlike tiotropium, have a rapid onset of action.  New LAMAs and their combination with ultra-LABA and, possibly, inhaled corticosteroids, seem to open new perspectives in the management of COPD.  Dual-pharmacol. muscarinic antagonist-beta2 agonist (MABA) mols. present a novel approach to the treatment of COPD by combining muscarinic antagonism and beta2 agonism in a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYOw4zXsYanrVg90H21EOLACvtfcHk0ljkw-J_CWfZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLg%253D&md5=3e12b45f2c1c0bc03f7d54f62096b48f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120002%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DMacagno%26aufirst%3DF.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DFuso%26aufirst%3DL.%26atitle%3DInhaled%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%2520for%2520treatment%2520of%2520COPD%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1464%26epage%3D76%26doi%3D10.2174%2F0929867311320120002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Alveolar macrophages as orchestrators of COPD</span> <span class="citation_source-journal">COPD</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1081/COPD-120028701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1081%2FCOPD-120028701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16997739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BD28rmslWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=59-70&author=P.+J.+Barnes&title=Alveolar+macrophages+as+orchestrators+of+COPD&doi=10.1081%2FCOPD-120028701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Alveolar macrophages as orchestrators of COPD</span></div><div class="casAuthors">Barnes Peter J</div><div class="citationInfo"><span class="NLM_cas:title">COPD</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-70</span>
        ISSN:<span class="NLM_cas:issn">1541-2555</span>.
    </div><div class="casAbstract">Alveolar macrophages play a critical role in the pathophysiology of COPD and are a major target for future anti-inflammatory therapy.  Macrophage numbers are markedly increased in the lung and alveolar space of patients with COPD and are localized to sites of alveolar destruction.  The increased numbers of macrophages may result from increased recruitment of blood monocytes, prolonged survival in the lung and to a lesser extent to increased proliferation in the lung.  Alveolar macrophages from COPD patients have an increased baseline and stimulated secretion of inflammatory proteins, including certain cytokines, chemokines, reactive oxygen species and elastolytic enzymes, which together could account for all of the pathophysiological features of COPD.  Alveolar macrophages form COPD appear to be resistant to the anti-inflammatory effects of corticosteriods and this is linked to reduced activity and expression of histone deacetylase 2, a nuclear enzyme that switches off inflammatory genes activated through the transcription factor nuclear factor-KB.  Alternative anti-inflammatory therapies that inhibit macrophages are therefore needed in the future to deal with the chronic inflammation of COPD.  These drugs may include resveratrol, theophylline derivatives, MAP kinase inhibitors and phosphodiesterase-4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvAY_iJApUW2HOrQ6qeX-mfW6udTcc2eZRH_LjYxB817ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rmslWhsQ%253D%253D&md5=1c47f079210b93257599e964cf0b438c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1081%2FCOPD-120028701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FCOPD-120028701%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DAlveolar%2520macrophages%2520as%2520orchestrators%2520of%2520COPD%26jtitle%3DCOPD%26date%3D2004%26volume%3D1%26spage%3D59%26epage%3D70%26doi%3D10.1081%2FCOPD-120028701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Mediators of Chronic Obstructive Pulmonary Disease</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">548</span><span class="refDoi"> DOI: 10.1124/pr.56.4.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1124%2Fpr.56.4.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=15602009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=515-548&author=P.+J.+Barnes&title=Mediators+of+Chronic+Obstructive+Pulmonary+Disease&doi=10.1124%2Fpr.56.4.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mediators of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">515-548</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem that is now a leading cause of death.  COPD is assocd. with a chronic inflammatory response, predominantly in small airways and lung parenchyma, which is characterized by increased nos. of macrophages, neutrophils, and T lymphocytes.  The inflammatory mediators involved in COPD have not been clearly defined, in contrast to asthma, but it is now apparent that many lipid mediators, inflammatory peptides, reactive oxygen and nitrogen species, chemokines, cytokines, and growth factors are involved in orchestrating the complex inflammatory process that results in small airway fibrosis and alveolar destruction.  Many proteases are also involved in the inflammatory process and are responsible for the destruction of elastin fibers in the lung parenchyma, which is the hallmark of emphysema.  The identification of inflammatory mediators and understanding their interactions is important for the development of anti-inflammatory treatments for this important disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpISgwqcjIYtLVg90H21EOLACvtfcHk0ljkw-J_CWfZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWlt7s%253D&md5=937a8351bde4c91872e956746a7d46e2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fpr.56.4.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.56.4.2%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DMediators%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2004%26volume%3D56%26spage%3D515%26epage%3D548%26doi%3D10.1124%2Fpr.56.4.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Hoogsteden, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dongen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hal, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delahaye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilvering, C.</span><span> </span><span class="NLM_article-title">Phenotype of blood monocytes and alveolar macrophages in interstitial lung disease</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">574</span><span class="NLM_x">–</span> <span class="NLM_lpage">577</span><span class="refDoi"> DOI: 10.1378/chest.95.3.574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1378%2Fchest.95.3.574" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1989&pages=574-577&author=H.+C.+Hoogstedenauthor=J.+J.+van+Dongenauthor=P.+T.+van+Halauthor=M.+Delahayeauthor=W.+Hopauthor=C.+Hilvering&title=Phenotype+of+blood+monocytes+and+alveolar+macrophages+in+interstitial+lung+disease&doi=10.1378%2Fchest.95.3.574"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1378%2Fchest.95.3.574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.95.3.574%26sid%3Dliteratum%253Aachs%26aulast%3DHoogsteden%26aufirst%3DH.%2BC.%26aulast%3Dvan%2BDongen%26aufirst%3DJ.%2BJ.%26aulast%3Dvan%2BHal%26aufirst%3DP.%2BT.%26aulast%3DDelahaye%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DW.%26aulast%3DHilvering%26aufirst%3DC.%26atitle%3DPhenotype%2520of%2520blood%2520monocytes%2520and%2520alveolar%2520macrophages%2520in%2520interstitial%2520lung%2520disease%26jtitle%3DChest%26date%3D1989%26volume%3D95%26spage%3D574%26epage%3D577%26doi%3D10.1378%2Fchest.95.3.574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Thorley, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tetley, T. D.</span><span> </span><span class="NLM_article-title">Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Int. J. Chron. Obstruct. Pulmon. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=409-428&author=A.+J.+Thorleyauthor=T.+D.+Tetley&title=Pulmonary+epithelium%2C+cigarette+smoke%2C+and+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThorley%26aufirst%3DA.%2BJ.%26aulast%3DTetley%26aufirst%3DT.%2BD.%26atitle%3DPulmonary%2520epithelium%252C%2520cigarette%2520smoke%252C%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DInt.%2520J.%2520Chron.%2520Obstruct.%2520Pulmon.%2520Dis.%26date%3D2007%26volume%3D4%26spage%3D409%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/j.jaci.2012.12.1564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2Fj.jaci.2012.12.1564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=23360759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2013&pages=636-45&author=P.+J.+Barnes&title=Corticosteroid+resistance+in+patients+with+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.jaci.2012.12.1564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">636-645</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Reduced responsiveness to the anti-inflammatory effects of corticosteroids is a major barrier to effective management of asthma in smokers and patients with severe asthma and in the majority of patients with chronic obstructive pulmonary disease (COPD).  The mol. mechanisms leading to steroid resistance are now better understood, and this has identified new targets for therapy.  In patients with severe asthma, several mol. mechanisms have been identified that might account for reduced steroid responsiveness, including reduced nuclear translocation of glucocorticoid receptor (GR) α after binding corticosteroids.  This might be due to modification of the GR by means of phosphorylation as a result of activation of several kinases (p38 mitogen-activated protein kinase α, p38 mitogen-activated protein kinase γ, and c-Jun N-terminal kinase 1), which in turn might be due to reduced activity and expression of phosphatases, such as mitogen-activated protein kinase phosphatase 1 and protein phosphatase A2.  Other mechanisms proposed include increased expression of GRβ, which competes with and thus inhibits activated GRα; increased secretion of macrophage migration inhibitory factor; competition with the transcription factor activator protein 1; and reduced expression of histone deacetylase (HDAC) 2.  HDAC2 appears to mediate the action of steroids to switch off activated inflammatory genes, but in patients with COPD, patients with severe asthma, and smokers with asthma, HDAC2 activity and expression are reduced by oxidative stress through activation of phosphoinositide 3-kinase δ.  Strategies for managing steroid resistance include alternative anti-inflammatory drugs, but a novel approach is to reverse steroid resistance by increasing HDAC2 expression, which can be achieved with theophylline and phosphoinositide 3-kinase δ inhibitors.  Long-acting β2-agonists can also increase steroid responsiveness by reversing GRα phosphorylation.  Identifying the mol. mechanisms of steroid resistance in asthmatic patients and patients with COPD can thus lead to more effective anti-inflammatory treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7NxvF8RwhRrVg90H21EOLACvtfcHk0lhGTLJ7cuPjTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWmtrY%253D&md5=b9f464c23387722c42b85280cc106d07</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2012.12.1564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2012.12.1564%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DCorticosteroid%2520resistance%2520in%2520patients%2520with%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2013%26volume%3D131%26spage%3D636%26epage%3D45%26doi%3D10.1016%2Fj.jaci.2012.12.1564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Saklatvala, J.</span><span> </span><span class="NLM_article-title">The p38 MAP kinase pathway as a therapeutic target in inflammatory disease</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">372</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span><span class="refDoi"> DOI: 10.1016/j.coph.2004.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2Fj.coph.2004.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=15251131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Wgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=372-377&author=J.+Saklatvala&title=The+p38+MAP+kinase+pathway+as+a+therapeutic+target+in+inflammatory+disease&doi=10.1016%2Fj.coph.2004.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The p38 MAP kinase pathway as a therapeutic target in inflammatory disease</span></div><div class="casAuthors">Saklatvala, Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">372-377</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  The p38 MAPK signalling pathway plays an important role in inflammation and other physiol. processes.  Specific inhibitors of p38 α and β MAPK block prodn. of the major inflammatory cytokines (i.e. tumor necrosis factor-α and interleukin-1) and other proteins (e.g. cyclooxygenase-2), and are anti-inflammatory in animal models of disease.  A major function of the pathway is post-transcriptional control of inflammatory gene expression.  Many of the mRNAs are unstable (or untranslatable) because of AU-rich elements in the 3'untranslated region.  Signalling in the p38 pathway counteracts these and stabilizes the mRNAs by preventing their otherwise rapid de-adenylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglO4EVBhJ-LVg90H21EOLACvtfcHk0lhGTLJ7cuPjTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Wgu7s%253D&md5=5678936250f1dbc9c27707bd7edf6108</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2004.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2004.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DSaklatvala%26aufirst%3DJ.%26atitle%3DThe%2520p38%2520MAP%2520kinase%2520pathway%2520as%2520a%2520therapeutic%2520target%2520in%2520inflammatory%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2004%26volume%3D4%26spage%3D372%26epage%3D377%26doi%3D10.1016%2Fj.coph.2004.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wang, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diener, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan-Hui, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantlo, N.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">23668</span><span class="NLM_x">–</span> <span class="NLM_lpage">23674</span><span class="refDoi"> DOI: 10.1074/jbc.272.38.23668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1074%2Fjbc.272.38.23668" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=23668-23674&author=X.+S.+Wangauthor=K.+Dienerauthor=C.+L.+Mantheyauthor=S.+Wangauthor=B.+Rosenzweigauthor=J.+Brayauthor=J.+Delaneyauthor=C.+N.+Coleauthor=P.+Chan-Huiauthor=N.+Mantlo&title=Molecular+cloning+and+characterization+of+a+novel+p38+mitogen-activated+protein+kinase&doi=10.1074%2Fjbc.272.38.23668"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.38.23668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.38.23668%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BS.%26aulast%3DDiener%26aufirst%3DK.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DRosenzweig%26aufirst%3DB.%26aulast%3DBray%26aufirst%3DJ.%26aulast%3DDelaney%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DC.%2BN.%26aulast%3DChan-Hui%26aufirst%3DP.%26aulast%3DMantlo%26aufirst%3DN.%26atitle%3DMolecular%2520cloning%2520and%2520characterization%2520of%2520a%2520novel%2520p38%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D23668%26epage%3D23674%26doi%3D10.1074%2Fjbc.272.38.23668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Mercado, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span> </span><span class="NLM_article-title">p38 Mitogen-activated protein kinase−γ inhibition by long-acting β2 adrenergic agonists reversed steroid insensitivity in severe asthma</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">1128</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1124/mol.111.071993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1124%2Fmol.111.071993" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=1128-35&author=N.+Mercadoauthor=Y.+Toauthor=Y.+Kobayashiauthor=I.+M.+Adcockauthor=P.+J.+Barnesauthor=K.+Ito&title=p38+Mitogen-activated+protein+kinase%E2%88%92%CE%B3+inhibition+by+long-acting+%CE%B22+adrenergic+agonists+reversed+steroid+insensitivity+in+severe+asthma&doi=10.1124%2Fmol.111.071993"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.071993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.071993%26sid%3Dliteratum%253Aachs%26aulast%3DMercado%26aufirst%3DN.%26aulast%3DTo%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DAdcock%26aufirst%3DI.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DIto%26aufirst%3DK.%26atitle%3Dp38%2520Mitogen-activated%2520protein%2520kinase%25E2%2588%2592%25CE%25B3%2520inhibition%2520by%2520long-acting%2520%25CE%25B22%2520adrenergic%2520agonists%2520reversed%2520steroid%2520insensitivity%2520in%2520severe%2520asthma%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D1128%26epage%3D35%26doi%3D10.1124%2Fmol.111.071993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabbagh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phippard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suttmann, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leaffer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aud, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Porto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. R.</span><span> </span><span class="NLM_article-title">Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span><span class="refDoi"> DOI: 10.1124/jpet.108.139006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1124%2Fjpet.108.139006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=18776065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=610-619&author=R.+J.+Hillauthor=K.+Dabbaghauthor=D.+Phippardauthor=C.+Liauthor=R.+T.+Suttmannauthor=M.+Welchauthor=E.+Pappauthor=K.+W.+Songauthor=K.-C.+Changauthor=D.+Leafferauthor=Y.-N.+Kimauthor=R.+T.+Robertsauthor=T.+S.+Zabkaauthor=D.+Audauthor=J.+Dal+Portoauthor=A.+M.+Manningauthor=S.+L.+Pengauthor=D.+M.+Goldsteinauthor=B.+R.+Wong&title=Pamapimod%2C+a+novel+p38+mitogen-activated+protein+kinase+inhibitor%3A+preclinical+analysis+of+efficacy+and+selectivity&doi=10.1124%2Fjpet.108.139006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity</span></div><div class="casAuthors">Hill, Ronald J.; Dabbagh, Karim; Phippard, Deborah; Li, Ching; Suttmann, Rebecca T.; Welch, Mary; Papp, Eva; Song, Kyung W.; Chang, Kung-ching; Leaffer, David; Kim, Yong-Nam; Roberts, Richard T.; Zabka, Tanja S.; Aud, Dee; Dal Porto, Joseph; Manning, Anthony M.; Peng, Stanford L.; Goldstein, David M.; Wong, Brian R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">610-619</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P38α is a protein kinase that regulates the expression of inflammatory cytokines, suggesting a role in the pathogenesis of diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus.  Here, we describe the preclin. pharmacol. of pamapimod, a novel p38 mitogen-activated protein kinase inhibitor.  Pamapimod inhibited p38α and p38β enzymic activity, with IC50 values of 0.014±0.002 and 0.48±0.04 μM, resp.  There was no activity against p38δ or p38γ isoforms.  When profiled across 350 kinases, pamapimod bound only to four kinases in addn. to p38.  Cellular potency was assessed using phosphorylation of heat shock protein-27 and c-Jun as selective readouts for p38 and c-Jun NH2-terminal kinase (JNK), resp.  Pamapimod inhibited p38 (IC50, 0.06 μM), but inhibition of JNK was not detected.  Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) α prodn. by monocytes, interleukin (IL)-1β prodn. in human whole blood, and spontaneous TNFα prodn. by synovial explants from RA patients.  LPS- and TNFα-stimulated prodn. of TNFα and IL-6 in rodents also was inhibited by pamapimod.  In murine collagen-induced arthritis, pamapimod reduced clin. signs of inflammation and bone loss at 50 mg/kg or greater.  In a rat model of hyperalgesia, pamapimod increased tolerance to pressure in a dose-dependent manner, suggesting an important role of p38 in pain assocd. with inflammation.  Finally, an analog of pamapimod that has equiv. potency and selectivity inhibited renal disease in lupus-prone MRL/lpr mice.  Our study demonstrates that pamapimod is a potent, selective inhibitor of p38α with the ability to inhibit the signs and symptoms of RA and other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoImm011NnzW7Vg90H21EOLACvtfcHk0ljA0pbBXmFQ4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtL3F&md5=9311aa6b1a51544ac755d1cc77cdd92f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.139006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.139006%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DDabbagh%26aufirst%3DK.%26aulast%3DPhippard%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DSuttmann%26aufirst%3DR.%2BT.%26aulast%3DWelch%26aufirst%3DM.%26aulast%3DPapp%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DK.%2BW.%26aulast%3DChang%26aufirst%3DK.-C.%26aulast%3DLeaffer%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.-N.%26aulast%3DRoberts%26aufirst%3DR.%2BT.%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DAud%26aufirst%3DD.%26aulast%3DDal%2BPorto%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DS.%2BL.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DB.%2BR.%26atitle%3DPamapimod%252C%2520a%2520novel%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%253A%2520preclinical%2520analysis%2520of%2520efficacy%2520and%2520selectivity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D610%26epage%3D619%26doi%3D10.1124%2Fjpet.108.139006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Cohen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chindalore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimany, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, J. P.</span><span> </span><span class="NLM_article-title">Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1002/art.24266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1002%2Fart.24266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=19180516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1CgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=335-44&author=S.+B.+Cohenauthor=T.+T.+Chengauthor=V.+Chindaloreauthor=N.+Damjanovauthor=R.+Burgos-Vargasauthor=P.+Deloraauthor=K.+Zimanyauthor=H.+Traversauthor=J.+P.+Caulfield&title=Evaluation+of+the+efficacy+and+safety+of+pamapimod%2C+a+p38+MAP+kinase+inhibitor%2C+in+a+double-blind%2C+methotrexate-controlled+study+of+patients+with+active+rheumatoid+arthritis&doi=10.1002%2Fart.24266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active Rheumatoid arthritis</span></div><div class="casAuthors">Cohen, Stanley B.; Cheng, Tien-Tsai; Chindalore, Vishala; Damjanov, Nemanja; Burgos-Vargas, Ruben; DeLora, Patricia; Zimany, Kathleen; Travers, Helen; Caulfield, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">335-344</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To det. the efficacy and safety of pamapimod (a selective inhibitor of the α-isoform of p38 MAP kinase) as monotherapy in comparison with methotrexate (MTX) treatment in adult patients with active rheumatoid arthritis (RA).  Methods: Patients were randomly assigned to 1 of 4 treatment groups and received 12 wk of double-blind treatment.  One group received MTX (7.5 mg/wk with planned escalation to 20 mg/wk), and 3 groups received pamapimod (50, 150, or 300 mg) once daily.  The primary efficacy end point was the proportion of patients meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at 12 wk.  Secondary end points included ACR50 and ACR70 responses, change from baseline in the Disease Activity Score in 28 joints (DAS28), categorical analyses of DAS28/European League Against Rheumatism response, and change from baseline in each parameter of the ACR core set of measures.  Safety monitoring included recording of adverse events (AEs), lab. testing, immunol. assessments, administration of electrocardiograms, and assessment of vital signs.  Results: Patients assigned to receive MTX and pamapimod had similar demographics and baseline characteristics.  At week 12, fewer patients taking pamapimod had an ACR20 response (23%, 18%, and 31% in the 50-, 150-, and 300-mg groups, resp.) compared with patients taking MTX (45%).  Secondary efficacy end points showed a similar pattern.  AEs were typically characterized as mild and included infections, skin disorders, and dizziness.  Pamapimod was generally well tolerated, but the 300-mg dose appeared to be more toxic than either the 2 lower doses or MTX.  Conclusion: The present results showed that pamapimod was not as effective as MTX in the treatment of active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp98GB6seTS2rVg90H21EOLACvtfcHk0ljA0pbBXmFQ4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1CgtL4%253D&md5=d76a0ea256ab02b1c16d388be13c2f3e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fart.24266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24266%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DCheng%26aufirst%3DT.%2BT.%26aulast%3DChindalore%26aufirst%3DV.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DDelora%26aufirst%3DP.%26aulast%3DZimany%26aufirst%3DK.%26aulast%3DTravers%26aufirst%3DH.%26aulast%3DCaulfield%26aufirst%3DJ.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520pamapimod%252C%2520a%2520p38%2520MAP%2520kinase%2520inhibitor%252C%2520in%2520a%2520double-blind%252C%2520methotrexate-controlled%2520study%2520of%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D335%26epage%3D44%26doi%3D10.1002%2Fart.24266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wofsy, D.</span><span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled phase 2 study of an oral p38αMAPK inhibitor, SCIO-469, in patients with active rheumatoid arthritis. [abstract 715]</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">S431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=S431&issue=Suppl&author=M.+C.+Genoveseauthor=S.+B.+Cohenauthor=D.+Wofsy&title=A+randomized%2C+double-blind%2C+placebo-controlled+phase+2+study+of+an+oral+p38%CE%B1MAPK+inhibitor%2C+SCIO-469%2C+in+patients+with+active+rheumatoid+arthritis.+%5Babstract+715%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DWofsy%26aufirst%3DD.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25202%2520study%2520of%2520an%2520oral%2520p38%25CE%25B1MAPK%2520inhibitor%252C%2520SCIO-469%252C%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis.%2520%255Babstract%2520715%255D%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26issue%3DSuppl%26spage%3DS431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lijE2z6fUtv9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Selness, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devadas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durley, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rucker, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerome, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrufo, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Promo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickory, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvira, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blevis-Bal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yalamanchili, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonder Embse, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, J. B.</span><span> </span><span class="NLM_article-title">Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4066</span><span class="NLM_x">–</span> <span class="NLM_lpage">4071</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2Fj.bmcl.2011.04.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=21641211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4066-4071&author=S.+R.+Selnessauthor=R.+V.+Devrajauthor=B.+Devadasauthor=J.+K.+Walkerauthor=T.+L.+Boehmauthor=R.+C.+Durleyauthor=H.+Shiehauthor=L.+Xingauthor=P.+V.+Ruckerauthor=K.+D.+Jeromeauthor=A.+G.+Bensonauthor=L.+D.+Marrufoauthor=H.+M.+Madsenauthor=J.+Hitchcockauthor=T.+J.+Owenauthor=L.+Christieauthor=M.+A.+Promoauthor=B.+S.+Hickoryauthor=E.+Alviraauthor=W.+Naingauthor=R.+Blevis-Balauthor=D.+Messingauthor=J.+Yangauthor=M.+K.+Maoauthor=G.+Yalamanchiliauthor=R.+Vonder+Embseauthor=J.+Hirschauthor=M.+Saabyeauthor=S.+Bonarauthor=E.+Webbauthor=G.+Andersonauthor=J.+B.+Monahan&title=Discovery+of+PH-797804%2C+a+highly+selective+and+potent+inhibitor+of+p38+MAP+kinase&doi=10.1016%2Fj.bmcl.2011.04.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase</span></div><div class="casAuthors">Selness, Shaun R.; Devraj, Rajesh V.; Devadas, Balekudru; Walker, John K.; Boehm, Terri L.; Durley, Richard C.; Shieh, Huey; Xing, Li; Rucker, Paul V.; Jerome, Kevin D.; Benson, Alan G.; Marrufo, Laura D.; Madsen, Heather M.; Hitchcock, Jeff; Owen, Tom J.; Christie, Lance; Promo, Michele A.; Hickory, Brian S.; Alvira, Edgardo; Naing, Win; Blevis-Bal, Radhika; Messing, Dean; Yang, Jerry; Mao, Michael K.; Yalamanchili, Gopi; Vonder Embse, Richard; Hirsch, Jeffrey; Saabye, Matthew; Bonar, Sheri; Webb, Elizabeth; Anderson, Gary; Monahan, Joseph B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4066-4071</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and SAR studies of a novel N-arylpyridinone class of p38 kinase inhibitors are described.  Systematic structural modifications to the HTS lead led to the identification of a clin. candidate (phase II clin. studies) for the treatment of inflammatory diseases.  Addnl., the chiral synthesis and properties of said clin. candidate are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL54FATgVMdbVg90H21EOLACvtfcHk0lijE2z6fUtv9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVCisLk%253D&md5=eb900d70d0c84f642e3b09ecbeb0cf91</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.121%26sid%3Dliteratum%253Aachs%26aulast%3DSelness%26aufirst%3DS.%2BR.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DDevadas%26aufirst%3DB.%26aulast%3DWalker%26aufirst%3DJ.%2BK.%26aulast%3DBoehm%26aufirst%3DT.%2BL.%26aulast%3DDurley%26aufirst%3DR.%2BC.%26aulast%3DShieh%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DRucker%26aufirst%3DP.%2BV.%26aulast%3DJerome%26aufirst%3DK.%2BD.%26aulast%3DBenson%26aufirst%3DA.%2BG.%26aulast%3DMarrufo%26aufirst%3DL.%2BD.%26aulast%3DMadsen%26aufirst%3DH.%2BM.%26aulast%3DHitchcock%26aufirst%3DJ.%26aulast%3DOwen%26aufirst%3DT.%2BJ.%26aulast%3DChristie%26aufirst%3DL.%26aulast%3DPromo%26aufirst%3DM.%2BA.%26aulast%3DHickory%26aufirst%3DB.%2BS.%26aulast%3DAlvira%26aufirst%3DE.%26aulast%3DNaing%26aufirst%3DW.%26aulast%3DBlevis-Bal%26aufirst%3DR.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DM.%2BK.%26aulast%3DYalamanchili%26aufirst%3DG.%26aulast%3DVonder%2BEmbse%26aufirst%3DR.%26aulast%3DHirsch%26aufirst%3DJ.%26aulast%3DSaabye%26aufirst%3DM.%26aulast%3DBonar%26aufirst%3DS.%26aulast%3DWebb%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DG.%26aulast%3DMonahan%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520PH-797804%252C%2520a%2520highly%2520selective%2520and%2520potent%2520inhibitor%2520of%2520p38%2520MAP%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4066%26epage%3D4071%26doi%3D10.1016%2Fj.bmcl.2011.04.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">MacNee, W.; Allan, R.; Jones, I.; De Salvo, M. C.; Tan, L.</span><span> </span><span class="NLM_article-title">A Randomised, Placebo Controlled Trial of 6 Weeks’ Treatment with a Novel Oral p38 Inhibitor in Patients with COPD</span>, <span class="NLM_conf-name">European Respiratory Society Meeting</span>, <span class="NLM_conf-loc">Barcelona, Spain</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&conference=European+Respiratory+Society+Meeting&author=W.+MacNee&author=R.+Allan&author=I.+Jones&author=M.+C.+De+Salvo&author=L.+Tan&title=A+Randomised%2C+Placebo+Controlled+Trial+of+6+Weeks%E2%80%99+Treatment+with+a+Novel+Oral+p38+Inhibitor+in+Patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMacNee%26aufirst%3DW.%26atitle%3DA%2520Randomised%252C%2520Placebo%2520Controlled%2520Trial%2520of%25206%2520Weeks%25E2%2580%2599%2520Treatment%2520with%2520a%2520Novel%2520Oral%2520p38%2520Inhibitor%2520in%2520Patients%2520with%2520COPD%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willits, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keene, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnacle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tal-Singer, R.</span><span> </span><span class="NLM_article-title">An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1177/0091270010397050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1177%2F0091270010397050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=22090363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvV2htro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=416-424&author=D.+A.+Lomasauthor=D.+A.+Lipsonauthor=B.+E.+Millerauthor=L.+Willitsauthor=O.+Keeneauthor=H.+Barnacleauthor=N.+C.+Barnesauthor=R.+Tal-Singer&title=An+oral+inhibitor+of+p38+MAP+kinase+reduces+plasma+fibrinogen+in+patients+with+chronic+obstructive+pulmonary+disease&doi=10.1177%2F0091270010397050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Lomas, David A.; Lipson, David A.; Miller, Bruce E.; Willits, Lisa; Keene, Oliver; Barnacle, Helen; Barnes, Neil C.; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">416-424</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aims were to det. the effect of an oral inhibitor of the signaling mediator p38 mitogen-activated protein kinase (GW856553, losmapimod) on sputum neutrophils, pulmonary function, and blood biomarkers of inflammation in chronic obstructive pulmonary disease (COPD).  Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 μg/500 μg combination (SFC), or placebo in a 12-wk, randomized, double-blind, double-dummy study (MKI102428/NCT00642148).  Neither losmapimod nor SFC had an effect on the primary end point of sputum neutrophils.  Losmapimod was well tolerated and reduced plasma fibrinogen by 11% (-0.4 g/L, ratio of effect of losmapimod/placebo 0.89; 95% confidence interval, 0.83-0.96; P = .002) with nonsignificant redns. in interleukin-6, interleukin-8, and C-reactive protein.  There was evidence of improvement in hyperinflation with losmapimod compared with placebo (overall P = .02).  Inhaled SFC significantly improved lung function and reduced serum CC-16 (ratio of effect of SFC/placebo 0.87; 95% confidence interval, 0.82-0.93; P < .001).  It was concluded that oral losmapimod significantly reduced plasma fibrinogen in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDLEldspAO5LVg90H21EOLACvtfcHk0lhpmZWBvZAyyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvV2htro%253D&md5=31913fca689b64e4f958eee382cd55f9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1177%2F0091270010397050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270010397050%26sid%3Dliteratum%253Aachs%26aulast%3DLomas%26aufirst%3DD.%2BA.%26aulast%3DLipson%26aufirst%3DD.%2BA.%26aulast%3DMiller%26aufirst%3DB.%2BE.%26aulast%3DWillits%26aufirst%3DL.%26aulast%3DKeene%26aufirst%3DO.%26aulast%3DBarnacle%26aufirst%3DH.%26aulast%3DBarnes%26aufirst%3DN.%2BC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DAn%2520oral%2520inhibitor%2520of%2520p38%2520MAP%2520kinase%2520reduces%2520plasma%2520fibrinogen%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D52%26spage%3D416%26epage%3D424%26doi%3D10.1177%2F0091270010397050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Watz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnacle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, R.</span><span> </span><span class="NLM_article-title">Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/S2213-2600(13)70200-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2FS2213-2600%2813%2970200-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=24461903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFagsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=63-72&author=H.+Watzauthor=H.+Barnacleauthor=B.+F.+Hartleyauthor=R.+Chan&title=Efficacy+and+safety+of+the+p38+MAPK+inhibitor+losmapimod+for+patients+with+chronic+obstructive+pulmonary+disease%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS2213-2600%2813%2970200-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Watz, Henrik; Barnacle, Helen; Hartley, Benjamin F.; Chan, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The p38 MAPK pathway seems to be involved in pathogenesis of chronic obstructive pulmonary disease (COPD).  Losmapimod is a potent and selective inhibitor of p38 MAPK.  We assessed the effect of losmapimod on exercise tolerance in patients with COPD.  We did this randomised, parallel-group, placebo-controlled trial at 46 secondary care centers in Argentina, Czech Republic, Estonia, Germany, Norway, South Korea, Ukraine, and USA between Nov 4, 2010, and Dec 22, 2011.  We enrolled patients aged 40 years or older with moderate-to-severe COPD (6 min walking distance <350 m) who were current or previous smokers.  Patients were randomly assigned (1:1:1:1) by a computer generated sequence to one of losmapimod 2·5 mg, 7·5 mg, or 15 mg, or placebo, twice daily for 24 wk.  Randomisation was stratified by country and exacerbation history (block size eight).  Patients and investigators were masked to treatment assignment.  The primary outcome was change in 6 min walking distance between baseline and week 24, assessed in the intention-to-treat population.  This study is registered with ClinicalTrial.gov, no. NCT01218126.  We screened 886 patients, of whom 602 were enrolled and received treatment.  The difference between the placebo group and the losmapimod groups for mean change of 6 min walk distance was not significant: -6·7 m (95% CI -18·2 to 4·9) for losmapimod 2·5 mg, -4·7 m (-16·1 to 6·8) for losmapimod 7·5 mg, and -3·4 m (-15·1 to 8·2) for losmapimod 15 mg.  The safety profile was much the same in each group, although drug-related adverse events were more common with losmapimod 7·5 mg (n=19, 13%) and losmapimod 15 mg (n=20, 13%) than with placebo (n=11, 7%) and losmapimod 2·5 mg (n=13, 9%).  The most common serious adverse events were COPD exacerbation resulting in admission to hospital (eight patients [5%] taking placebo, six [4%] taking losmapimod 2·5 mg, two [1%] taking losmapimod 7·5 mg, and three [2%] taking losmapimod 15 mg) and pneumonia (four [3%] vs 0 [0%] vs 1 [1%] vs 4 [3%]).  Losmapimod did not cause an improvement in exercise tolerance or lung function, despite being well-tolerated in this COPD population.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfxc1a62NhF7Vg90H21EOLACvtfcHk0lhpmZWBvZAyyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFagsA%253D%253D&md5=b737200c2467329d4da544ca7b009e14</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2813%2970200-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252813%252970200-5%26sid%3Dliteratum%253Aachs%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DBarnacle%26aufirst%3DH.%26aulast%3DHartley%26aufirst%3DB.%2BF.%26aulast%3DChan%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520p38%2520MAPK%2520inhibitor%2520losmapimod%2520for%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2014%26volume%3D2%26spage%3D63%26epage%3D72%26doi%3D10.1016%2FS2213-2600%2813%2970200-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Regan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capolino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroe, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pargellis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torcellini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span> </span><span class="NLM_article-title">Structure-Activity Relationships of the p38 MAP Kinase Inhibitor 1-(5-<i>tert</i>-Butyl-2-<i>p</i>-tolyl-2<i>H</i>-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph-thalen-1-yl]urea (BIRB-796)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4676</span><span class="NLM_x">–</span> <span class="NLM_lpage">4686</span><span class="refDoi"> DOI: 10.1021/jm030121k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030121k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4676-4686&author=J.+Reganauthor=A.+Capolinoauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=E.+Hickeyauthor=R.+R.+Kroeauthor=J.+Madwedauthor=M.+Moriakauthor=R.+Nelsonauthor=C.+A.+Pargellisauthor=A.+Swinamerauthor=C.+Torcelliniauthor=M.+Tsangauthor=N.+Moss&title=Structure-Activity+Relationships+of+the+p38+MAP+Kinase+Inhibitor+1-%285-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl%29-3-%5B4-%282-morpholin-4-yl-ethoxy%29naph-thalen-1-yl%5Durea+%28BIRB-796%29&doi=10.1021%2Fjm030121k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm030121k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030121k%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DCapolino%26aufirst%3DA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DKroe%26aufirst%3DR.%2BR.%26aulast%3DMadwed%26aufirst%3DJ.%26aulast%3DMoriak%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DR.%26aulast%3DPargellis%26aufirst%3DC.%2BA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DTorcellini%26aufirst%3DC.%26aulast%3DTsang%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520the%2520p38%2520MAP%2520Kinase%2520Inhibitor%25201-%25285-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl%2529-3-%255B4-%25282-morpholin-4-yl-ethoxy%2529naph-thalen-1-yl%255Durea%2520%2528BIRB-796%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4676%26epage%3D4686%26doi%3D10.1021%2Fjm030121k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Branger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Blink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weijer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polmar, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olszyna, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deventer, S. J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peppelenbosch, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Poll, T.</span><span> </span><span class="NLM_article-title">Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">168</span><span class="NLM_x">, </span> <span class="NLM_fpage">4070</span><span class="NLM_x">–</span> <span class="NLM_lpage">4077</span><span class="refDoi"> DOI: 10.4049/jimmunol.168.8.4070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.4049%2Fjimmunol.168.8.4070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2002&pages=4070-4077&author=J.+Brangerauthor=B.+van+den+Blinkauthor=S.+Weijerauthor=J.+Madwedauthor=C.+L.+Bosauthor=A.+Guptaauthor=C.-L.+Yongauthor=S.+H.+Polmarauthor=D.+P.+Olszynaauthor=E.+Hackauthor=S.+J.+H.+van+Deventerauthor=M.+P.+Peppelenboschauthor=T.+van+der+Poll&title=Anti-inflammatory+effects+of+a+p38+mitogen-activated+protein+kinase+inhibitor+during+human+endotoxemia&doi=10.4049%2Fjimmunol.168.8.4070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.168.8.4070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.168.8.4070%26sid%3Dliteratum%253Aachs%26aulast%3DBranger%26aufirst%3DJ.%26aulast%3Dvan%2Bden%2BBlink%26aufirst%3DB.%26aulast%3DWeijer%26aufirst%3DS.%26aulast%3DMadwed%26aufirst%3DJ.%26aulast%3DBos%26aufirst%3DC.%2BL.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DYong%26aufirst%3DC.-L.%26aulast%3DPolmar%26aufirst%3DS.%2BH.%26aulast%3DOlszyna%26aufirst%3DD.%2BP.%26aulast%3DHack%26aufirst%3DE.%26aulast%3Dvan%2BDeventer%26aufirst%3DS.%2BJ.%2BH.%26aulast%3DPeppelenbosch%26aufirst%3DM.%2BP.%26aulast%3Dvan%2Bder%2BPoll%26aufirst%3DT.%26atitle%3DAnti-inflammatory%2520effects%2520of%2520a%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%2520during%2520human%2520endotoxemia%26jtitle%3DJ.%2520Immunol.%26date%3D2002%26volume%3D168%26spage%3D4070%26epage%3D4077%26doi%3D10.4049%2Fjimmunol.168.8.4070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feagan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Haens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geboes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurcov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golovenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffgen, J.</span><span> </span><span class="NLM_article-title">Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Clin. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.cgh.2005.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2Fj.cgh.2005.11.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16527696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFOqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=325-234&author=S.+Schreiberauthor=B.+Feaganauthor=G.+D%E2%80%99Haensauthor=J.+F.+Colombelauthor=K.+Geboesauthor=M.+Yurcovauthor=V.+Isakovauthor=O.+Golovenkoauthor=C.+N.+Bernsteinauthor=D.+Ludwigauthor=T.+Winterauthor=U.+Meierauthor=C.+Yongauthor=J.+Steffgen&title=Oral+p38+mitogen-activated+protein+kinase+inhibition+with+BIRB+796+for+active+Crohn%E2%80%99s+disease%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2Fj.cgh.2005.11.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double- blind, placebo- controlled trial</span></div><div class="casAuthors">Schreiber, Stefan; Feagan, Brian; D'Haens, Geert; Colombel, Jean-Frederic; Geboes, Karel; Yurcov, Mikhail; Isakov, Vasily; Golovenko, Oleg; Bernstein, Charles N.; Ludwig, Diether; Winter, Trevor; Meier, Ulrich; Yong, Chan; Steffgen, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Gastroenterology and Hepatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-334</span>CODEN:
                <span class="NLM_cas:coden">CGHLAW</span>;
        ISSN:<span class="NLM_cas:issn">1542-3565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein kinase (MAPK) regulates the expression of proinflammatory cytokines, which play a crit. role in the pathophysiol. of Crohn's disease (CD).  This study investigated the efficacy and safety of BIRB 796, a highly potent inhibitor of p38 MAPK, in chronic active CD.  In a multicenter, multinational trial, 284 patients with moderate to severe CD were randomized to receive placebo, or 10, 20, 30, or 60 mg of BIRB 796 twice daily for 8 wk.  Clin. endpoints were based on std. safety assessments, CD Activity Index, C-reactive protein levels, and quality of life (Inflammatory Bowel Disease Questionnaire).  In a substudy, the Crohn's Disease Endoscopic Index of Severity and histol. results of biopsy specimens were assessed.  No clin. efficacy (primary end point, clin. remission; secondary end point, clin. response; Inflammatory Bowel Disease Questionnaire; Crohn's Disease Endoscopic Index of Severity) was seen for BIRB 796 in comparison with placebo.  A significant, dose-dependent decrease of C-reactive protein level was obsd. transiently after BIRB 796 after 1 wk with a return to baseline level over time.  The incidence of adverse events was comparable between all treatment groups, with the exception of a mild increase of transaminase levels that was seen more frequently in the BIRB 796 groups.  Geog. center effects were obsd. with Russian centers producing distinctly higher remission and response rates and lower adverse event rates than in other countries in both placebo and active treatment groups.  There was no evidence for clin. efficacy of BIRB 796 in CD.  A remarkable difference in the course of CD exists between Russia and non-Russian centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPlk4HFJbHhrVg90H21EOLACvtfcHk0lijxikbKW_7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFOqsrs%253D&md5=f99fbaeea2b16c7e5fa11069b99518f1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2005.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2005.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DFeagan%26aufirst%3DB.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DGeboes%26aufirst%3DK.%26aulast%3DYurcov%26aufirst%3DM.%26aulast%3DIsakov%26aufirst%3DV.%26aulast%3DGolovenko%26aufirst%3DO.%26aulast%3DBernstein%26aufirst%3DC.%2BN.%26aulast%3DLudwig%26aufirst%3DD.%26aulast%3DWinter%26aufirst%3DT.%26aulast%3DMeier%26aufirst%3DU.%26aulast%3DYong%26aufirst%3DC.%26aulast%3DSteffgen%26aufirst%3DJ.%26atitle%3DOral%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibition%2520with%2520BIRB%2520796%2520for%2520active%2520Crohn%25E2%2580%2599s%2520disease%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2006%26volume%3D4%26spage%3D325%26epage%3D234%26doi%3D10.1016%2Fj.cgh.2005.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer-Green, G. T.</span><span> </span><span class="NLM_article-title">Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1232</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1002/art.24485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1002%2Fart.24485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=19404957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A280%3ADC%252BD1MzkvFarsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1232-41&author=N.+Damjanovauthor=R.+S.+Kauffmanauthor=G.+T.+Spencer-Green&title=Efficacy%2C+pharmacodynamics%2C+and+safety+of+VX-702%2C+a+novel+p38+MAPK+inhibitor%2C+in+rheumatoid+arthritis%3A+results+of+two+randomized%2C+double-blind%2C+placebo-controlled+clinical+studies&doi=10.1002%2Fart.24485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies</span></div><div class="casAuthors">Damjanov Nemanja; Kauffman Robert S; Spencer-Green George T</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1232-41</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To assess the efficacy and safety of VX-702, a p38 MAPK inhibitor, in patients with active, moderate-to-severe rheumatoid arthritis (RA).  METHODS:  Two 12-week, double-blind, placebo-controlled studies of VX-702 were conducted in patients with active, moderate-to-severe RA.  In the VeRA study, 313 patients received placebo or 2 daily doses of VX-702.  In Study 304, 117 patients received placebo, daily VX-702, or twice weekly VX-702 in addition to concomitant methotrexate (MTX).  Study end points included the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (an ACR20 response), ACR50 and ACR70 responses, changes in the serum levels of biomarkers of inflammation, and safety assessments.  RESULTS:  The numerically superior ACR20 response rates among patients receiving VX-702 compared with those receiving placebo in both studies did not reach pairwise statistical significance at the highest doses in either study.  At week 12 in the VeRA study, ACR20 response rates were 40%, 36%, and 28% among patients receiving 10 mg of VX-702, 5 mg of VX-702, and placebo, respectively.  In Study 304, the response rates were 40%, 44%, and 22% for patients receiving 10 mg VX-702 daily plus MTX, 10 mg VX-702 twice weekly plus MTX, and placebo, respectively.  Reductions in the levels of C-reactive protein, soluble tumor necrosis factor receptor p55, and serum amyloid A were observed as early as week 1 in both studies, but these levels rapidly returned to baseline values by week 4.  The overall frequency of adverse events was similar between the VX-702 and placebo groups.  In the VeRA study, serious infections were more frequent in the VX-702 groups compared with the placebo group (2.4% versus 0%) but not in Study 304 (2.6% versus 4.9%).  CONCLUSION:  The modest clinical efficacy plus the transient suppression of biomarkers of inflammation observed in this study suggest that p38 MAPK inhibition may not provide meaningful, sustained suppression of the chronic inflammation seen in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuFLVCXOhEpYkFb3mqPUYDfW6udTcc2eZiGfnSUeWenrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzkvFarsQ%253D%253D&md5=f23f3b448939ed3cafd7d20410ff81f7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fart.24485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24485%26sid%3Dliteratum%253Aachs%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DSpencer-Green%26aufirst%3DG.%2BT.%26atitle%3DEfficacy%252C%2520pharmacodynamics%252C%2520and%2520safety%2520of%2520VX-702%252C%2520a%2520novel%2520p38%2520MAPK%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%253A%2520results%2520of%2520two%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520clinical%2520studies%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1232%26epage%3D41%26doi%3D10.1002%2Fart.24485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Barouch-Bentov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, K.</span><span> </span><span class="NLM_article-title">Mechanisms of Drug-Resistance in Kinase</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span><span class="refDoi"> DOI: 10.1517/13543784.2011.546344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1517%2F13543784.2011.546344" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=153-208&author=R.+Barouch-Bentovauthor=K.+Sauer&title=Mechanisms+of+Drug-Resistance+in+Kinase&doi=10.1517%2F13543784.2011.546344"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.546344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.546344%26sid%3Dliteratum%253Aachs%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DSauer%26aufirst%3DK.%26atitle%3DMechanisms%2520of%2520Drug-Resistance%2520in%2520Kinase%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D153%26epage%3D208%26doi%3D10.1517%2F13543784.2011.546344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Millan, D. S.</span><span> </span><span class="NLM_article-title">What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1635</span><span class="NLM_x">–</span> <span class="NLM_lpage">1645</span><span class="refDoi"> DOI: 10.4155/fmc.11.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.4155%2Ffmc.11.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=21942253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1635-1645&author=D.+S.+Millan&title=What+is+the+potential+for+inhaled+p38+inhibitors+in+the+treatment+of+chronic+obstructive+pulmonary+disease%3F&doi=10.4155%2Ffmc.11.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?</span></div><div class="casAuthors">Millan, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1635-1645</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  P38 has been an intensely studied therapeutic target in the pharmaceutical industry.  With more than 20 compds. entering human trials, none have progressed beyond Phase II to the best of our knowledge.  The transient efficacy seen in many of the Phase II trials has raised some concerns for the future potential of this target, particularly in rheumatoid arthritis.  With this caveat, there is good evidence for p38 inhibition to be efficacious in chronic obstructive pulmonary disease and there are now several oral compds. currently in development for this disease, with encouraging data beginning to emerge.  With an inhaled agent likely to improve the therapeutic window between efficacy and some of the common adverse events obsd. with oral p38 inhibitors it would seem a sensible approach to take for a disease of the lung.  This review will highlight the potential for an inhaled p38 inhibitor in chronic obstructive pulmonary disease, as well as some of the design principles that are important to consider when developing an inhaled kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4waRvOu6S_LVg90H21EOLACvtfcHk0lijxikbKW_7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvK&md5=81104fda424ad56be567693b9207b4f3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.96%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26atitle%3DWhat%2520is%2520the%2520potential%2520for%2520inhaled%2520p38%2520inhibitors%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1635%26epage%3D1645%26doi%3D10.4155%2Ffmc.11.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Millan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilty, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaitre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahnke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathias, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefaniak, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, C.</span><span> </span><span class="NLM_article-title">Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7797</span><span class="NLM_x">–</span> <span class="NLM_lpage">7814</span><span class="refDoi"> DOI: 10.1021/jm200677b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200677b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7797-7814&author=D.+S.+Millanauthor=M.+E.+Bunnageauthor=J.+L.+Burrowsauthor=K.+J.+Butcherauthor=P.+G.+Doddauthor=T.+J.+Evansauthor=D.+A.+Fairmanauthor=S.+J.+Hughesauthor=I.+C.+Kiltyauthor=A.+Lemaitreauthor=R.+A.+Lewthwaiteauthor=A.+Mahnkeauthor=J.+P.+Mathiasauthor=J.+Philipauthor=R.+T.+Smithauthor=M.+H.+Stefaniakauthor=M.+Yeadonauthor=C.+Phillips&title=Design+and+synthesis+of+inhaled+p38+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm200677b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Millan, David S.; Bunnage, Mark E.; Burrows, Jane L.; Butcher, Kenneth J.; Dodd, Peter G.; Evans, Timothy J.; Fairman, David A.; Hughes, Samantha J.; Kilty, Iain C.; Lemaitre, Arnaud; Lewthwaite, Russell A.; Mahnke, Axel; Mathias, John P.; Philip, James; Smith, Robert T.; Stefaniak, Mark H.; Yeadon, Michael; Phillips, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7797-7814</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes the identification and optimization of a novel series of DFG-out binding p38 inhibitors as inhaled agents for the treatment of chronic obstructive pulmonary disease.  Structure based drug design and "inhalation by design" principles have been applied to the optimization of the lead series exemplified by compd. I.  Analogs have been designed to be potent and selective for p38, with an emphasis on slow enzyme dissocn. kinetics to deliver prolonged lung p38 inhibition.  Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimize systemic exposure and reduce systemically driven adverse events.  High CYP mediated clearance and glucuronidation were targeted to achieve high intrinsic clearance coupled with multiple routes of clearance to minimize drug-drug interactions.  Furthermore, pharmaceutical properties such as stability, crystallinity, and soly. were considered to ensure compatibility with a dry powder inhaler.  P38 Inhibitor II (PF-03715455) was subsequently identified as a clin. candidate from this series with efficacy and safety profiles confirming its potential as an inhaled agent for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzy5ivwDBL6rVg90H21EOLACvtfcHk0linXrjIkiod6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu73E&md5=9bc6cccf04a78831f50fb402bf7cb4b1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm200677b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200677b%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DButcher%26aufirst%3DK.%2BJ.%26aulast%3DDodd%26aufirst%3DP.%2BG.%26aulast%3DEvans%26aufirst%3DT.%2BJ.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLemaitre%26aufirst%3DA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMahnke%26aufirst%3DA.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BT.%26aulast%3DStefaniak%26aufirst%3DM.%2BH.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DC.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520inhaled%2520p38%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7797%26epage%3D7814%26doi%3D10.1021%2Fjm200677b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Smith, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenwick, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschenbaum, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finney-Hayward, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giembycz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, L. E.</span><span> </span><span class="NLM_article-title">Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. B</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0706885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1038%2Fsj.bjp.0706885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16953188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOmu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2006&pages=393-404&author=S.+J.+Smithauthor=P.+S.+Fenwickauthor=A.+G.+Nicholsonauthor=F.+Kirschenbaumauthor=T.+K.+Finney-Haywardauthor=L.+S.+Higginsauthor=M.+A.+Giembyczauthor=P.+J.+Barnesauthor=L.+E.+Donnelly&title=Inhibitory+effect+of+p38+mitogen-activated+protein+kinase+inhibitors+on+cytokine+release+from+human+macrophages.+B&doi=10.1038%2Fsj.bjp.0706885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages</span></div><div class="casAuthors">Smith, S. J.; Fenwick, P. S.; Nicholson, A. G.; Kirschenbaum, F.; Finney-Hayward, T. K.; Higgins, L. S.; Giembycz, M. A.; Barnes, P. J.; Donnelly, L. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-404</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Macrophages release cytokines that may contribute to pulmonary inflammation in conditions such as chronic obstructive pulmonary disease.  Thus, inhibition of macrophage cytokine prodn. may have therapeutic benefit.  P38 MAPK may regulate cytokine prodn., therefore, the effect of two p38 MAPK inhibitors, SB239063 and SD-282, on the release of TNF-α, GM-CSF and IL-8 from human macrophages was investigated.  Cytokine release was measured by ELISA.  Immunoblots and mRNA expression studies were performed to confirm p38 MAPK isoform expression and activity.  Macrophages were isolated from lung tissue of current smokers, ex-smokers and emphysema patients and exposed to lipopolysaccharide.  These cells then released cytokines in a concn.-dependent manner.  SB239063 only inhibited TNF-α release (EC50 0.3±0.1 μM).  Disease status had no effect on the efficacy of SB239063.  SD-282 inhibited both TNF-α and GM-CSF release from macrophages (EC50 6.1±1.4 nM and 1.8±0.6 μM resp.) but had no effect on IL-8 release.  In contrast, both inhibitors suppressed cytokine prodn. in monocytes.  The differential effects of p38 MAPK inhibitors between macrophages and monocytes could not be explained by differences in p38 MAPK isoform expression or activity.  However, the stability of TNF-α mRNA was significantly increased in macrophages compared to monocytes.  These data suggest a differential involvement for p38 MAPK in macrophage cytokine prodn. compared with monocytes.  These effects are not due to lack of p38 activation or p38α expression in macrophages but may reflect differential effects on the stability of cytokine mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBx3hSnKxEsrVg90H21EOLACvtfcHk0linXrjIkiod6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOmu7fK&md5=24084ac9798291eb4ee62133b779b7c4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706885%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%2BJ.%26aulast%3DFenwick%26aufirst%3DP.%2BS.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DKirschenbaum%26aufirst%3DF.%26aulast%3DFinney-Hayward%26aufirst%3DT.%2BK.%26aulast%3DHiggins%26aufirst%3DL.%2BS.%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DInhibitory%2520effect%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitors%2520on%2520cytokine%2520release%2520from%2520human%2520macrophages.%2520B%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D149%26spage%3D393%26epage%3D404%26doi%3D10.1038%2Fsj.bjp.0706885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Yanagisawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamagata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akamatsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koarai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minakata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, M.</span><span> </span><span class="NLM_article-title">The possible role of hematopoietic cell kinase in the pathophysiology of COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1378/chest.07-3020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1378%2Fchest.07-3020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2009&pages=94-101&author=S.+Yanagisawaauthor=H.+Sugiuraauthor=T.+Yokoyamaauthor=T.+Yamagataauthor=T.+Ichikawaauthor=K.+Akamatsuauthor=A.+Koaraiauthor=T.+Hiranoauthor=M.+Nakanishiauthor=K.+Matsunagaauthor=Y.+Minakataauthor=M.+Ichinose&title=The+possible+role+of+hematopoietic+cell+kinase+in+the+pathophysiology+of+COPD&doi=10.1378%2Fchest.07-3020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1378%2Fchest.07-3020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.07-3020%26sid%3Dliteratum%253Aachs%26aulast%3DYanagisawa%26aufirst%3DS.%26aulast%3DSugiura%26aufirst%3DH.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DYamagata%26aufirst%3DT.%26aulast%3DIchikawa%26aufirst%3DT.%26aulast%3DAkamatsu%26aufirst%3DK.%26aulast%3DKoarai%26aufirst%3DA.%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DM.%26aulast%3DMatsunaga%26aufirst%3DK.%26aulast%3DMinakata%26aufirst%3DY.%26aulast%3DIchinose%26aufirst%3DM.%26atitle%3DThe%2520possible%2520role%2520of%2520hematopoietic%2520cell%2520kinase%2520in%2520the%2520pathophysiology%2520of%2520COPD%26jtitle%3DChest%26date%3D2009%26volume%3D135%26spage%3D94%26epage%3D101%26doi%3D10.1378%2Fchest.07-3020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Smolinska, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbaniak, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutch, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horwood, N. J.</span><span> </span><span class="NLM_article-title">Hck Tyrosine Kinase Regulates TLR4-Induced TNF and IL-6 Production via AP-1</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">187</span><span class="NLM_x">, </span> <span class="NLM_fpage">6043</span><span class="NLM_x">–</span> <span class="NLM_lpage">6051</span><span class="refDoi"> DOI: 10.4049/jimmunol.1100967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.4049%2Fjimmunol.1100967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=6043-6051&author=M.+J.+Smolinskaauthor=T.+H.+Pageauthor=A.+M.+Urbaniakauthor=B.+E.+Mutchauthor=N.+J.+Horwood&title=Hck+Tyrosine+Kinase+Regulates+TLR4-Induced+TNF+and+IL-6+Production+via+AP-1&doi=10.4049%2Fjimmunol.1100967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1100967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1100967%26sid%3Dliteratum%253Aachs%26aulast%3DSmolinska%26aufirst%3DM.%2BJ.%26aulast%3DPage%26aufirst%3DT.%2BH.%26aulast%3DUrbaniak%26aufirst%3DA.%2BM.%26aulast%3DMutch%26aufirst%3DB.%2BE.%26aulast%3DHorwood%26aufirst%3DN.%2BJ.%26atitle%3DHck%2520Tyrosine%2520Kinase%2520Regulates%2520TLR4-Induced%2520TNF%2520and%2520IL-6%2520Production%2520via%2520AP-1%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D6043%26epage%3D6051%26doi%3D10.4049%2Fjimmunol.1100967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Ziegler, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlmutter, R. M.</span><span> </span><span class="NLM_article-title">Novel Protein-Tyrosine Kinase Gene (hck) Preferentially Expressed in Cells of Hematopoietic Origin</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2276</span><span class="NLM_x">–</span> <span class="NLM_lpage">2285</span><span class="refDoi"> DOI: 10.1128/MCB.7.6.2276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1128%2FMCB.7.6.2276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=3453117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADyaL2sXlvFajsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1987&pages=2276-2285&author=S.+F.+Zieglerauthor=J.+D.+Marthauthor=D.+B.+Lewisauthor=R.+M.+Perlmutter&title=Novel+Protein-Tyrosine+Kinase+Gene+%28hck%29+Preferentially+Expressed+in+Cells+of+Hematopoietic+Origin&doi=10.1128%2FMCB.7.6.2276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin</span></div><div class="casAuthors">Ziegler, Steven F.; Marth, Jamey D.; Lewis, David B.; Perlmutter, Roger M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2276-85</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">Protein-tyrosine kinases are implicated in the control of cell growth by virtue of their frequent appearance as products of retroviral oncogenes and as components of growth factor receptors.  A novel human protein-tyrosine kinase gene (hck) was studied that is primarily expressed in hematopoietic cells, particularly granulocytes.  The hck gene encodes a 505-residue polypeptide that is closely related to pp56lck, as lymphocyte-specific protein-tyrosine kinase.  The exon breakpoints of the hck gene, partially defined by using murine genomic clones, demonstrate that hck is a member of the src gene family and has been subjected to strong selection pressure during mammalian evolution.  High-level expression of hck transcripts in granulocytes is esp. provocative since these cells are terminally differentiated and typically survive in vivo for only a few hours.  Thus, the hck gene, like other members of the src gene family, appears to function primarily in cells with little growth potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzU8u9VR4CC7Vg90H21EOLACvtfcHk0lgS9xPEvRgCuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXlvFajsL8%253D&md5=c39c6db9d7302f3c3a81f811840cb396</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FMCB.7.6.2276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.7.6.2276%26sid%3Dliteratum%253Aachs%26aulast%3DZiegler%26aufirst%3DS.%2BF.%26aulast%3DMarth%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DD.%2BB.%26aulast%3DPerlmutter%26aufirst%3DR.%2BM.%26atitle%3DNovel%2520Protein-Tyrosine%2520Kinase%2520Gene%2520%2528hck%2529%2520Preferentially%2520Expressed%2520in%2520Cells%2520of%2520Hematopoietic%2520Origin%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1987%26volume%3D7%26spage%3D2276%26epage%3D2285%26doi%3D10.1128%2FMCB.7.6.2276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Morphy, R.</span><span> </span><span class="NLM_article-title">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1413</span><span class="NLM_x">–</span> <span class="NLM_lpage">1437</span><span class="refDoi"> DOI: 10.1021/jm901132v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901132v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1413-1437&author=R.+Morphy&title=Selectively+Nonselective+Kinase+Inhibition%3A+Striking+the+Right+Balance&doi=10.1021%2Fjm901132v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span></div><div class="casAuthors">Morphy, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1413-1437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Marketed kinase inhibitors (MKIs) can deliver superior efficacy compared to inhibitors with high specificity for a single kinase, and the recent introduction of several MKIs to the market opens the door to a new era of safer and effective anticancer therapy.  The key to combining high efficacy with acceptable safety is to inhibit multiple targets in a selectively nonselective fashion.  Strategies for intentionally designing MKIs are emerging, but the field is still in its infancy and we are as medicinal chemists currently on the steepest part of the learning curve.  MTDD can be time-consuming and expensive, and we need to become more proficient first at identifying disease-relevant target combinations and second at discovering MKIs that combine optimal physicochem. and biol. properties.  Bold and innovative medicinal chem. strategies are required to tackle "difficult combinations" where the disease rationale is compelling but where it is a struggle to combine all the desired attributes of an oral MKI drug into a single mol.  At present it is unclear to what extent MKIs with highly tuned selectivity profiles can be rationally designed, particularly for targets that are unrelated by sequence.  In addn. to the well-known selectivity challenge, the physicochem. property profiles of AT P-competitive MKIs can be inherently challenging and limited scope for patentability can also be a serious hindrance.  On the plus side, the amt. of kinase-specific structural information is growing very rapidly, and ultimately this may reveal distinct features and design rules that enable a medicinal chemist to rationally modify and refine the profile of MKIs.  In addn., increasing SAR knowledge is emerging from large scale panel screening with the binding profiles starting to reveal to medicinal chemists how chem. structure affects cross-reactivity across large parts of the kinome.  The merit of MKIs compared with single kinase inhibitors is a subject of controversy in drug discovery that is unlikely to be resolved in the near future.  At the start of a new MTDD project, a rigorous debate needs to take place as to whether it makes more sense to seek a combination of highly selective agents or a DML.  Many factors need to be taken into account in this decision such as the no., similarity, and promiscuity of the targets in the profile and the disease area.  Conformational plasticity and the occurrence of multiple binding modes complicate the in silico prediction of kinase polypharmacol. based solely upon protein structure.  The use of ligand-based similarity to assess the feasibility of a given combination can add real value.  Currently, serendipity plays a significant role in MKI discovery and many, if not most, MKIs have been discovered by chance during the search for selective inhibitors.  Medicinal chemists need to be alert to the possibilities when a surprising combination is found by chance.  To exploit such serendipity, you need a good appreciation of when you have a sufficiently high quality starting compd. and then you need to be able to make and test sufficient analogs to explore your new disease-based hypothesis.  MKIs are costly to develop and are consequently priced at a premium level, so they will need to show clear improvements in order to get reimbursement.  There have already been problems with reimbursement for some MKIs in some markets due to concerns from funding bodies over insufficient efficacy.  The true value of MKIs relative to other anticancer drugs still has to be established, and the results from recent clin. trials have been mixed.  Despite the broad activity profile of many MKIs, the patient response can be inconsistent and unpredictable.  The identification of predictive biomarkers of response or resistance is a crit. step to ascertain which specific combination of targets produces a significant clin. benefit with respect to specific tumor types.  More clin. feedback is needed to facilitate the design of the next generation of inhibitors with more precisely defined profiles.  Although it might seem immeasurably distant at the present time, the ultimate goal should be to derive the prerequisite knowledge and tools so that MTDD becomes a rational endeavor rather than a black box approach that relies upon serendipity.  This will help banish claims that MKIs are merely dirty, nonspecific drugs with insufficient specificity for treating a wider range of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-L-NWmtdikbVg90H21EOLACvtfcHk0lgS9xPEvRgCuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmtbfF&md5=3c915b5debf9d005993c8ad31c68bc2e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm901132v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901132v%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DSelectively%2520Nonselective%2520Kinase%2520Inhibition%253A%2520Striking%2520the%2520Right%2520Balance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1413%26epage%3D1437%26doi%3D10.1021%2Fjm901132v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lorusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eder, J. P.</span><span> </span><span class="NLM_article-title">Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1517/13543784.17.7.1013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1517%2F13543784.17.7.1013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1013-28&author=P.+M.+Lorussoauthor=J.+P.+Eder&title=Therapeutic+potential+of+novel+selective-spectrum+kinase+inhibitors+in+oncology&doi=10.1517%2F13543784.17.7.1013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.7.1013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.7.1013%26sid%3Dliteratum%253Aachs%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520potential%2520of%2520novel%2520selective-spectrum%2520kinase%2520inhibitors%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D1013%26epage%3D28%26doi%3D10.1517%2F13543784.17.7.1013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span>Protein Data Bank. <a href="http://www.pdb.org" class="extLink">www.pdb.org</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Protein+Data+Bank.+www.pdb.org."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Data%2520Bank" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Cirillo, P. F.; Gilmore, T. A.; Hickey, E. R.; Regan, J. R.; Zhang, L.-H.</span><span> </span><span class="NLM_article-title">Preparation of aromatic heterocyclic ureas as anti-inflammatory agents</span>. Patent WO2000043384,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=P.+F.+Cirillo&author=T.+A.+Gilmore&author=E.+R.+Hickey&author=J.+R.+Regan&author=L.-H.+Zhang&title=Preparation+of+aromatic+heterocyclic+ureas+as+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26atitle%3DPreparation%2520of%2520aromatic%2520heterocyclic%2520ureas%2520as%2520anti-inflammatory%2520agents%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Aicher, T. D.; Boyd, S. A.; Chicarelli, M. J.; Condroski, K. R.; Hinklin, R. J.; Singh, A.; Turner, T. M.; Rustam, F. G.</span><span> </span><span class="NLM_article-title">Preparation of heterocyclic compounds as glucokinase activators</span>. Patent WO2007089512,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+D.+Aicher&author=S.+A.+Boyd&author=M.+J.+Chicarelli&author=K.+R.+Condroski&author=R.+J.+Hinklin&author=A.+Singh&author=T.+M.+Turner&author=F.+G.+Rustam&title=Preparation+of+heterocyclic+compounds+as+glucokinase+activators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAicher%26aufirst%3DT.%2BD.%26atitle%3DPreparation%2520of%2520heterocyclic%2520compounds%2520as%2520glucokinase%2520activators%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Simeone, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bugianesi, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponpipom, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yudkovitz, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mount, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, M. T.</span><span> </span><span class="NLM_article-title">Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3329</span><span class="NLM_x">–</span> <span class="NLM_lpage">3332</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00751-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2FS0960-894X%2802%2900751-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=3329-3332&author=J.+P.+Simeoneauthor=R.+L.+Bugianesiauthor=M.+M.+Ponpipomauthor=Y.+T.+Yangauthor=J.+L.+Loauthor=J.+B.+Yudkovitzauthor=J.+Cuiauthor=G.+R.+Mountauthor=R.+N.+Renauthor=M.+Creightonauthor=A.+Maoauthor=S.+H.+Vincentauthor=K.+Chengauthor=M.+T.+Goulet&title=Modification+of+the+pyridine+moiety+of+non-peptidyl+indole+GnRH+receptor+antagonists&doi=10.1016%2FS0960-894X%2802%2900751-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900751-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900751-5%26sid%3Dliteratum%253Aachs%26aulast%3DSimeone%26aufirst%3DJ.%2BP.%26aulast%3DBugianesi%26aufirst%3DR.%2BL.%26aulast%3DPonpipom%26aufirst%3DM.%2BM.%26aulast%3DYang%26aufirst%3DY.%2BT.%26aulast%3DLo%26aufirst%3DJ.%2BL.%26aulast%3DYudkovitz%26aufirst%3DJ.%2BB.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DMount%26aufirst%3DG.%2BR.%26aulast%3DRen%26aufirst%3DR.%2BN.%26aulast%3DCreighton%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DS.%2BH.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DGoulet%26aufirst%3DM.%2BT.%26atitle%3DModification%2520of%2520the%2520pyridine%2520moiety%2520of%2520non-peptidyl%2520indole%2520GnRH%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D3329%26epage%3D3332%26doi%3D10.1016%2FS0960-894X%2802%2900751-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Bonfanti, J. F.; Muller, P.; Fortin, J. M. C.; Doublet, F. M. M.</span><span> </span><span class="NLM_article-title">Preparation of heterocyclylaminoalkyl substituted benzimidazoles as respiratory syncytial virus (RSV) replication inhibitors</span>. Patent WO2006136562,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=J.+F.+Bonfanti&author=P.+Muller&author=J.+M.+C.+Fortin&author=F.+M.+M.+Doublet&title=Preparation+of+heterocyclylaminoalkyl+substituted+benzimidazoles+as+respiratory+syncytial+virus+%28RSV%29+replication+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBonfanti%26aufirst%3DJ.%2BF.%26atitle%3DPreparation%2520of%2520heterocyclylaminoalkyl%2520substituted%2520benzimidazoles%2520as%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520replication%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L. H.</span><span> </span><span class="NLM_article-title">Preparation of aromatic heterocyclic ureas as antiinflammatory agents</span>. Patent WO 2000043384,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=P.+F.+Cirilloauthor=T.+A.+Gilmoreauthor=E.+R.+Hickeyauthor=J.+R.+Reganauthor=L.+H.+Zhang&title=Preparation+of+aromatic+heterocyclic+ureas+as+antiinflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%2BA.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DRegan%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%2BH.%26atitle%3DPreparation%2520of%2520aromatic%2520heterocyclic%2520ureas%2520as%2520antiinflammatory%2520agents%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Montuschi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciabattoni, G.</span><span> </span><span class="NLM_article-title">Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4131</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1021/jm5013227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5013227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4131-64&author=P.+Montuschiauthor=G.+Ciabattoni&title=Bronchodilating+drugs+for+chronic+obstructive+pulmonary+disease%3A+current+status+and+future+trends&doi=10.1021%2Fjm5013227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends</span></div><div class="casAuthors">Montuschi, Paolo; Ciabattoni, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4131-4164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacol. treatment of stable chronic obstructive pulmonary disease (COPD).  Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h.  New LAMA are under development for COPD.  Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration.  New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development.  LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler.  Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a std. pharmacol. strategy for COPD.  Inhaled dual-pharmacol. compds., combining muscarinic antagonism and β2-agonism (MABA) in a single mol., potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β2-agonist monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLB6Vc0-8tzbVg90H21EOLACvtfcHk0ljLbxhwPP7gFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVygtA%253D%253D&md5=816e44be469a0396d859cd3576514085</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm5013227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5013227%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DCiabattoni%26aufirst%3DG.%26atitle%3DBronchodilating%2520drugs%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520current%2520status%2520and%2520future%2520trends%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4131%26epage%3D64%26doi%3D10.1021%2Fjm5013227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting β2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6652</span><span class="refDoi"> DOI: 10.1021/jm1005989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2ktLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+L.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+J.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B22-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup&doi=10.1021%2Fjm1005989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by Design: Novel Ultra-Long-Acting β2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup</span></div><div class="casAuthors">Glossop, Paul A.; Lane, Charlotte A. L.; Price, David A.; Bunnage, Mark E.; Lewthwaite, Russell A.; James, Kim; Brown, Alan D.; Yeadon, Michael; Perros-Huguet, Christelle; Trevethick, Michael A.; Clarke, Nicholas P.; Webster, Robert; Jones, Rhys M.; Burrows, Jane L.; Feeder, Neil; Taylor, Stefan C. J.; Spence, Fiona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6640-6652</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of potent and selective sulfonamide derived β2-adrenoreceptor agonists are described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease.  Analogs from this series mediate very long-lasting smooth muscle relaxation in guinea pig tracheal strips.  The sulfonamide agonist headgroup confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state.  Optimization of pharmacokinetic properties was achieved through targeted introduction of a phenolic moiety to support rapid phase II clearance, thereby minimizing systemic exposure following inhalation and reducing systemically mediated adverse events.  Compd. 38 (PF-610355) is identified as a clin. candidate from this series, with in vivo duration of action studies confirming its potential for once-daily use in humans.  Compd. 38 is currently in advanced phase II clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGaBcfoYeu7Vg90H21EOLACvtfcHk0ljLbxhwPP7gFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2ktLjJ&md5=34cf266aa0f796ee5ec370369c726f6e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%2BL.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%2BJ.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B22-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652%26doi%3D10.1021%2Fjm1005989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0linTL3ey8VH9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Ito, K.; Charron, C. E.; Murray, P. J.; Onions, S. T.; Rapeport, G.; Strong, P.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ito%2C+K.%3B+Charron%2C+C.+E.%3B+Murray%2C+P.+J.%3B+Onions%2C+S.+T.%3B+Rapeport%2C+G.%3B+Strong%2C+P.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DK." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">To, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Failla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">905</span><span class="refDoi"> DOI: 10.1164/rccm.200906-0937OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1164%2Frccm.200906-0937OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=20224070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlymsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=897-905&author=Y.+Toauthor=K.+Itoauthor=Y.+Kizawaauthor=M.+Faillaauthor=M.+Itoauthor=T.+Kusamaauthor=W.+M.+Elliottauthor=J.+C.+Hoggauthor=I.+M.+Adcockauthor=P.+J.+Barnes&title=Targeting+Phosphoinositide-3-Kinase-%CE%B4+with+Theophylline+Reverses+Corticosteroid+Insensitivity+in+Chronic+Obstructive+Pulmonary+Disease&doi=10.1164%2Frccm.200906-0937OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease</span></div><div class="casAuthors">To, Yasuo; Ito, Kazuhiro; Kizawa, Yasuo; Failla, Marco; Ito, Misako; Kusama, Tadashi; Elliott, W. Mark; Hogg, James C.; Adcock, Ian M.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">897-904</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Patients with chronic obstructive pulmonary disease (COPD) show a poor response to corticosteroids.  This has been linked to a redn. of histone deacetylase-2 as a result of oxidative stress and is reversed by theophylline.  Objectives: To det. the role of phosphoinositide-3-kinase-delta (PI3K-δ) on the development of corticosteroid insensitivity in COPD and under oxidative stress, and as a target for theophylline.  Methods: Corticosteroid sensitivity was detd. as the 50% inhibitory concn. of dexamethasone on tumor necrosis factor-α-induced interleukin-8 release in peripheral blood mononuclear cells from patients with COPD (n = 17) and compared with that of nonsmoking (n = 8) and smoking (n = 7) control subjects.  The effect of theophylline and a selective PI3K-δ inhibitor (IC87114) on restoration of corticosteroid sensitivity was confirmed in cigarette smoke-exposed mice.  Measurements and Main Results: Peripheral blood mononuclear cells of COPD (50% inhibitory concn. of dexamethasone: 156.8 ± 32.6 nM) were less corticosteroid sensitive than those of nonsmoking (41.2 ± 10.5 nM; P = 0.018) and smoking control subjects (47.5 ± 19.6 nM; P = 0.031).  Corticosteroid insensitivity and reduced histone deacetylase-2 activity after oxidative stress were reversed by a non-selective PI3K inhibitor (LY294002) and low concns. of theophylline.  Theophylline was a potent selective inhibitor of oxidant-activated PI3K-δ, which was up-regulated in peripheral lung tissue of patients with COPD.  Furthermore, cells with knock-down of PI3K-δ failed to develop corticosteroid insensitivity with oxidative stress.  Both theophylline and IC87114, combined with dexamethasone, inhibited corticosteroid-insensitive lung inflammation in cigarette-smoke-exposed mice in vivo.  Conclusions: Inhibition of oxidative stress dependent PI3K-δ activation by a selective inhibitor or theophylline provides a novel approach to reversing corticosteroid insensitivity in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrntINJnOqMbrVg90H21EOLACvtfcHk0linTL3ey8VH9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlymsbzO&md5=5338bbb7050e1700b0e4eda068cdb05c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1164%2Frccm.200906-0937OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200906-0937OC%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DKizawa%26aufirst%3DY.%26aulast%3DFailla%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DKusama%26aufirst%3DT.%26aulast%3DElliott%26aufirst%3DW.%2BM.%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26aulast%3DAdcock%26aufirst%3DI.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DTargeting%2520Phosphoinositide-3-Kinase-%25CE%25B4%2520with%2520Theophylline%2520Reverses%2520Corticosteroid%2520Insensitivity%2520in%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D897%26epage%3D905%26doi%3D10.1164%2Frccm.200906-0937OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Tadashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuniaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasunori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanae, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taeko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuzo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sataro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazuhisa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshinosuke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akihito, I.</span><span> </span><span class="NLM_article-title">Senescence marker protein-30 protects mice lungs from oxidative stress, aging, and smoking</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span><span class="refDoi"> DOI: 10.1164/rccm.200511-1816OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=10.1164%2Frccm.200511-1816OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;key=16728709" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2006&pages=530-537&author=S.+Tadashiauthor=S.+Kuniakiauthor=S.+Yasunoriauthor=M.+Hiroakiauthor=S.+Sanaeauthor=A.+Taekoauthor=K.+Yuzoauthor=M.+Takanoriauthor=G.+Sataroauthor=T.+Kazuhisaauthor=F.+Yoshinosukeauthor=M.+Naokiauthor=I.+Akihito&title=Senescence+marker+protein-30+protects+mice+lungs+from+oxidative+stress%2C+aging%2C+and+smoking&doi=10.1164%2Frccm.200511-1816OC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1164%2Frccm.200511-1816OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200511-1816OC%26sid%3Dliteratum%253Aachs%26aulast%3DTadashi%26aufirst%3DS.%26aulast%3DKuniaki%26aufirst%3DS.%26aulast%3DYasunori%26aufirst%3DS.%26aulast%3DHiroaki%26aufirst%3DM.%26aulast%3DSanae%26aufirst%3DS.%26aulast%3DTaeko%26aufirst%3DA.%26aulast%3DYuzo%26aufirst%3DK.%26aulast%3DTakanori%26aufirst%3DM.%26aulast%3DSataro%26aufirst%3DG.%26aulast%3DKazuhisa%26aufirst%3DT.%26aulast%3DYoshinosuke%26aufirst%3DF.%26aulast%3DNaoki%26aufirst%3DM.%26aulast%3DAkihito%26aufirst%3DI.%26atitle%3DSenescence%2520marker%2520protein-30%2520protects%2520mice%2520lungs%2520from%2520oxidative%2520stress%252C%2520aging%252C%2520and%2520smoking%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2006%26volume%3D174%26spage%3D530%26epage%3D537%26doi%3D10.1164%2Frccm.200511-1816OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1kv2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1kv2','PDB','1kv2'); return false;">PDB: 1kv2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2','PDB','1KV2'); return false;">PDB: 1KV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1CM8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1CM8','PDB','1CM8'); return false;">PDB: 1CM8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FLN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FLN','PDB','3FLN'); return false;">PDB: 3FLN</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01029" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01029" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679aa8915c6f3d30","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
